Fused heterocyclic compounds and its uses thereof

Abstract

The present invention provides a fused heterocyclic compound of formula (I), or salts, stereoisomers, metal complexes, polymorphs or N-oxides thereof (I) wherein, Q, R1, Y, R2 and R2a are as defined in the detailed description. The present invention also provides methods for their preparation and use of the compounds of formula (I) as a pest control agent.

Description

FIELD OF THE INVENTION The present invention relates to compounds of formula (I). More particularly, the present invention relates to fused heterocyclic compounds of formula (I) and a process for the preparation thereof. The present invention further relates to the composition comprising those compounds, and to their use as pest control agents. BACKGROUND OF THE INVENTION The currently available modern insecticides and acaricides have to satisfy many requirements, for example, level of activity, long lasting efficacy, broadness of insecticidal spectrum as well as environmental and toxicological safeness and additional beneficial effects, and the possible use thereof. During the past decades, efforts to develop selective insecticides have been made that are acting specifically on biochemical modes of action being present only in insects or mites, but additionally showing properties that differ from known insecticides in an advantageous way. Heterocyclic compounds with pesticidal activity are known and described, for example, in WO2020250183. However, there is a continuous need for new compounds which are more effective, less toxic, and environmentally safer. Furthermore, some of those existing pesticides are highly toxic, or remain for a long time in the environment because of their residual properties, which may become a growing problem due to the disruption of the ecosystem. Thus, there is a constant need for new pest control agents with improved pesticidal activity, a broader spectrum of efficacy, longer lasting activity, increased plant compatibility, better environmental safety, and improved formulation properties as well as a low risk of resistance development. Therefore, the present invention envisages such compounds that satisfy or overcome drawbacks associated with the prior art. Surprisingly, we have found that certain novel pesticidally active fused heterocyclic compounds with sulfur containing substituents being subject of this invention have favorable properties as pesticides and are environmentally safer, as desired. SUMMARY OF THE INVENTION Accordingly, the present invention provides fused heterocyclic compounds of formula (I) or salts, stereoisomers, metal complexes, polymorphs or N-oxides thereof (I) wherein, R1, Y, Q, R2 and R2a are as defined in the detailed description. The present invention also provides a process for preparing the compound of formula (I) or salts thereof. The present invention provides a composition for controlling or preventing invertebrate pests comprising a compound of formula (I), salts, stereoisomers, metal complexes, polymorphs, or N-oxides thereof and at least one additional component selected from the group consisting of surfactants and auxiliaries. The composition additionally comprises at least one additional biologically active and compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients. The present invention provides use of the compound of formula (I), salts, stereoisomers, metal complexes, polymorphs, or N-oxides, compositions or combinations thereof, for combating invertebrate pests in agricultural crops and / or horticultural crops or parasites on animals or wooden dwellings and commercial structures. The present invention provides a method of combating invertebrate pests comprising contacting the invertebrate pests, their habitat, breeding ground, food supply, plant, seed, soil, area, material or environment in which the invertebrate pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from pest attack or infestation with a biologically effective amount of the compounds of formula (I) or salts, stereoisomers, metal complexes, polymorphs, or N-oxides thereof as well as their composition or combination thereof. DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS: The definitions provided herein for the terminologies used in the present disclosure are for illustrative purposes only and in no manner limit the scope of the present invention disclosed in the present disclosure. As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", "contains", "containing", "characterized by" or any other variation thereof, are intended to cover a nonexclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process or method that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process or method. The transitional phrase "consisting of" excludes any element, step or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase "consisting of" appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole. The transitional phrase "consisting essentially of" is used to define a composition or method that includes materials, steps, features, components or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term "consisting essentially of" occupies a middle ground between "comprising" and "consisting of". Further, unless expressly stated to the contrary, "or" refers to an inclusive "or" and not to an exclusive "or". For example, a condition A "or" B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present). Also, the indefinite articles "a" and "an" preceding an element or component of the present invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore "a" or "an" should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular. As referred to in this disclosure, the term "invertebrate pest" includes arthropods, gastropods and nematodes of economic importance as pests. The term "arthropod" includes but is not limited to insects, mites, spiders, scorpions, centipedes, millipedes, pill bugs and symphylans. The term "gastropod" includes but is not limited to snails, slugs and other Stylommatophora. The term "nematode" refers to a living organism of the Phylum Nematoda. The term "helminths" includes but is not limited to roundworms, heartworms, phytophagous nematodes (Nematoda), flukes (Tematoda), acanthocephala and tapeworms (Cestoda). The term "agronomic" refers to the production of field crops such as for food and fiber and includes the growth of corn, soybeans and other legumes, rice, cereal (e.g., wheat, oats, barley, rye, rice, maize), leafy vegetables (e.g., lettuce, cabbage, and other cole crops), fruiting vegetables (e.g., tomatoes, pepper, eggplant, crucifers and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g., pome, stone and citrus), small fruit (berries, cherries) and other specialty crops (e.g., canola, sunflower, olives). The term "nonagronomic" refers to other than field crops, such as horticultural crops (e.g., greenhouse, nursery or ornamental plants not grown in a field), residential, agricultural, commercial and industrial structures, turf (e.g., sod farm, pasture, golf course, lawn, sports field, etc.), wood products, stored product, agro-forestry and vegetation management, public health (i.e. human) and animal health (e.g., domesticated animals such as pets, livestock and poultry, undomesticated animals such as wildlife) applications. Nonagronomic applications include protecting an animal from an invertebrate parasitic pest by administering a parasiticidally effective (i.e. biologically effective) amount of a compound of the present invention, typically in the form of a composition formulated for veterinary use, to the animal to be protected. As referred to in the present disclosure and claims, the terms "parasiticidal" and "parasiticidally" refers to observable effects on an invertebrate parasite pest to provide protection of an animal from the pest. Parasiticidal effects typically relate to diminishing the occurrence or activity of the target invertebrate parasitic pest. Such effects on the pest include necrosis, death, retarded growth, diminished mobility or lessened ability to remain on or in the host animal, reduced feeding and inhibition of reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal. The compounds of the present disclosure may be present either in pure form or as mixtures of different possible isomeric forms such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present disclosure. One skilled in the art will appreciate that one stereoisomer may be more active and / or may exhibit beneficial effects when enriched relative to the other isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technology to separate, enrich, and / or to selectively prepare said isomers. The meaning of various terms used in the description shall now be illustrated. The term "aliphatic compound / s" or "aliphatic group / s" used herein is an organic compound / s whose carbon atoms are linked in straight chains, branched chains, or non-aromatic rings. The term "alkyl", used either alone or in compound words such as "alkylthio" or "haloalkyl" or -N(alkyl) or alkylcarbonylalkyl or alkylsuphonylamino includes straight-chain or branched Ci to C24 alkyl, preferably Ci to C15 alkyl, more preferably Ci to Cw alkyl, most preferably Ci to C& alkyl. Representative examples of alkyl include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and l-ethyl-2-methylpropyl or the different isomers. If the alkyl is at the end of a composite substituent, as, for example, in alkylcycloalkyl, the part of the composite substituent at the start, for example the cycloalkyl, may be mono- or polysubstituted identically or differently and independently by alkyl. The same also applies to composite substituents in which other radicals, for example alkenyl, alkynyl, hydroxyl, halogen, carbonyl, carbonyloxy and the like, are at the end. The term "alkenyl", used either alone or in compound words includes straight-chain or branched C2 to C24 alkenes, preferably C2 to C15 alkenes, more preferably C2 to Cw alkenes, most preferably C2 to C& alkenes. Representative examples of alkenes include ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-l-propenyl, l-methyl-2 -propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-l -butenyl, 3-methyl-1-butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, l,l-dimethyl-2-propenyl, 1,2-dimethyl-l-propenyl, 1,2-dimethyl-2 -propenyl, 1-ethyl-1-propenyl, l-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-l-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, l-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, l-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, l,l-dimethyl-2- butenyl, butenyl, butenyl, 1,1 -dimethyl-3-butenyl, 1,3 -dimethyl-1 -butenyl, 2,3 -dimethyl-1 -butenyl, 1,2-dimethyl-1 -butenyl, 1,3-dimethyl-2-butenyl, 2,3-dimethyl-2-butenyl, 1,2-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,3 -dimethyl-3 -butenyl, l,2-dimethyl-3- 2,2-dimethyl-3- 3,3-dimethyl-1- butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, l-ethyl-3-butenyl, 2-ethyl- 1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, l,l,2-trimethyl-2-propenyl, 1 -ethyl- l-methyl-2-propenyl, l-ethyl-2-methyl-l-propenyl and l-ethyl-2-methyl-2-propenyl and the different isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. This definition also applies to alkenyl as a part of a composite substituent, for example haloalkenyl and the like, unless defined specifically elsewhere. The term "alkynyl", used either alone or in compound words includes straight-chain or branched C2 to C24 alkynes, preferably C2 to C15 alkynes, more preferably C2 to Cw alkynes, most preferably C2 to C& alkynes. Non-limiting examples of alkynes include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, l-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, l-methyl-2-butynyl, l-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, l,l-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, l-methyl-2-pentynyl, 1-methyl-3-pentynyl, l-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-l-pentynyl, 4-methyl-2-pentynyl, l,l-dimethyl-2-butynyl, l,l-dimethyl-3-butynyl, l,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-l-butynyl, 1- ethyl-2-butynyl, l-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1 -ethyl-l-methyl-2-propynyl and the different isomers. This definition also applies to alkynyl as a part of a composite substituent, for example haloalkynyl etc., unless specifically defined elsewhere. The term "alkynyl" can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. The term "cycloalkyl" means alkyl closed to form a ring. Non-limiting examples include but are not limited to cyclopropyl, cyclopentyl and cyclohexyl. This definition also applies to cycloalkyl as a part of a composite substituent, for example cycloalkylalkyl etc., unless specifically defined elsewhere. The term "cycloalkylalkyl" denotes cycloalkyl substitution on an alkyl group. It refers to a cycloalkyl group attached via an alkyl linkage to the rest of the molecule. For example, as used herein, the term “Cs-Ce-cycloalkyl-Ci-Cn-alkyl-” refers to a Ci-Cn-alkyl radical as generally defined above substituted by one or more Cs-Ce-cycloalkyl groups as generally defined above. Cs-Ce-cycloalkyl-Ci-Cs-alkyl is to be construed accordingly. Examples include but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl and cyclohexylmethyl. The term "cycloalkenyl" means alkenyl closed to form a ring including monocyclic, partially unsaturated hydrocarbyl groups. Non-limiting examples include but are not limited to cyclopropenyl, cyclopentenyl and cyclohexenyl. This definition also applies to cycloalkenyl as a part of a composite substituent, for example cycloalkenylalkyl etc., unless specifically defined elsewhere. The term "cycloalkynyl" means alkynyl closed to form a ring including monocyclic, partially unsaturated groups. Non-limiting examples include but are not limited to cyclopropynyl, cyclopentynyl and cyclohexynyl. This definition also applies to cycloalkynyl as a part of a composite substituent, for example cycloalkynylalkyl etc., unless specifically defined elsewhere. The term "cycloalkoxy", "cycloalkenyloxy" and the like are defined analogously. Non limiting examples of cycloalkoxy include cyclopropyloxy, cyclopentyloxy and cyclohexyloxy. This definition also applies to cycloalkoxy as a part of a composite substituent, for example cycloalkoxy alkyl etc., unless specifically defined elsewhere. The term "halogen", either alone or in compound words such as "haloalkyl", includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as "haloalkyl", said alkyl may be partially or fully substituted with one or more halogen atoms which may be the same or different. Nonlimiting examples of "haloalkyl" include chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, l,l-dichloro-2,2,2-trifluoroethyl, and l,l,l-trifluoroprop-2-yl. This definition also applies to haloalkyl as a part of a composite substituent, for example haloalkylaminoalkyl etc., unless specifically defined elsewhere. The terms "haloalkenyl", "haloalkynyl" are defined analogously except that, instead of alkyl groups, alkenyl and alkynyl groups are present as a part of the substituent. The term "haloalkoxy" means straight-chain or branched alkoxy groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkoxy include chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and l,l,l-trifluoroprop-2-oxy. This definition also applies to haloalkoxy as a part of a composite substituent, for example haloalkoxyalkyl etc., unless specifically defined elsewhere. The term "haloalkylthio" means straight-chain or branched alkylthio groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Non-limiting examples of haloalkylthio include chloromethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1-bromoethylthio, 1- fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2- fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio, pentafluoroethylthio and l,l,l-trifluoroprop-2-ylthio. This definition also applies to haloalkylthio as a part of a composite substituent, for example haloalkylthioalkyl etc., unless specifically defined elsewhere. Non-limiting examples of "haloalkylsulfinyl" include CF3S(O), CC13S(O), CF3CH2S(O) and CF3CF2S(O). Examples of "haloalkylsulfonyl" include CF3S(O)2, CC13S(O)2, CF3CH2S(O)2 and CF3CF2S(O)2. The term "hydroxy" means -OH, and "Amino" means -NRR, wherein R can be H or any possible substituent such as alkyl. The term "carbonyl " means -C(O)-, "carbonyloxy" means -OC(O)-, “oxo” means =0, "sulfinyl" means SO, and "sulfonyl" means S(O)2. The term "alkoxy" used either alone or in compound words included Ci to C24 alkoxy, preferably Ci to Cis alkoxy, more preferably Ci to Cw alkoxy, most preferably Ci to C& alkoxy. Examples of alkoxy include methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy and l-ethyl-2-methylpropoxy and the different isomers. This definition also applies to alkoxy as a part of a composite substituent, for example haloalkoxy, alkynylalkoxy, etc., unless specifically defined elsewhere. The term "Alkoxyalkyl" denotes alkoxy substitution on alkyl. Non-limiting examples of "alkoxyalkyl" include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2 and CH3CH2OCH2CH2. The term "alkoxyalkoxy" denotes alkoxy substitution on alkoxy. The term "alkylthio" includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 2,2-dimethylpropylthio, 1-ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1-methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio,     1,1,2-trimethylpropylthio,     1,2,2- trimethylpropylthio, 1-ethyl-1-methylpropylthio and l-ethyl-2-methylpropylthio and the different isomers. Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylcarbonyl, cycloalkylcarbonyl, haloalkoxylalkyl, and the like, are defined analogously to the above examples. The term "alkylthioalkyl" denotes alkylthio substitution on alkyl. Representative examples of "alkylthioalkyl" include -CH2SCH2, -CH2SCH2CH2, CH3CH2SCH2, CH3CH2CH2CH2SCH2 and CH3CH2SCH2CH2. The term "Alkylthioalkoxy" denotes alkylthio substitution on alkoxy. The term "cycloalkylalkylamino" denotes cycloalkyl substitution on alkyl amino. The terms alkoxyalkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkylaminoalkyl, cycloalkylaminocarbonyl and the like, are defined analogously to "alkylthioalkyl" or cycloalkylalkylamino. The term "alkoxycarbonyl" is an alkoxy group bonded to a skeleton via a carbonyl group (-CO-). This definition also applies to alkoxycarbonyl as a part of a composite substituent, for example cycloalkylalkoxycarbonyl and the like, unless specifically defined elsewhere. The term "alkoxycarbonylalkylamino" denotes alkoxy carbonyl substitution on alkyl amino. "Alkylcarbonylalkylamino" denotes alkyl carbonyl substitution on alkyl amino. The terms alkylthioalkoxycarbonyl, cycloalkylalkylaminoalkyl and the like are defined analogously. Non-limiting examples of "alkylsulfinyl" include but are not limited to methylsulfinyl, ethylsulfinyl, propylsulfinyl, 1-methylethylsulfinyl, butylsulfinyl, 1-methylpropylsulfinyl, 2-methylpropylsulfinyl, 1,1-dimethylethylsulfinyl, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methylbutylsulfinyl, 2,2-dimethylpropylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl, 1,1-dimethylpropylsulfinyl, 1,2-dimethylpropylsulfinyl, 1-methylpentylsulfinyl, 2-methylpentylsulfinyl, 3-methylpentylsulfinyl, 4-methylpentylsulfinyl, 1,1 -dimethylbutylsulfinyl, 1,2-dimethylbutylsulfinyl, 1,3-dimethylbutylsulfinyl, 2,2-dimethylbutylsulfinyl, 2,3-dimethylbutylsulfinyl, 3,3-dimethylbutylsulfinyl, 1-ethylbutylsulfinyl, 2-ethylbutylsulfinyl, 1,1,2-trimethylpropylsulfinyl, 1,2,2-trimethylpropylsulfinyl, 1-ethyl-1-methylpropylsulfinyl and l-ethyl-2-methylpropylsulfinyl and the different isomers. The term "arylsulfinyl" includes Ar-S(O), wherein Ar can be any carbocyle or heterocylcle. This definition also applies to alkylsulfinyl as a part of a composite substituent, for example haloalkylsulfinyl etc., unless specifically defined elsewhere. The term Ci-Ce alkylsulfonyl denotes a radical of the formula -S(O)2R in which R is Ci-Ce alkyl radical as generally defined above. Non-limiting examples of "alkylsulfonyl" include but are not limited to methylsulfonyl, ethylsulfonyl, propylsulfonyl, 1-methylethylsulfonyl, butylsulfonyl, 1-methylpropylsulfonyl, 2-methylpropylsulfonyl, 1,1-dimethylethylsulfonyl, pentylsulfonyl, 1-methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 2,2-dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl, 1,1-dimethylpropylsulfonyl, 1,2-dimethylpropylsulfonyl, 1-methylpentylsulfonyl, 2-methylpentylsulfonyl, 3-methylpentylsulfonyl, 4-methylpentylsulfonyl, 1,1 -dimethylbutylsulfonyl, 1,2-dimethylbutylsulfonyl, 1,3-dimethylbutylsulfonyl, 2,2-dimethylbutylsulfonyl, 2,3-dimethylbutylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethylbutylsulfonyl, 2-ethylbutylsulfonyl, 1,1,2-trimethylpropylsulfonyl, 1,2,2-trimethylpropylsulfonyl, 1-ethyl-1-methylpropylsulfonyl and l-ethyl-2-methylpropylsulfonyl and the different isomers. The term "arylsulfonyl" includes Ar-S(O)2, wherein Ar can be any carbocyle or heterocylcle. This definition also applies to alkylsulfonyl as a part of a composite substituent, for example alkylsulfonylalkyl etc., unless defined elsewhere. "Alkylamino", "dialkylamino", and the like, are defined analogously to the above examples. The term Ci-Ce-hydroxyalkyl denotes a radical of the formula in which Ci-Ce alkyl is substituted with hydroxy group. Non-limiting examples include -CH2OH, -CH(CH3)-OH, CH2CH2-OH. Tire term “optionally substituted” as used herein means that the group referenced is either unsubstituted or is substituted by a designated substituent, for example, “Cb-Ca-cycloalkyl is optionally substituted with 1 or 2 halo atoms” means C3-C4-cycloalkyl, C3-C.4-cycloalkyl substituted with 1 halo atom and C3-C4cycloalkyl substituted with 2 halo atoms. The term “optionally substituted” can be used interchangeably with “unsubstituted or substituted” The term "carbocycle" includes "aromatic carbocyclic ring system" and "non aromatic carbocyclic ring system" or polycyclic or bicyclic (spiro, fused, bridged, nonfused) ring compounds in which ring may be aromatic or non-aromatic (where aromatic indicates that the Huckel rule is satisfied and non-aromatic indicates that the Huckel rule is not satisfied). The term "phenylalkyl" denotes phenyl substitution on an alkyl group. It refers to a phenyl group attached via an alkyl linkage to the rest of the molecule. For example, non-limiting examples of phenyl-Ci-Ce-alkyl include phenyl methyl (benzyl), phenyl ethyl, and phenyl propyl. The term "hetero" in connection with rings refers to a ring in which at least one ring atom is not carbon and which can contain 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur, provided that each ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. The term "aromatic" indicates that the Huckel rule is satisfied and the term "non aromatic" indicates that the Huckel rule is not satisfied. The term "heterocycle" or "heterocyclic" or "heterocyclic ring system " includes "aromatic heterocycle" or "heteroaryl bicyclic ring system" and "non aromatic heterocycle ring or ring system" or polycyclic or bicyclic (spiro, fused, bridged, non-fused) ring compounds in which ring may be aromatic or nonaromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(0)o 2, and or C ring member of the heterocycle may be replaced by C(=O), C(=S), C(=CR*R*) and C=NR*, * indicates integers. The term "non aromatic heterocycle" or "non aromatic heterocyclic" means three- to fifteen-membered, preferably three- to twelve-membered, saturated or partially unsaturated heterocycle containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur: mono, bi- or tricyclic heterocycles which contain, in addition to carbon ring members, one to three nitrogen atoms and / or one oxygen or sulphur atom or one or two oxygen and / or sulphur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; for example (but not limited to) oxiranyl, aziridinyl,oxetanyl, thietanyl, azetidinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4-oxadiazolidin-3-yl, l,2,4-oxadiazolidin-5-yl, l,2,4-thiadiazolidin-3-yl, l,2,4-thiadiazolidin-5-yl, 1,2,4-triazolidin-l-yl, l,2,4-triazolidin-3-yl, l,3,4-oxadiazolidin-2-yl, l,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-l-yl, l,3,4-triazolidin-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl, pyrrolinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-l-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyrazynyl, morpholinyl, thiomorphlinyl, l,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, l,3,5-hexahydrotriazin-2-yl, 1,2,4-hexahydrotriazin-3-yl, cycloserines, 2,3,4,5-tetrahydro[lH]azepin-l- or -2- or -3- or -4- or -5- or -6- or -7- yl, 3,4,5,6-tetra-hydro[2H]azepin-2- or -3- or -4- or -5- or -6- or-7-yl, 2,3,4,7-tetrahydro[lH]azepin-1- or -2- or -3- or -4- or -5- or -6- or-7- yl, 2,3,6,7-tetrahydro[lH]azepin-l- or -2- or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-1- or -2- or -3- or -4- yl, tetra- and hexahydrooxepinyl such as 2,3,4,5- tetrahydro[l H]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,4,7-tetrahydro[lH]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, 2,3,6,7-tetrahydro[lH]oxepin-2- or -3- or -4- or -5- or -6- or -7- yl, hexahydroazepin-1- or -2- or -3- or -4- yl, tetra- and hexahydro-1,3-diazepinyl, tetra- and hexahydro-1,4-diazepinyl, tetra- and hexahydro-1,3-oxazepinyl, tetra- and hexahydro-1,4-oxazepinyl, tetra- and hexahydro-1,3-dioxepinyl, tetra- and hexahydro-1,4-dioxepinyl. This definition also applies to heterocyclyl as a part of a composite substituent, for example, heterocyclylalkyl etc., unless specifically defined elsewhere. The term "heteroaryl" or "aromatic heterocyclic" means 5 or 6-membered, fully unsaturated monocyclic ring system containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom as ring members, for example (but not limited thereto) furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,3,4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzofused nitrogen-bonded 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-l,3-diene-l,4-diyl group in which one or two carbon atoms may be replaced by nitrogen atoms, where these rings are attached to the skeleton via one of the nitrogen ring members, for example (but not limited to) 1-pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-l-yl, 1-imidazolyl, 1,2,3-triazol-l-yl and 1,3,4-triazol-l-yl. 6-membered heteroaryl which contains one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen atoms as ring members, for example (but not limited thereto) 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl and l,2,4,5-tetrazin-3-yl; benzofused 5-membered heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulphur atom: for example (but not limited to) indol-l-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl, indazol-l-yl, indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol-6-yl, indazol-7-yl, indazol-2-yl, l-benzofuran-2-yl, l-benzofuran-3-yl, 1-benzofuran-4-yl, l-benzofuran-5-yl, l-benzofuran-6-yl, l-benzofuran-7-yl, l-benzothiophen-2-yl, 1-benzothiophen-3-yl, l-benzothiophen-4-yl, l-benzothiophen-5-yl, l-benzothiophen-6-yl, 1-benzothiophen-7-yl, l,3-benzothiazol-2-yl, 1,3- benzothiazol-4-yl, l,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, l,3-benzothiazol-7-yl, l,3-benzoxazol-2-yl, l,3-benzoxazol-4-yl, l,3-benzoxazol-5-yl, l,3-benzoxazol-6-yl and l,3-benzoxazol-7-yl; benzofused 6-membered heteroaryl which contains one to three nitrogen atoms: for example (but not limited to) quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. This definition also applies to heteroaryl as a part of a composite substituent, for example heteroarylalkyl etc., unless specifically defined elsewhere. The term "heteroarylalkyl" denotes heteroaryl substitution on an alkyl group. It refers to a heteroaryl group attached via an alkyl linkage to the rest of the molecule. The term "Trialkylsilyl" includes three branched and / or straight-chain alkyl radicals attached to and linked through a silicon atom such as trimethylsilyl, triethylsilyl and t-butyl-dimethylsilyl. "Halotrialkylsilyl" denotes at least one of the three alkyl radicals is partially or fully substituted with halogen atoms which may be the same or different. The term "alkoxytrialkylsilyl" denotes at least one of the three alkyl radicals is substituted with one or more alkoxy radicals which may be the same or different. The term "trialkylsilyloxy" denotes a trialkylsilyl moiety attached through oxygen. Non-limiting examples of "alkylcarbonyl" include C(O)CH3, QCOCHzCHzCFb and C(O)CH(CH3)2-Non-limiting examples of "alkoxycarbonyl" include CH3OC(=O), CH3CH2OC(=O), CH3CH2CH2OC(=O), (CH3)2CHOC(=O) and the different butoxy or pentoxycarbonyl isomers. Nonlimiting examples of "alkylaminocarbonyl" include CH3NHC(=O), CH3CH2NHC(=O), CH3CH2CH2NHC(=O), (CH3)2CHNHC(=O) and the different butylamino -or pentylaminocarbonyl isomers. Non-limiting examples of "dialkylaminocarbonyl" include (CH3)2NC(=O), (CH3CH2)2NC(=O), CH3CH2(CH3)NC(=O), CH3CH2CH2(CH3)NC(=O) and (CH3)2CHN(CH3)C(=O). Non-limiting examples of "alkoxyalkylcarbonyl" include CH3OCH2C(=O), CH3OCH2CH2C(=O), CH3CH2OCH2C(=O), CH3CH2CH2CH2OCH2C(=O) and CH3CH2OCH2CH2C(=O). Non-limiting examples of "alkylthioalkylcarbonyl" include CH3SCH2C(=O), CH3SCH2CH2C(=O), CH3CH2SCH2C(=O), CH3CH2CH2CH2SCH2C(=O) and CH3CH2SCH2CH2C(=O). The term haloalkylsufonylaminocarbonyl, alkylsulfonylaminocarbonyl, alkylthioalkoxycarbonyl, alkoxycarbonylalkyl amino and the like are defined analogously. Non-limiting examples of "alkylaminoalkylcarbonyl" include CH3NHCH2C(=O), CH3NHCH2CH2C(=O), CH3CH2NHCH2C(=O), CH3CH2CH2CH2NHCH2C(=O) and CH3CH2NHCH2CH2C(=O). The term "amide" means A-R'C(=O)NR"-B, wherein R' and R" indicates substituents and A and B indicate any group. The term "thioamide" means A-R'C(=S)NR"-B, wherein R' and R” indicates substituents and A and B indicate any group. The total number of carbon atoms in a substituent group is indicated by the "Q-Cj" prefix where i and j are numbers from 1 to 21. For example, C1-C3 alkylsulfonyl designates methylsulfonyl through propylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CFbCH / OCFb), CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH3CH2CH2OCH2 and CH3CH2OCH2CH2. In the above recitations, when a compound of formula (I) is comprised of one or more heterocyclic rings, all substituents are attached to these rings through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen. When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript m in (R)m indicates an integer ranging from for example 0 to 4 then the number of substituents may be selected from the integers between 0 and 4 inclusive. When a group contains a substituent that can be hydrogen, then, when this substituent is taken as hydrogen, it is recognized that said group is being un-substituted. The embodiments herein, and the various features and advantageous details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein. The description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein. Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is solely for the purpose of providing a context for the disclosure. It is not to be taken as an admission that any or all of these matters form a part of the prior art base or were common general knowledge in the field relevant to the disclosure as it existed anywhere before the priority date of this application. The numerical values mentioned in the description and the description / claims though might form a critical part of the present invention of the present invention, any deviation from such numerical values shall still fall within the scope of the present invention if that deviation follows the same scientific principle as that of the present invention disclosed in the present invention.The inventive compound of the present invention may, if appropriate, be present as mixtures of different possible isomeric forms, especially of stereoisomers, for example E and Z, threo and erythro, and also optical isomers, but if appropriate also of tautomers. Both the E and the Z isomers, and also the threo and erythro isomers, and the optical isomers, any desired mixtures of these isomers and the possible tautomeric forms are disclosed and claimed. The term "pest" for the purpose of the present disclosure includes but is not limited to fungi, stramenopiles (oomycetes), bacteria, nematodes, mites, ticks, insects and rodents. Also pest is an animal or plant detrimental to humans or human concerns including crops, livestock, and forestry. The term "plant" is understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and the plant cultivars which are protectable and non-protectable by plant breeders' rights. For the purpose of the present disclosure the term "plant" includes a living organism of the kind exemplified by trees, shrubs, herbs, grasses, ferns, and mosses, typically growing in a site, absorbing water and required substances through its roots, and synthesizing nutrients in its leaves by photosynthesis. Examples of "plant" for the purpose of the present invention include but are not limited to agricultural crops such as wheat, rye, barley, triticale, oats or rice; beet, e.g. sugar beet or fodder beet; fruits and fruit trees, such as pomes, stone fruits or soft fruits, e.g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit and citrus trees, such as oranges, lemons, grapefruits or mandarins; any horticultural plants, vegetables, such as spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; cucurbitaceae; oleaginous plants; energy and raw material plants, such as cereals, corn, soybean, other leguminous plants, rape, sugar cane or oil palm; tobacco; nuts; coffee; tea; cacao; bananas; peppers; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broadleaved trees or evergreens, e.g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants. Preferably, the plant for the purpose of the present invention includes but is not limited to cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and vegetables, ornamentals, any floricultural plants and other plants for use of human and animals. The term "plant parts" is understood to mean all parts and organs of plants above and below the ground. For the purpose of the present disclosure, the term plant parts includes but is not limited to cuttings, leaves, twigs, tubers, flowers, seeds, branches, roots including taproots, lateral roots, root hairs, root apex, root cap, rhizomes, slips, shoots, fruits, fruit bodies, bark, stem, buds, auxiliary buds, meristems, nodes and internodes. The term "locus thereof" includes soil, surroundings of plant or plant parts and equipment or tools used before, during or after sowing / planting a plant or a plant part. Application of the compounds of the present disclosure or the compound of the present disclosure in a composition optionally comprising other compatible compounds to a plant or a plant material or locus thereof include application by a technique known to a person skilled in the art which include but is not limited to spraying, coating, dipping, fumigating, impregnating, injecting and dusting. The term "applied" means adhered to a plant or plant part either physically or chemically including impregnation. Embodiments according to the invention are provided as set out below: Embodiment 01: Accordingly, the present invention provides fused heterocyclic compounds of formula (I), (I) wherein, R1 is Ci-Ce-alkyl; Y is selected from oxygen (0) or NRY; RYis selected from the group consisting of hydrogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl, Cs-Cs-cycloalkyl, Cs-Cs-cycloalkyl-Ci-Cs-alkyl and -C(O)Rla; Rla is selected from the group consisting of Ci-Ce-alkyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Cs-alkyl; R2 is C(=W)R7; wherein W is selected from oxygen (0) or sulfur (S); R7 is selected from the group consisting of OR4 and NR5R6; R2a is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, CVCT-cycloalkyl, Ci-Ce-alkoxy, Ci-Ce-alkoxy-Cs-Ce-cycloalkyl, Ci-Ce-haloalkyl and Ci-Ce-haloalkoxy; R4 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and CT-CVcycloalkyl; R5 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C&-alkynyl, OR5a, NR5cR5d, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, C3-Cs-cycloalkyl, C3-Cs-cycloalkyl-Ci-C6-alkyl, -C(O)OR5d, -Ci-C3-alkyl-C(O)OR5d, -Ci-C3-alkyl-C(O)N(R5d)2, 3- to 6- membered non aromatic heterocyclic ring, 3- to 6- membered non aromatic heterocyclic ring-Ci-Ce-alkyl, phenyl and phenyl-Ci-Ce-alkyl; wherein each group may optionally be substituted with one or more groups of R5b; R5a is selected from the group consisting of Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C3-C6-cycloalkyl-Ci-C6-alkyl, phenyl-Ci-Ce-alkyl, and 3- to 6- membered non aromatic heterocyclic ring; wherein said heterocyclic ring and phenyl-Ci-Ce-alkyl groups may optionally be substituted with one or more groups selected from Ci-Ce-alkyl, Ci-Ce-alkoxy or halogen; R5b is selected from the group consisting of halogen, cyano, oxo, hydroxy, Ci-Ce-alkyl, Ci-Ce-alkylthio, Ci-Ce-haloalkyl, Ci-Ce-hydroxyalkyl, -C(O)O-Ci-C6-alkyl and Ci-Ce-alkoxy; R5c is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C&-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and C3-Cs-cycloalkyl; R5dis independently selected from the group consisting of hydrogen and Ci-Ce-alkyl; R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-alkoxy, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and C3-C6-cycloalkyl; or R5 and R6 together with the nitrogen atom to which they are attached may form a 3 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-Ce-alkyl, Ci-Ce-alkoxy or Ci-Ce-haloalkyl; or NR5R6 represents -N=S(O)RxRXa, wherein Rx and RXa are independently selected from the group consisting of cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl, benzyl and 3- to 6- membered non aromatic heterocyclic ring; wherein said phenyl and benzyl rings are may optionally be substituted by one or more groups selected from halogen or Ci-Ce-alkyl; or Rx and RXa together with the sulfur atom to which they are attached may form a 3 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-Ce-alkyl, Ci-Ce-alkoxy or Ci-Ce-haloalkyl; Q represents partially saturated or unsaturated 5- to 12-membered heterocyclic ring which is substituted by one or more groups of R3 and optionally substituted by one group of R10; preferably Q is 6- to 12- membered heteroaryl ring which is substituted by one or more groups of R3 and optionally substituted by one group of R10; R3 is selected from the group consisting of halogen, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Ci-Ce-haloalkoxy, -S(O)0 2Ci-C3-haloalkyl and -S(0)o iR8=NR9; R8 is selected from the group consisting of C i-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and CVCVcycloalkyl; R9 is selected from the group consisting of hydrogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, CVCs-cycloalkyl and C(=O)R'; R10 is selected from hydrogen or Ci-Ce-alkyl; or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof. Embodiment-02: In an embodiment of the present invention, the compounds of formula (I) are represented by the compounds of formula (1-1), (1-2) or (1-3); (1-1) m=1or2                  (1-2)                         (1-3) wherein, m is 1 or 2; R2a is selected from hydrogen, halogen, cyano, Ci-Ce-alkyl, Cs-Ce-cycloalkyl, Ci-Ce-alkoxy, Ci-Ce-alkoxy-Cs-Ce-cycloalkyl, Ci-Ce-haloalkyl or Ci-Ce-haloalkoxy; R1, Q, R2, and RY are as defined above for the compounds of formula (I). Embodiment-03: According to embodiment 01, the compounds of formula (I) are represented by the compounds of formula (IA); (IA) wherein, R1, Q, R2, R2a and Y are as defined above for the compounds of formula (I). Embodiment-04: According to embodiments 01 or 03, the compounds of formula (I) are preferably represented by the compounds of formula (IA-1), (IA-1X) (IA-2) or (IA-2X); (IA-1)                        (IA-1X) (IA-2) (IA-2X) wherein, R1, Q, R2, R2a and Y are as defined above for the compounds of formula (I). Embodiment-05: According to embodiments 01 or 03, the compounds of formula (I) are preferably represented by the compounds of formula (IA-3), (IA-4) or (IA-5); (IA-3)                      (IA-4)                       (IA-5) 5         wherein, R1, Q, R2 and Y are as defined above for the compounds of formula (I). The following list provides definitions, including preferred definitions, for the substituents Q, Y, RY, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, Rla, R2a, Rx, RXa, R5a, R5b R5c and R5d with reference to the compounds of formula (I), (1-1 to 1-3), (IA), (IA-1), (IA-1X), (IA-2), (IA-2X), (IA-3), (IA-4) or (IA-5) (IB), (IBX), (IC), (ICX) of the present invention. For any one of these substituents, any of the definitions 10 given below may be combined with any definition of any other substituent given below or elsewhere in this document. Embodiment 06: According to any of the above embodiments, Q is selected from 6- to 12-membered heteroaryl ring which is substituted by one or more groups of R3 and optionally substituted by one group of R10; Preferably Q is selected from the group consisting of Qla to Qlp, wherein R10 is selected from 15 hydrogen or Ci-Ce-alkyl and R3 and n have the same meaning as described above: wherein, # denotes the point of attachment to pyrazolopyrimidine ring. Embodiment 07: According to embodiment 06, Q is selected from the group consisting of Qla-1 to Qlp-1, wherein R3is the same as defined above: Q1a-1 Q1i-1 Q1n-1 Q1k'1                 Q1 / -1 Q1m-1 Q1o-1 Embodiment 08: According to embodiments 01 or 06 or 07, R3 is selected from the group consisting of halogen, Ci-Ce-haloalkyl and Ci-Ce-haloalkoxy. Embodiment 09: According to any of the embodiments 01 or 06 to 08, preferably R3 is selected from the group consisting of halogen, Ci-Cs-haloalkyl and Ci-Cs-haloalkoxy. Embodiment 10: According to any of the embodiments 01 or 06 to 09, more preferably R3 is selected from fluoro, fluoromethyl group, a difluoromethyl group, a chlorofluoromethyl group, a dichlorofluoromethyl group, a chlorodifluoromethyl group, a trifluoromethyl group, a pentafluoropropoxy group, a trifluoropropoxy group or a pentafluoroethoxy group. Embodiment 11: According to any of the above embodiments, more preferably when Q is Qlg or Qlg-1, R3 is fluoro. Embodiment 12: According to any of the above embodiments, more preferably when Q is Q1Z to Qlp, Q1Z-1, Qlm-1, Qln-1, Qlo-1 or Qlp-1, R3 is a pentafluoropropoxy group. Embodiment 13: According to any of the above embodiments, more preferably when Q is Qla to Qlf, Qlh, Qli, Qlj, Qlk, Qla-1, Qlb-1, Qlc-1, Qld-1, Qle-1, Qle-2, Qlf-1, Qlf-2, Qlh-1 or Qli-1, Qlj-1, Qlk-1, R3 is a a trifluoromethyl group. Embodiment 14: According to embodiments 01 or 06, preferably R10 is Ci-Cs-alkyl, more preferably R10 methyl. Embodiment 15: According to embodiments 01 or 06, preferably n is 1. Embodiment 16: According to any of the above embodiments, R1 is Ci-Cs-alkyl. Embodiment 17: According to embodiment 16, preferably R1 is Ci-Cs-alkyl selected from methyl, ethyl, n-propyl or isopropyl. Embodiment 18: According to embodiments 16 or 17, more preferably R1 is ethyl. Embodiment 19: According to any of the above embodiments, preferably Y is oxygen (0). Embodiment 20: According to any of the above embodiments, preferably Y is NRY. Embodiment 21: According to embodiment 20, RYis selected from the group consisting of hydrogen, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, Cs-Cs-cycloalkyl, Cs-Cs-cycloalkyl-Ci-Cs-alkyl and -C(O)Rla. Embodiment 22: According to embodiments 20 or 21, RYis selected from the group consisting of hydrogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, Cs-Cs-cycloalkyl, Cs-Cs-cycloalkyl-Ci-Cs-alkyl and -C(O)Rla. Embodiment 23: According to embodiments 20 or 21 or 22, preferably RYis selected from the group consisting of hydrogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl and -C(O)Rla. Embodiment 24: According to embodiments 21 or 22 or 23, Rla is selected from the group consisting of Ci-C4-alkyl, Ci-C4-haloalkyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Cs-alkyl. Embodiment 25: According to embodiments 21 or 22 or 23 or 24, preferably Rla is selected from the group consisting of Ci-C4-alkyl, Ci-C4-haloalkyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Cs-alkyl. Embodiment 26: According to embodiments 21 or 22 or 23 or 24 or 25, more preferably Rla is selected from Ci-Cs-alkyl or Ci-Cs-haloalkyl. Embodiment 27: According to any of the above embodiments, R2 is C(=W)R7; wherein W is selected from oxygen (0) or sulfur (S). Embodiment 28: According to embodiments 01 or 27, preferably W is oxygen (0). Embodiment 29: According to embodiments 01 or 27 or 28, preferably R7 is OR4. Embodiment 30: According to embodiments 01 or 27 or 28, preferably R7 is NR5R6. Embodiment 31: According to embodiments 01 or 29, R4 is selected from the group consisting of hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl and C3-C6-cycloalkyl. Embodiment 32: According to embodiments 01 or 29 or 31, R4 is selected from hydrogen or C1-C4-alkyl. Embodiment 33: According to embodiments 01 or 30, R5 is selected from the group consisting of hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, OR5a, NR5cR5d, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-Ci-C4-alkyl, -C(O)OR5d, Ci-C3-alkyl-C(O)OR5d, Ci-C3-alkyl-C(O)N(R5d)2, 4- to 6- membered non aromatic heterocyclic ring, 4- to 6- membered non aromatic heterocyclic ring-Ci-C4-alkyl, phenyl and phenyl-Ci-C4-alkyl; wherein each group may optionally be substituted with one or more groups of R5b. Embodiment 34: According to embodiments 01 or 33, RSa is selected from the group consisting of Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C3-C6-cycloalkyl-Ci-C4-alkyl, phenyl-Ci-C4-alkyl, and 3- to 6- membered non aromatic heterocyclic ring; wherein said heterocyclic ring and phenyl-Ci-C4-alkyl groups may optionally be substituted with one or more groups selected from Ci-C4-alkyl, Ci-C4-alkoxy or halogen. Embodiment 35: According to embodiments 01 or 33 or 34, R5a is selected from the group consisting of Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, Cs-Ce-cycloalkyl-Ci-Cs-alkyl, phenyl Ci-Cs-alkyl, and 5- to 6- membered non aromatic heterocyclic ring; wherein said heterocyclic ring and phenyl-Ci-Cs-alkyl groups may optionally be substituted with one or more groups selected from C1-C3-alkyl, Ci-Cs-alkoxy or halogen. Embodiment 36: According to embodiments 01 or 33, R5b is selected from the group consisting of halogen, cyano, oxo, hydroxy, Ci-C4-alkyl, Ci-C4-alkylthio, Ci-C4-haloalkyl, Ci-C4-hydroxyalkyl, -C(O)O-Ci-C4-alkyl and Ci-C4-alkoxy. Embodiment 37: According to embodiments 01 or 33, R5c is selected from the group consisting of hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl and C3-C6-cycloalkyl. Embodiment 38: According to embodiments 01 or 33 or 37, R5c is selected from hydrogen or C1-C4-alkyl. Embodiment 39: According to embodiments 01 or 33, R5d is selected hydrogen or Ci-C4-alkyl. Embodiment 40: According to embodiments 01 or 30, R6 is selected from the group consisting of hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-alkoxy, Ci-C4-haloalkyl, C2-C4-haloalkenyl and CVCe-cycloalkyl. Embodiment 41: According to embodiments 01 or 30 or 40, R6 is selected from the group consisting of hydrogen, Ci-Cs-alkyl, Ci-Cs-alkoxy, Ci-Cs-haloalkyl and CVCe-cycloalkyl. Embodiment 42: According to embodiments 01 or 30 or 40 or 41, R6 is selected from the group consisting of hydrogen, Ci-Cs-alkyl and Ci-Cs-alkoxy. Embodiment 43: According to embodiments 01 or 30, NR5R6 represents -N=S(O)RxRXa, wherein Rx and RXa are independently selected from the group consisting of cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, phenyl, benzyl and 3- to 6- membered non aromatic heterocyclic ring; wherein said phenyl and benzyl rings are may optionally be substituted by one or more groups selected from halogen or Ci-C4-alkyl; or Rx and RXa together with the sulfur atom to which they are attached may form a 3 - to 6-membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-Ce-alkyl, Ci-Ce-alkoxy or Ci-Ce-haloalkyl. Embodiment 44: According to embodiments 01 or 30 or 43, NR5R6 represents -N=S(O)RxRXa, wherein Rx and RXa are independently selected from cyano, Ci-Cs-alkyl, phenyl or benzyl; wherein said phenyl and benzyl rings are may optionally be substituted by one or more groups selected from halogen or Ci-Cs-alkyl; or Rx and RXa together with the sulfur atom to which they are attached may form a 5 - to 6-membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2. Embodiment 45: According to embodiments 01 or 30, R5andR6 together with the nitrogen atom to which they are attached may form a 3- to 6-membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl. Embodiment 46: According to embodiments 01 or 30 or 45, R5 and R6 together with the nitrogen atom to which they are attached may form a 3- to 6-membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-Cs-alkyl, Ci-Cs-alkoxy or Ci-Cs-haloalkyl. Embodiment 47: According to any of the above embodiments, R2a is selected from the group consisting of halogen, cyano, Ci-C4-alkyl, CVCe-cycloalkyl, Ci-C4-alkoxy, Ci-C4-alkoxy-C3-C6-cycloalkyl, Ci-C4-haloalkyl and Ci-C4-haloalkoxy. Embodiment 48: According to embodiment 47, R2a is selected from the group consisting of halogen, cyano, Ci-Cs-alkyl, Cs-Cs-cycloalkyl, Ci-Cs-alkoxy, Ci-Cs-alkoxy-Cs-Ce-cycloalkyl, Ci-Cs-haloalkyl and Ci-Cs-haloalkoxy. Embodiment 49: According to embodiments 47 or 48, R2a is selected from the group consisting of halogen, Ci-Cs-alkyl and Cs-Cs-cycloalkyl. Embodiment 50: According to embodiment 1, R8 is selected from the group consisting of Ci-Cs-alkyl, C2-C3-alkenyl, C2-C3-alkynyl, C i-CVhaloalkyl, C2-C3-haloalkenyl and Cs-Ce-cycloalkyl. Embodiment 51: According to embodiment 1, R9 is selected from the group consisting of hydrogen, cyano, Ci-Cs-alkyl, C2-C3-alkenyl, C2-C3-alkynyl, Ci-CVhaloalkyl, C2-C3-haloalkenyl, C3-C6-cycloalkyl and C(=O)R'. Embodiment 52: According to this embodiment, for compounds of formula (I) or (IA) or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof; values of each group are as follows: wherein, R1 is Ci-Cs-alkyl; Y is selected from oxygen (0) or NRY; RYis selected from the group consisting of hydrogen, cyano, Ci-Cs-alkyl, Ci-CVhaloalkyl, C2-C4-haloalkenyl, Cs-Cs-cycloalkyl, Cs-Cs-cycloalkyl-Ci-Cs-alkyl and -C(O)Rla; Rla is selected from the group consisting of Ci-C4-alkyl, Ci-C4-haloalkyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Cs-alkyl; R2 is C(=W)R7; wherein W is oxygen (O); R7 is selected from the group consisting of OR4 and NR5R6; R2a is selected from the group consisting of halogen, cyano, Ci-C3-alkyl, C3-C6-cycloalkyl; R4 is selected from hydrogen or Ci-C4-alkyl; R5 is selected from the group consisting of hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, OR5a, NR5cR5d, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-Ci-C4-alkyl, -C(O)OR5d, Ci-C3-alkyl-C(O)OR5d, Ci-C3-alkyl-C(O)N(R5d)2, 4- to 6- membered non aromatic heterocyclic ring, 4- to 6membered non aromatic heterocyclic ring-Ci-C4-alkyl, phenyl and phenyl-Ci-C4-alkyl; wherein each group may optionally be substituted with one or more groups of R5b; R5a is selected from the group consisting of Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl-Ci-C3-alkyl, phenyl-Ci-C3-alkyl, and 5- to 6- membered non aromatic heterocyclic ring; wherein said heterocyclic ring and phenyl-Ci-C3-alkyl groups may optionally be substituted with one or more groups selected from Ci-C3-alkyl, Ci-C3-alkoxy or halogen; R5b is selected from the group consisting of halogen, cyano, oxo, hydroxy, Ci-C4-alkyl, C1-C4-alkylthio, Ci-C4-haloalkyl, Ci-C4-hydroxyalkyl, -C(O)O-Ci-C4-alkyl and Ci-C4-alkoxy; R5c is selected from hydrogen or Ci-C4-alkyl; R5dis independently selected from hydrogen or Ci-C4-alkyl; R6 is selected from the group consisting of hydrogen, Ci-C3-alkyl and Ci-C3-alkoxy; or R5 and R6 together with the nitrogen atom to which they are attached may form a 3 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-C3-alkyl, Ci-C3-alkoxy or Ci-C3-haloalkyl; or NR5R6 represents -N=S(O)RxRXa, wherein Rx and RXa are independently selected from cyano, Ci-C3-alkyl, phenyl or benzyl; wherein said phenyl and benzyl rings are may optionally be substituted by one or more groups selected from halogen or Ci-C3-alkyl; or Rx and RXa together with the sulfur atom to which they are attached may form a 5 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; Q is selected from the group consisting of QI a to Q Ip; wherein, # denotes the point of attachment to the pyrazolopyrimidine ring; R3 is selected from halogen, Ci-Cs-haloalkyl or Ci-Cs-haloalkoxy; R10 is Ci-C3-alkyl; 5            "n" is an integer ranging from 1 to 2. Embodiment 53: According to any of the above embodiments, Q is preferably selected from embodiment 06; wherein R3 is fluoro for Qlg-1 and for other Q, R3is selected from Ci-Cs-haloalkyl or Ci-Cs-haloalkoxy. Embodiment 54: According to this embodiment, the compounds of formula (I) or (IA) are preferably 10 represented by the compounds of formula (IB) or (IBX); (IB)                                 «BX) wherein, Q, R1, RY and R7 are as defined for the compounds of formula (I) or as defined in any of the above embodiments. Embodiment 55: According to this embodiment, the compounds of formula (I) or (IA) are preferably 15 represented by the compounds of formula (IC) or (ICX); (IC) wherein, Q, R1, RY, R5 and R6 are as defined for the compounds of formula (I) or as defined in any of the above embodiments. Embodiment 56: According to this embodiment, the present invention provides the compounds of formula (Z); R1 (Z) wherein, R1, Q, R2 and R2a are as defined above for the compounds of formula (I) or as defined in any of the above embodiments. Embodiment 57: According to this embodiment, the present invention provides the compounds of formula (A); (A) wherein, R1 and Q are as defined above for the compounds of formula (I) or as defined in any of the above embodiments with the proviso that 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one, 2-(ethylthio)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l ,5-a]pyrimidin-7(4H)-one, and 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one are excluded from the definition of compound of formula (A). Embodiment 58: According to this embodiment, the present invention provides the compounds of formula (B); (B) wherein, Q is as defined above for the compounds of formula (I) or as defined in any of the above embodiments with the proviso that 3-(ethylthio)-4-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)-lH-pyrazol-5-amine, and 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-5-amine are excluded from the definition of compound of formula (B). Embodiment-59: According to this embodiment, the compounds of formula (Z), (A) and (B) are intermediates for preparing the compounds of formula (I). Embodiment-60: According to a preferred embodiment of the present invention, the compound of formula (I) of the present invention disclosed in Table-A are selected from ethyl 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxylate; 2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(2,2-difluoroethyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid; N-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyclopropylmethyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(prop-2-yn-l-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isobutyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (3,3-difluoroazetidin-l-yl)(2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7-yl)methanone; 2-(ethylsulfonyl)-N,N-dimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;               N-allyl-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,3,3- trifluoropropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2,2,3,3,3-pentafluoropropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7-yl)(3- fluoroazetidin-l-yl)methanone; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(l-methylcyclopropyl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           N-(cyanomethyl)-2- (ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-phenylpyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l-cyanocyclopropyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;         2-(ethylsulfonyl)-N-methyl-3-(6-(trifluoromethyl)imidazo[l,2- a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(6-(2,2,3,3,3- pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N,N-dimethyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7-yl)(morpholino)methanone; 2-(ethylsulfonyl)-N-isopropyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide;         2-(ethylsulfonyl)-N,N-dimethyl-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2-methylcyclopropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(l,l,l- trifluoropropan-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide; N-cyclobutyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-propylpyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methyl-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; ethyl 2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate;         2-(ethylsulfonyl)-N,N-dimethyl-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N,N-dimethyl-3-(7-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butyl)-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy )pyrazin- 2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l,l-dioxidothietan-3-yl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;               N-(cyclopropylmethyl)-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;              N-ethyl-2- (ethylsulfonyl)-N-methyl-3-(5-(2,2,3,3,3-pentafluoropropoxy )pyrazin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                 N- (cyclopropylmethyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l, 5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy )pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid;    N,N-diethyl-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy )pyrazin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (3,3-difluoroazetidin-l-yl)(2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidin-7-yl)methanone;             2- (ethylsulfonyl)-N-(3-methylbutan-2-yl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyr azin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(oxetan-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;            2- (ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(thietan-3- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l, 5-a]pyrazin-3- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           N,N-diethyl-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-benzyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid; (2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidin-7-yl)(3-fluoroazetidin-l-yl)methanone; N-(cyclopropylmethyl)-2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2- (ethylsulfonyl)-N-methyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)-N-(prop-2-yn-l-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N-methyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(2,2-difluoroethyl)-2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)-N-(thietan-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (3,3-difluoroazetidin-l-yl)(2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidin-7-yl)methanone; N,N-diethyl-2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;        N-cyclobutyl-2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy )pyridazin-3- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;          2-(ethylsulfonyl)-N-neopentyl-3-(6-(2,2,3,3,3- pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyanomethyl)-2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;             N-ethyl-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5- a]pyrimidine-7-carboxylate;              2-(ethylsulfonyl)-N-(2-methylcyclopropyl)-3-(6-(2,2,3,3,3- pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                N-(l- cyanocyclopropyl)-2-(ethylsulfonyl)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(prop-2-yn-l-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(2,2,3,3,3-pentafluoropropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-propylpyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N,N-diethyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyanomethyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;                            2-(ethylsulfonyl)-N-methyl-3-(8-(2,2,3,3,3- pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5- a]pyrimidine-7-carboxylic acid; (3,3-difluoroazetidin-l-yl)(2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidin-7-yl)methanone; 2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(8-(2,2,3,3,3- pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)-N-(prop-2-yn-l-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;        (2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l, 5-a]pyrazin-3- yl)pyrazolo[ 1,5-a]pyrimidin-7-yl)(3-fluoroazetidin-1 -yl)methanone; N-( 1 -cyanocyclopropyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;                     N-(cyanomethyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3- pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2- (ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7-carboxylate;                3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7- carboxylic acid; 3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l-cyanocyclopropyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(l,l,l-trifluoropropan-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N,N-dimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                            N-(l-cyclopropylethyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3- pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-allyl-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;                          2-(ethylsulfonyl)-N-isopropyl-3-(8-(2,2,3,3,3- pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l, 5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyclobutylmethyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)-N-(2,2,3,3,3- pentafluoropropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-N-ethyl-2-(ethylsulfonyl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;          3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2- d]imidazol-6-yl)-2-(ethylsulfonyl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-N-(2,2-difluoroethyl)-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;            3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)-N-(2,2,3,3,3- pentafluoropropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)-N-(thietan-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                       N-(cyanomethyl)-3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l-cyanocyclopropyl)-3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)-N- methoxypyrazolo[l,5-a]pyrimidine-7-carboxamide;                  (3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidin-7-yl)(3,3-difluoroazetidin-l-yl)methanone; N-ethoxy-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-N-methyl-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;         2-(ethylsulfonyl)-N-isobutyl-3-(8- (2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(3,3-difluorocyclobutyl)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(l-methylcyclopropyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l, 5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l,5-a]pyrazin-3-yl)-N-(l,l,l-trifluoropropan-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(allyloxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(benzyloxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butoxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butoxy)-2-(ethylsulfonyl)-3-(8-(2,2,3,3,3-pentafluoropropoxy)imidazo[l, 5-a]pyrazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                          3-(2,2-difluoro-5-methyl-5H- [l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)-N-methylpyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isopropoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-2-(ethylsulfonyl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;          3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2- d]imidazol-6-yl)-2-(ethylsulfonyl)-N-(prop-2-yn-l-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2-d]imidazol-6-yl)-N-ethoxy-2- (ethylsulfonyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-((tetrahydro-2H-pyran-2-yl)oxy)pyrazolo[l,5- a]pyrimidine-7-carboxamide;          3-(2,2-difluoro-5-methyl-5H-[l,3]dioxolo[4',5':4,5]benzo[l,2- d]imidazol-6-yl)-2-(ethylsulfonyl)-N-(l-methylcyclopropyl)pyrazolo[l,5-a]pyrimidine-7- carboxamide; 2-(ethylsulfonyl)-N-isopropoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(allyloxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butoxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-((4-chlorobenzyl)oxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-((3-chlorobenzyl)oxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-((2-chlorobenzyl)oxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-((4- methylbenzyl)oxy)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-((3-methylbenzyl)oxy)pyr azolof 1,5- a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-((2-methylbenzyl)oxy)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-((4-fluorobenzyl)oxy)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-((3-fluorobenzyl)oxy)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-((2-fluorobenzyl)oxy)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(benzyloxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-((3-chlorobenzyl)oxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-((3-methoxybenzyl)oxy)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-((4-methoxybenzyl)oxy)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-phenethoxypyrazolo[l,5-a]pyrimidine-7- carboxamide; 2-(ethylsulfonimidoyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; methyl 2-(N-(2,2-difluoroacetyl)ethylsulfonimidoyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxylate; methyl 3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-2-(N-(2,2,2- trifluoroacetyl)ethylsulfonimidoyl)pyrazolo[l ,5-a]pyrimidine-7-carboxylate;      methyl 2-(N- acetylethylsulfonimidoyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate; 2-(ethylsulfonyl)-N-(2-methoxyethyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(2-(ethylthio)ethyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(3-methoxypropyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2- (methylthio)ethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(2-hydroxy-2-methylpropyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;                N-(2,2-difluoropropyl)-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(l-methoxypropan-2-yl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(2-hydroxypropyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(oxetan-2-ylmethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (S)-N-(2-ethyl-3-oxoisoxazolidin-4-yl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (S)-N-(2-ethyl-3-oxoisoxazolidin-4-yl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;             N-ethoxy-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylate;           N-(2- cyanopropan-2-yl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(dimethyl(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide; 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylic acid; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(2-(trifluoromethyl)cyclopropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide;          N-(cyanomethyl)-2- (ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide;            N- (ethyl(methyl)(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; methyl (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carbonyl)glycinate;               N-(l-cyanocyclopropyl)-2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'- bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; N-(2-cyanoethyl)-2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; methyl (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbonyl)glycinate; 2-(ethylsulfonyl)-N-(2,2,2-trifluoroethyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; N-(allyloxy)-2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; ethyl (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbonyl)glycinate;               2-(ethylsulfonyl)-N-isopropoxy-2'- (trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(2-(methylamino)-2-oxoethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; methyl    1 -(2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamido)cyclopropane-l-carboxylate; N-(2-(tert-butylamino)-2-oxoethyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 2-(ethylsulfonyl)-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate; 2-(ethylsulfonyl)-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid; 2-(ethylsulfonyl)-N-methoxy-3-(7-(trifluoromethyl)-[l ,2,4]triazolo[l ,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonimidoyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(N-cyanoethylsulfonimidoyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(2-(dimethylamino)-2-oxoethyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                          2-(ethylsulfonyl)-N-methoxy-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;            N-ethoxy-2- (ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N-methyl-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                      2-(ethylsulfonyl)-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)-N-(prop-2-yn-l-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate;                            N-(allyloxy)-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)-N-(l-(trifluoromethyl)cyclopropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                        2-(ethylsulfonyl)-N-isopropoxy-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate;          2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           N-(tert-butyl)-2- (ethylsulfonyl)-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyclopropylmethoxy)-2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isobutoxy-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; (2-(ethylsulfonyl)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidin-7-yl)(3-isopropoxyazetidin-l-yl)methanone;                            2-(ethylsulfonyl)-N-(3-methyloxetan-3-yl)-3-(5-(2,2,3,3,3- pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyanomethyl)-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N'-(tert-butyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbohydrazide; N-(2-cyanopropan-2-yl)-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;               2-(ethylsulfonyl)-3-(6-(trifluoromethyl)- [l,2,4]triazolo[l,5-a]pyridin-2-yl)-N-(l-(trifluoromethyl)cyclopropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(l,l,l-trifluoro-2-methylpropan-2-yl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l-cyclopropylethyl)-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N-methyl-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;             2-(ethylsulfonyl)-N-(2,2,3,3,3- pentafluoropropyl)-3-(6-(trifluoromethyl)-[l, 2,4]triazolo[l,5-a]pyridin-2-yl)pyr azolof 1,5-a]pyrimidine-7-carboxamide; N'-(tert-butyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbohydrazide; N-(2-cyanoethyl)-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyclopropylmethoxy)-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2,2,2-trifluoroethoxy)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(2,2,2-trifluoroethoxy)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl 7-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate; ethyl 7-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate; ethyl 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate;          7-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l ,5-a]pyrimidine-6-carboxylic acid; N-(tert-butoxy)-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;                N-cyclopropyl-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)- [l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid; N-cyclopropyl-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)-N-(l-(trifluoromethyl)cyclopropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;                N-cyclopropyl-2-(ethylsulfonyl)-3-(7-(trifluoromethyl)- [l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isopropoxy-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isobutoxy-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; ethyl 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate; ethyl 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate;         2- (ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid; 2-(ethylsulfonyl)-N,N-dimethyl-3-(7-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(dimethyl(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(4-oxido-l,416-oxathian-4-ylidene)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-N-(methyl(oxo)(phenyl)-16-sulfaneylidene)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(benzyl(methyl)(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;             2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-N-isopropoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; N-ethyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; N-(cyanomethyl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5- a]pyrimidine-6-carboxamide;                N-(cyclopropylmethyl)-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N- neopentylpyrazolo[l,5-a]pyrimidine-6-carboxamide;                2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(l-methylcyclopropyl)pyrazolo[l,5- a]pyrimidine-6-carboxamide;              N-(l-cyanocyclopropyl)-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide;           2-(ethylsulfonyl)-N-methoxy-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-N,N-dimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-N-isopropoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide;           N,N-diethyl-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; N-ethyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-6-carboxamide; N-ethoxy-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide;          N-(cyanomethyl)-2- (ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-(l-methylcyclopropyl)pyrazolo[l,5-a]pyrimidine-6-carboxamide; 2-(ethylsulfonyl)-N-(methyl(oxo)(p-tolyl)-16-sulfaneylidene)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-neopentylpyrazolo[l,5-a]pyrimidine-6- carboxamide;             N-(ethyl(methyl)(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(diethyl(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; isobutyl (2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbonyl)(methoxy)carbamate; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-neopentylpyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-N-methoxy-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-b]pyridin-2-yl)pyrazolo[l ,5-a]pyrimidine-7-carboxamide;      isobutyl ethoxy(2- (ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbonyl)carbamate; ethyl ethoxy(2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbonyl)carbamate;             N-(2,2- difluoropropyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N,N,6-trimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyanomethyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(l-methylcyclopropyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N,6-dimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine- 7-carboxamide; N-(dimethyl(oxo)-16-sulfaneylidene)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;         2-(ethylsulfonyl)-N,6-dimethyl-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; methyl 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate; 2-(ethylsulfonimidoyl)-N-methoxy-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; isobutyl (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carbonyl)(methoxy)carbamate; ethyl (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carbonyl)(methoxy)carbamate; methyl (2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carbonyl)(methoxy)carbamate;          N- (cyclopropylmethoxy)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonimidoyl)-N-methoxy-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isopropyl-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl- 6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N- propylpyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(tert-butyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l- cyanocyclopropyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyclopropylmethyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-N-neopentylpyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide;         2-(ethylsulfonyl)-N-isopropoxy-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-methoxy-N,6-dimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N,N,6-trimethyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(2-cyanopropan-2-yl)-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(l-(hydroxymethyl)cyclopropyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N- propylpyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isopropoxy-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; ethyl              l-(2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamido)cyclopropane-l-carboxylate;         N-cyclopropyl-2- (ethylsulfonimidoyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;              2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-N-(2,2,2-trifluoroethyl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethyl-2-(ethylsulfonimidoyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isopropyl-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l-cyclopropylethyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-isobutyl-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5- a]pyrimidine-7-carboxamide;              N-(tert-butoxy)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(l-cyanocyclopropyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-((l-cyanocyclopropyl)methyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonimidoyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-(cyclopropylmethyl)-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; 2-(ethylsulfonyl)-N-(2-methoxyethyl)-6- methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide;           2-(ethylsulfonyl)-N-methoxy-5-methyl-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-5-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-ethoxy-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-5-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-5-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; N-cyclopropyl-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-5-carboxamide; N-ethyl-2-(ethylsulfonyl)-3-(2-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyrimidin-5-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide; and 2-(ethylsulfonyl)-N-methyl-3-(2-(trifluoromethyl)imidazo[l,2-a]pyrimidin-7-yl)pyrazolo[l,5-a] pyrimidine-7-carboxamide. The compounds of the present invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and / or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and / or selectively prepare said stereoisomers. The compounds of the present invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. An anion part of the salt in case the compound of formula (I) is a cationic or capable of forming a cation can be inorganic or organic. Alternatively, a cation part of the salt in case the compound of formula (I) is an anionic or capable of forming an anion can be inorganic or organic. Examples of inorganic anion parts of the salt include but are not limited to chloride, bromide, iodide, fluoride, sulfate, phosphate, nitrate, nitrite, hydrogen carbonates and hydrogen sulfate. Examples of organic anion part of the salt include but are not limited to formate, alkanoates, carbonates, acetates, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate, lactate, succinate, malate, citrates, benzoates, cinnamates, oxalates, alkylsulphates, alkylsulphonates, arylsulphonates aryldisulphonates, alkylphosphonates, arylphosphonates, aryldiphosphonates, p-toluenesulphonate, and salicylate. Examples of inorganic cation part of the salt include but are not limited to alkali and alkaline earth metals. Examples of organic cation part of the salt include but are not limited to pyridine, methyl amine, imidazole, benzimidazole, phosphazene, tetramethyl ammonium, tetrabutylammonium, choline and trimethylamine. Metal ions in metal complexes of the compound of formula (I) are especially the ions of the elements of the second main group, especially calcium and magnesium, of the third and fourth main group, especially aluminium, tin and lead, and also of the first to eighth transition groups, especially chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to the metal ions of the elements of the fourth period and the first to eighth transition groups. Here, the metals can be present in the various valencies that they can assume. In one embodiment, the present invention provides a compound of formula (I), salts, metal complexes, stereoisomers, or N-oxides thereof and its composition with the excipient, inert carrier or any other essential ingredient such as surfactants, additives, solid diluents and liquid diluents. Salts of the compounds of the formula (I) are preferably veterinary and / or agriculturally acceptable salts, preferably agriculturally acceptable salts. They can be formed in a customary manner, e.g. by reacting the compound with an acid of the anion in question if the compound of formula (I) has a basic functionality. The term "N-oxide" includes any compound of formula (I) which has at least one tertiary nitrogen atom that is oxidized to an N-oxide moiety. The compounds of formula (I), (including all stereoisomers, N-oxides, and salts thereof), typically exist in more than one form, and formula (I) thus includes all crystalline and non-crystalline forms of the compounds that formula (I) represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and / or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by formula (I) can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by formula (I). Preparation and isolation of a particular polymorph of a compound represented by formula (I) can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. In an embodiment, the present invention provides a process for preparing the compound of formula (I) or salts thereof. The compound of the present invention as defined by formula (I) may be prepared, in a known manner, in a variety of ways as described in the following schemes, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I). The compound of formula (I) can be prepared according to schemes: 1-12 / chemistry examples described herein. The process for preparing a compound of formula (Z), more specifically a compound of formula (Za) comprises reacting a compound of formula (2a), with a compound of formula (3), wherein M is NR10 to obtain the compound of formula (Za). The process is summarized in scheme 1: Scheme: 1 (Za) wherein, R1, R2, R3 and n have the meanings as described above and A'= M, A4 and As= N or C. The compound of formula (3) is either commercially available or can be prepared by using the methods known or analogously described in WO200665703, WO2009131237, WO2010125985, WO2011043404, WO2011040629, WO2012086848, WO2013018928 and WO2015000715. In scheme 1, the carboxylic acid group in the compound of formula (2a) can be converted to a more reactive functional group, such as an acyl halide, mixed anhydride, acyl azide, A-Acylbenzotriazoles, active esters, or via an in situ activation by peptide coupling reagents such as bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-CI); dicyclohexyl carbodiimide (DCC) or l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), followed by amide bond formation with compound of formula (3) in solvents such as dichloromethane, dichloroethane, A,A-dimethylacetamide, tetrahydrofuran, acetonitrile or a mixture thereof to obtain a compound of formula (4). Organic non-nucleophilic bases such as triethyl amine, ethyldiisopropyl amine, pyridine, A-methyl pyrrolidine, 1,8-diazabicyclo[5.4.0]undec-7-ene may be used. The reaction can be conducted at a temperature in the range ofO°C to 150 °C. The compound of formula (4) can be converted to a compound of formula (Za) by dehydration, following conventional or under microwave conditions, in the presence of an acid catalyst, for example, methane sulfonic acid, or para-toluene sulfonic acid, in an inert solvent such as A-methyl pyrrolidine at a temperature in the range of 25 °C to 185 °C. Such processes have been described previously in WO2009131237,   WO2010125985,   WO2011043404,   WO2011040629,   WO2012086848, WO2013018928, WO2015000715 and WO2015121136. Alternatively, the compound of formula (4) can be converted to a compound of formula (Za) wherein M is oxygen under Mitsunobu reaction conditions well known to those skilled in the art using diisopropyl azodicarboxylate, triphenyl phosphine in an inert solvent such as diethyl ether, tetrahydrofuran at a temperature in the range of 25 °C to 50 °C. This process is described previously in WO2009131237. The compound of formula (I) wherein Y=O or Y=NRY can be obtained by sulfoxidation / sulfoximination of the corresponding sulfide compound of formula (Za) by using the analogous procedure as described in Org. Lett., 1999, 1, 189-191; J. Am. Chem. Soc., 2006, 128, 60126013; Tetrahedron Lett. 2005, 46, 8007-8008 and WO2015071180A1. Scheme 2 provides a process for preparing a compound of formula (Zb): Scheme: 2 wherein, R1, R2, R3 and n have the meanings as described above and Ai= N or C. The carboxylic acid of formula (2a) can be converted to the Weinreb amide of formula (5) upon reaction with A, O-dimethylhydroxylamine by methods as described in WO201175643 and EP2671582. Subsequent treatment of the Weinreb amide of formula (5) with Grignard reagents of formula (R’CH2MgHal) according to the method described in Tetrahedron Letters 1981, 22, 3815 to obtain a compound of formula (6). Cyclization of the compound of formula (6) to obtain the compound of formula (Zb) using an amine of formula (7) can be effected in the presence of a Lewis acid, such as Indium (III) triflate or Zinc (II) iodide, in solvents such as 1,2-dichlorobenzene, chlorobenzene, in the presence of catalytic copper (II) salts, such as copper (II) acetate, under oxygen or air atmosphere. The reaction can be carried out at a temperature in the range of 100 °C to 180 °C. Such reaction has precedence in the literature, for example in (Adv. Synth. Catalysis, 2013, 355, 1741; J. Org.Chem, 2013, 78, 12494). Alternatively, the compound of formula (6) can be converted to a compound of formula (8) wherein X is a halogen (preferably chlorine or bromine) with a halogenating agent such as A-chloro succinimide, A-bromo succinimide, A-iodo succinimide, E, CuBr2, Br2 in acetic acid or PhNMe3+Br3, typically in a solvent such as methanol, acetonitrile, tetrahydrofuran, ethylacetate, chloroform or dichloromethane, or mixtures thereof, at a temperature in the range of 0 °C to 150 °C, preferably between 25 °C to 120 °C, optionally under microwave heating conditions. Such processes have been described previously, for example, in WO2016 / 071214. The compound of formula (Zb) can be obtained by condensing the compound of formula (8) with compounds of formula (7), in an inert solvent, for example, ethanol or acetonitrile, optionally in the presence of a suitable base, such as sodium, potassium or cesium carbonate, at a temperature in the range of 80 °C to 150 °C, optionally under microwave heating conditions. Such processes have been described previously, for example, in WO2003 / 031587. The compound of formula (7) is either commercially available or may be prepared by known methods to those skilled in the art. The compound of formula (I) wherein Y=O or Y=NRY can be obtained by sulfoxidation / sulfoximination of the corresponding sulfide compound of formula (Zb) by using the analogous procedure as described in Org. Lett., 1999, 1,189-191; J. Am. Chem. Soc., 2006, 128, 60126013; Tetrahedron Lett. 2005, 46, 8007-8008 and WO2015071180A1. Scheme 3 provides a process for preparing a compound of formula (Zc) and (Zd): Scheme: 3 wherein, Ai = N or C, R1, R2, R3 and n have the meanings as described above. The compound of formula (Zc) can be prepared by reacting a compound of formula (9) with a compound of formula (11), optionally in the presence of a suitable base and in an inert solvent. The compound of formula (Zd) can be prepared by reacting a compound of formula (10), in which Y is a halide ion or mesityl sulfonate with the compound of formula (11), optionally in the presence of a suitable base and in an inert solvent. The compound of formula (9) or (10) can be prepared via / V-amination by reacting the compound of formula (7)   (7) with O-mesitylenesulfonylhydroxylamine (MSH) as an amination reagent or one of its equivalent, as described for example in WO201334506. The compound of formula (I) wherein Y=O or Y=NRY can be obtained by sulfoxidation / sulfoximination of the corresponding sulfide compound of formula (Zc) or (Zd) by using the analogous procedure as described in Org. Lett., 1999, 1, 189-191; J. Am. Chem. Soc., 2006, 128, 6012-6013; Tetrahedron Lett. 2005, 46, 8007-8008 and WO2015071180A1. Schemes 4 to 11 provide processes for the preparation of pyrzolo pyrimidine. A process for the synthesis of a compound of formula (2aa-2ab) is depicted in scheme 4: Scheme: 4 Y = OR' or NR’R' R' = lower alkyl R" = lower alkyl / base liable protecting group (PG) wherein, R1 and R2 have the meanings as described above. The compound of formula (2aa) depicted in scheme-4 can be prepared from the pyrazole derivative of formula (12) using alken-one reagents of formula (13) under cyclocondensation conditions, in the presence of a solvent or an acid. Examples of the acids include acetic acid, sulfonic acid (e.g. PTSA), sulfuric acid, and hydrochloric acid which liberate the reactive functional group. Examples of the solvents include but are not limited to methanol, ethanol, isopropanol or ethylene glycol or the like. The reaction can be carried out at a temperature in the range of 0 °C to 150 °C. The preparation of the compound of formula (12) has been described in the literature such as Journal of Heterocyclic Chemistry 2016, 53, 1231. In a similar way, a compound of formula (2ab) depicted in scheme-4 can be prepared from the pyrazole derivative of formula (12) using protected 2-formyl-3-oxopropanoic acid of formula (15) in the presence of a solvent like ethanol, 2-propanol and in the presence of an acid such as acetic acid. The reaction can be carried out at a temperature in the range of 50 °C to 130 °C. The compound of formula (2aa) can be obtained through acid hydrolysis of the cyano functional group of the compound of formula (14). Examples of an acid include sulfuric acid or hydrochloric acid and the reaction can be carried out at a temperature in the range of 60 °C to 150 °C. A process for the synthesis of a compound of formula (20a-b) is depicted in the scheme 5a: Scheme: 5a P = CN (12) P = CO2R' (17) R' = lower alkyl Step 2 R1 S P = CN (20a) P = CO2R' (20b) X = any halogen P = CN (19a) P = CO2R' (19b) wherein, R1 has the meanings as described above The pyrazole derivative of formula (17 or 12) can undergo a cyclocondensation reaction when treated with a dielectrophilic compound of formula (18) or it’s protected / masked (e.g. aldehyde masked as a ketal) version to provide a compound of formula (19). The condensation can be carried out in a solvent and in the presence of an acid. Examples of an acids include but are not limited to acetic acid, sulfonic acid (e.g. PTSA), sulfuric acid or hydrochloric acid which liberate the reactive functional group. Examples of the solvents include but are not limited to methanol, ethanol, isopropanol or ethylene glycol or the like. The reaction can be carried out at a temperature in the range of 0 °C to 150 °C. The conversion of the compound of formula (19) to the compound of formula (20) can be carried out in a solvent, in the presence of a halogenating agent and in the presence or absence of a base. Examples of the solvent include but are not limited to acetonitrile, chloroform, tetrahydrofuran, 1,4-dioxane, toluene or A,A-dimethylformamide or the like. Examples of halogenating agents include but are not limited to phosphorus oxychloride, thionyl chloride, phosphorus pentachloride or oxalyl chloride or the like. Examples of the base include but are not limited to A,A-dimethylaniline, diisopropylethylamine or / V-methyl morpholine or the like. The reaction can be carried out at a temperature in the range of 50 °C to 200 °C. A process for the synthesis of a compound of formula (22a-b) is depicted in the scheme 5b: Scheme: 5b p             Step 5 P = CN (12) P = CO2R'(17) R' = lower alkyl wherein, R1 and X have the meanings as described above. The compound of formula (22) can be prepared by the cyclization of the pyrazole derivative of formula (17 or 12) with commercially available 2-halo-malonaldehydes of formula (21) under acid catalyzed conditions. Examples of an acids include but are not limited to acetic acid, sulfonic acid (e.g PTSA), sulfuric acid, and hydrochloric acid. Examples of the solvents include but are not limited to methanol, ethanol, isopropanol, ethyleneglycol or the like. The reaction can be carried out at a temperature in the range of0°C to 150 °C. A process for the synthesis of a compound of formula (26a-b) is depicted in the scheme 5c: Scheme: 5c P = CN (12) P = CO2R'(17) R' = lower alkyl Step 2 P = CN (25a) P = CO2R' (25b) X =halogen R' = R" = lower alkyl wherein, R1 and X have the meanings as described above. The pyrazole derivative of formula (17 or 12) can undergo a cyclocondensation with 1,3-dimethyluracil of formula (23) or alkoxyacrylate derivatives of formula (24) in the presence of a suitable base to obtain pyrimidin-5-one derivatives of formula (25). Examples of the suitable base include sodium ethoxide, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium carbonate, cesium carbonate or potassium phosphate or the like. Examples of the solvent include methanol, ethanol, isopropanol, ethyleneglycol, / V, / V-dimcthylacctamidc or A,A-dimethylformamide or the like. The reaction can be carried out at a temperature in the range of 50 °C to 150 °C. Such a reaction is well known in the literature, and also alternative reactions are well described in the literature, for example, J. Org. Chem 2007, 72, 1046; WO2018081417. Halogenation of a compound of formula (25) with phosphorous oxychloride or phosphorous oxybromide can provide a compound of formula (26). Scheme: 6 P = CN 20a / 22a / 26a P = CO2R' 20b / 22b / 26b R' = lower alkyl X =halogen P = CN 27a / 28a / 29a P = CO2R' 27b / 28b / 29b R" = alkyl or aryl Step 2 R1-S (2aa / 2ab / 2ac) wherein, R1 and X have the meanings as described above. Compounds of formula (27-29) can be prepared from the halide compounds of formula (20 / 22 / 26) by a palladium catalysed carbonylation reaction, in the presence of a suitable palladium catalyst, organic base and suitable alcohol solvent at elevated temperature under an atmosphere of CO. When R” is methyl or ethyl or n-butyl or tert-butyl in the compound of formula (27 / 28 / 29), the preferred reaction condition comprises reaction of the bromide of formula (20 / 22 / 26) under an atmosphere of CO, pressure ranges vary from 1 bar to 20 bar in the presence of a suitable palladium catalyst such as Pd(dppf)C12, PdC12(ACN)2, PdC12(PhCN)2 or Pd(OAc)2, using a catalyst such as triphenyl phosphine or diphenyl phosphino ferrocene or 1,3-diphenyl phosphino propane or 1,3-dicylcohexyl phosphino propane, in the presence of an organic base such as triethyl amine or diisopropyl ethyl amine or DBU, in a solvent such as MeOH or EtOH or nBuOH or tBuOH and at a temperature in the range of 80 °C to 130 °C. Such kind of transformations are precedent in the literature such as in Angew. Chem., Int. Ed. 2009, 48, 4114. Alternatively, when R” is phenyl or phenyl derivatives, compounds of formula (27 / 28 / 29) may be prepared from the halide compounds of formula (20 / 22 / 26) by a palladium catalyzed reaction with CO surrogates such phenyl formate or formate of any active phenyl derivatives such as 2,4,6-trichlorophenyl, in the presence of a suitable palladium catalyst such as Pd(OAc)2 with a phosphinebased ligand such as BINAP or XantPhos or XPHOS, in the presence of a base such as N,N-diethylethanamine or triethyl amine, in a solvent such as MeCN, toluene or xylene and at a temperature in the range of 80 to 130 °C. Such reactions are precedent in the literatures such as as in Org. Lett. 2012, 20, 5370; Angew. Chem., Int. Ed. 2004,43, 5580; Modem Carbonylation Methods', Kollar, L. Ed.; 2008, pp 93-114. Ester hydrolysis of formula (27-29) can be carried out selectively with respect to the group R’. Alkaline hydrolysis can be carried out using a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide or Bis(tributyltin) oxide or the like; in the solvent such as tetrahydrofuran, water, methanol, ethanol, toluene or a mixture thereof, to obtain the compounds of formula (2aa / 2ab / 2ac). Acidic hydrolysis can be carried out using an acid such as hydrochloric acid or acetic acid or trifluoro acetic acid, in the presence of a solvent such as dichloromethane, 1,2-dichlorethane, toluene, xylene or dioxane, at a temperature in the range of 0 to 100 °C to obtain the compound of formula (2aa / 2ab / 2ac). Scheme: 7 Step-1 (31) Step-2 (30) Step-3 & 4 (33a-c) Step-5 (Z-1) R" = alkyl and aryl X = halogen wherein, R1 and Q have the meanings as described above A process for the synthesis of a compound of formula (33a-c) and (Z-1) is depicted in the scheme-7. Organo sulfanylalkenes of formula (31) can be formed by reacting a cyano compound of formula (30) with CS2 in the presence of a base such as alkali metal carbonates, alkali metal hydrides, lithium, sodium or potassium hexamethyl disilazane, sodium or potassium hydroxide, in a suitable solvent such as tetrahydrofuran, acetonitrile or A,A-dimethylfromamide, at a temperature in the range of 0 to 50 °C. The compound of formula (31) can be cyclized to an aminopyrazole derivative of formula (32) using hydrazine. Such method is described in the literature, for example, Russian Journal of Organic Chemistry, 2014, 50(3), 412-421. The aminopyrazole derivative can be converted to the compound of formula (33a-c) using the methods described in scheme 5a (Steps 1&2) or scheme 5b (Step 2 or Step 5) or scheme 5c (Steps 1&2). The compound of formula (Z-1) can be prepared by reacting the compound of formula (33a-c) using the conditions described in step-1 of scheme-6. Ester hydrolysis of formula (Z-1) can be carried out selectively with respect to the group R”. Alkaline hydrolysis can be carried out using a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide or Bis(tributyltin) oxide or the like; in a suitable solvent such as tetrahydrofuran, water, methanol, ethanol or toluene or mixtures thereof, to obtain the corresponding carboxylic acids. Acidic hydrolysis can be carried out using an acid such as hydrochloric acid, acetic acid or trifluoro acetic acid, in the presence of a suitable solvent such as dichloromethane, 1,2-dichlorethane, toluene, xylene or dioxane, at a temperature in the range of 0 to 100 °C to obtain the corresponding carboxylic acids. Scheme: 8 (32) O O (34) (Z-2) R" = Lower alkyl The compound of formula (Z-2) can be prepared according to scheme-8 by cyclocondensing the pyrazole derivative of formula (32) and keto ester compound of formula (34) with dimethylformamide -dimethylacetal or triethyl orthoformate or the like, in the presence of a suitable solvent such as ethanol or acetic acid, at a temperature in the range of 60 to 150 °C. Scheme: 9 0 (35) R" = Lower alkyl R” = Lower alkyl The compound of formula (32) can be condensed with pyruvates of formula (35) according to scheme-9, in the presence of a suitable solvent such as ethanol or methanol, at a temperature in the range of 60 to 150 °C to provide a separable mixture of regio isomers (Z-3) and (Z-4). Alternatively, the same product can be prepared by carrying the reaction in the presence of an acid such as hydrochloric acid or acetic acid at a temperature in the range of 60 to 150 °C. Scheme: 10 (36) G = -NMe2 or OEt R1'S^N CO2R" QX(N-<R2a N= / (Z-1';R2a = H)    R" = Lower alkyl Z-2': R2a = other than H The compound of formula (32) can be condensed with olefines of formula (36) according to scheme- 10, in the presence of a suitable solvent such as ethanol or methanol, at a temperature in the range of 60 to 150 °C to provide compounds of formula (Z-T) or (Z-2’). Alternatively, the same product can be prepared by carrying the reaction in the presence of an acid such as hydrochloric acid or acetic acid at a temperature in the range of 60 to 150 °C. Scheme: 11 (Z) (1-1) m=1or2 wherein, Q, R1, R2 and R2a have the meanings as described above. The compound of formula (1-1) wherein m=l (sulfoxide) and / or m=2 (sulfone), can be obtained by the oxidation of the corresponding sulfide compound of formula (Z) while applying appropriate oxidizing agents and conditions well known to those skilled in the art. Oxidizing agents such as m-chloroperoxybenozic acid (mCPBA), hydrogenperoxide / glacial acetic acid, hydrogenperoxide / trifluroacetic acid, hydrogenperoxide / potassium permanganate, hydrogenperoxide / p-toluenesuflonylimidazole, urea hydrogen peroxide / trifluoroacetic acid, oxone, sodium periodate, sodium hypochlorite or other organic peracids or the like can be used for this, at a temperature in the range of 0 to 100 °C. Examples of the solvent used in this reaction include aliphatic halogenated hydrocarbons such as dichloromethane, chloroform, alcohols such as methanol or ethanol or the mixtures thereof. Step-1 Scheme: 12 (1-2) Step-2 (1-3) wherein, Q, R1 R2, R2a and RY have the meanings as described above and R2a can be absent also. The compound of formula (1-2) wherein RY = H, can be obtained by reacting the compound of formula (Z) with a suitable nitrogen source, such as, for example, ammonia, ammonium carbamate or ammonium acetate, in the presence of hypervalent iodine reagents, such as diacetoxyiodobenzene PhI(OAc)2, in a suitable solvent such as toluene, acetonitrile or alcohols (preferably methanol, 2,2,2-trifluoromethanol or 2,2,3,3,4,4,5,5-octafluorpentan-l-ol, among others), at a temperature in the range of 0 to 100 °C, preferably around 25 °C. The compound of formula (1-3) wherein RY is other than ‘H’ can be prepared using a reagent RY-X, wherein X is a leaving group, for example, halides such as chloro, bromo or iodo, or an aryl or alkylsulfonate such as trifluoromethanesulfonate. Alkylation reaction can be performed in the presence of base such as sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate or triethylamine and in the presence of suitable solvents such as dichloromethane, dichloroethane, DMF, DMSO, ethanol or methanol and at a temperature in the range of 0 to 150 °C. Metal catalyzed coupling for the preparation of compounds of formula (1-3; RY = other than ‘H’) can be performed in the presence of a base, such as potassium carbonate, sodium carbonate, cesium carbonate or sodium hydroxide, in an inert solvent, such as toluene, DMF, N-methyl pyrrolidine (NMP), DMSO, dioxane or THF or the like, optionally in the presence of a catalyst, for example palladium(II)acetate,               his(dibenzylideneacetone)palladium(0)               (Pd(dba)2), tris(dibenzylideneacetone)dipalladium(0) (Pdzldba) ? optionally in form of its chloroform adduct, or a palldium pre-catalyst such as for example tert-BuBrettPhos Pd G3 [(2 Di-tert-butylphosphino-3,6-dimethoxy-2 ’ ,4 ’ ,6 ’ -triisopropyl-1,1’ -biphenyl)-2-(2 ’ -amino-1,1’ -biphenyl)]palladium(II) methanesulfonate or BrettPhos Pd G3 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’ -biphenyl)-2-(2 ’ -amino-1,1’ -biphenyl)]palladium(II) methanesulfonate, and optionally in the presence of a ligand, for example SPhos, t-BuBrettPhos or XantPhos, at a temperature in the range of 50 to 120 C°, optionally under microwave heating conditions. CHEMISTRY EXAMPLES: The following examples set forth the manner and process of making compounds of the present invention without being a limitation thereof and include the best mode contemplated by the inventors for carrying out the invention. Example-1: Synthesis of 2-(ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (Compound-02) Step-1: Synthesis of 2-Cyano-A-(2-(methylamino)-5-(trifluoromethyl)pyridin-3-yl)acetamide To a stirred solution of 2-cyanoacetic acid (33.4 g, 392 mmol) in dichloromethane (300 mL), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (48.1 g, 251 mmol) and N,N-diisopropylethylamine (82 mL, 471 mmol) were added and stirred at 0 °C for 0.5 h followed by the addition of A-2-methyl-5-(trifluoromethyl)pyridine-2,3-diamine (30.0 g, 157 mmol) at 0 °C. The resulting reaction mixture was stirred at 25 °C for 24 h under nitrogen atmosphere. After the completion of the reaction, the reaction mixture was concentrated and diluted with water (500 mL). The aqueous layer was extracted with ethyl acetate (4 x 250 mL). The combined organic layers were washed with water (250 mL), brine (250 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a residue which was further washed with hexane to obtain 2-cyano-A-(2-(methylamino)-5-(trifluoromethyl)pyridin-3-yl)acetamide (39 g, 151 mmol; 96 % yield). 'H-NMR (400 MHz, DMSO-A) 3 9.63 (s, 1H), 8.26 (d, J = 1.0 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 6.96 (d, J = 4.6 Hz, 1H), 3.85 (s, 2H), 2.87 (d, J = 4.6 Hz, 3H); ESI MS (m / z) 258.95 (MH)+. Step-2: Synthesis of 2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)acetonitrile A solution of 2-cyano-A-(2-(methylamino)-5-(trifluoromethyl)pyridin-3-yl)acetamide (39 g, 151 mmol) in acetic acid (230 mL) was heated at 110 °C for 2 h. After the completion of the reaction, the reaction mixture was evaporated under reduced pressure and diluted with ethyl acetate (250 mL) and water (250 mL). The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain a crude product which was further washed with hexane to obtain 2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)acetonitrile (31 g, 129 mmol; 85 % yield). 'H-NMR (400 MHz, DMSO-cL) <5 8.74 (d, J = 1.2 Hz, 1H), 8.54 (d, J = 1.7 Hz, 1H), 4.67 (s, 2H), 3.80 (s, 3H); ESI MS (m / z) 241.10 (MH)+. Step-3: Synthesis of 3,3-bis(ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)acrylonitrile To a mixture of potassium hydroxide (KOH) (17.0 g, 258 mmol) in acetonitrile (300 mL), 2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)acetonitrile (31 g, 129 mmol) was added at 0 °C. The resulting reaction mixture was stirred at 25 °C for 1 h and then cooled to 0 °C, followed by dropwise addition of carbon disulfide (8.60 mL, 142 mmol) over 10 minutes. The resulting reaction mixture was stirred at 0 °C for 1 h and then ethyl iodide (20.80 mL, 258 mmol) was added at the same temperature in a dropwise manner over 15 minutes. The resulting reaction mixture was stirred at 0 °C for 2 h and then warmed to 25 °C and stirred further at the same temperature for 12-15 h. After the completion of the reaction, the reaction mixture was evaporated under reduced pressure to obtain a crude compound which was purified by flash column chromatography to obtain 3,3-bis(ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)acrylonitrile (41 g, 110 mmol; 85 % yield). 'H-NMR (400 MHz, DMSO-< / 6) <5 8.84 (d, J = 1.5 Hz, 1H), 8.62 (d, J = 1.7 Hz, 1H), 3.87 (s, 3H), 3.25 (q, J = 7.3 Hz, 2H), 2.84 (q, J = 7.3 Hz, 2H), 1.36 (t, J = 7.3 Hz, 3H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 473.00 (MH)+. Step-4: Synthesis of 3-(Ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-5-amine To a stirred solution of 3,3-bis(ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)acrylonitrile (34.0 g, 91 mmol) in acetonitrile (150 mL) and ethanol (300 mL), hydrazine monohydrate (5.40 mL, 110 mmol) was added dropwise at 0 °C. The resulting reaction mixture was stirred at 0 °C for 1 h and then ice-cold water was added to the reaction mixture. The solid obtained was filtered and purified by flash column chromatography to obtain 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-5-amine (16 g, 46.7 mmol; 51.2 % yield). ’H-NMR (400 MHz, DMSO-t / 6) 3 12.00 (s, 1H), 8.68 (s, 1H), 8.39 (s, 1H), 5.73 (s, 2H), 3.76 (s, 3H), 2.88 (q, J = 7.1 Hz, 2H), 1.21-1.14 (m, 3H); ESI MS (m / z) 343.40 (MH)+. Step-5: Synthesis of Ethyl 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate To a stirred solution of 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-5-amine (3 g, 8.7 mmol) in acetic acid (40 mL), ethyl (E)-4-ethoxy-2-oxobut-3-enoate (2.26 g, 13.1 mmol) was added. The resulting reaction mixture was stirred at 110 °C for 4.5 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C, the reaction mixture was concentrated under reduced pressure to obtain a residue, which was suspended in ice cold water and stirred for 0.5 h. The solid obtained was filtered, washed with ice cold water (500 mL) followed by hexane (250 mL) and dried to obtain ethyl 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (2.2 g, 4.8 mmol, 55.7 % yield). 'H-NMR (400 MHz, CHLOROFORM-t / ) 5 8.68 (q, J = 0.9 Hz, 1H), 8.63 (d, J = 4.4 Hz, 1H), 8.36 (d, J = 1.5 Hz, 1H), 7.34 (d, J = 4.4 Hz, 1H), 4.60 (q, J = 7.2 Hz, 2H), 4.01 (d, J = 14.4 Hz, 3H), 3.36-3.30 (m, 2H), 1.53-1.46 (m, 6H); ESI MS (m / z) 450.70 (MH)+1. Step-6: Synthesis of 2-(Ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid To a stirred solution of ethyl 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (2 g, 4.4 mmol) in tetrahydrofuran (40 mL), lithium hydroxide, monohydrate (0.75 g, 17.7 mmol) in water (6.0 mL) was added. The resulting reaction mixture was stirred at 25 °C for 3 h. After the completion of the reaction, the reaction mixture was diluted with water (20 mL) and neutralized to pH=4 with IN HC1 solution. The aqueous layer was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over anhydrous sodium sulphate, evaporated under reduced pressure to obtain a crude 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (1.6 g, 3.8 mmol, 85 % yield), which was used in the next step without any purification. 1H-NMR (400 MHz, DMSO-< / 6) 5 8.78-8.77 (m, 2H), 8.55 (t, J = 1.1 Hz, 1H), 7.47 (d, J = 4.3 Hz, 1H), 3.91 (d, J = 14.7 Hz, 3H), 3.24-3.18 (m, 2H), 1.40-1.33 (m, 3H); ESI MS (m / z) 423.08 (MH)+. Step-7: Synthesis of 2-(Ethylthio)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (300 mg, 0.7 mmol) in A,A-dimethyl formamide (5 mL), pyridine (0.46 mL, 5.7 mmol), 1-propylphosphonic anhydride (0.63 mL, 1.06 mmol) and methanamine (0.89 mL, 1.8 mmol) were added at 0 °C. The resulting reaction mixture was stirred at 25 °C for 16 h. After the completion of the reaction, the reaction mixture was diluted with ice cold water (20 mL). The precipitate obtained was filtered, washed with diethyl ether (2x5 mL) and dried to obtain 2-(ethyhhio)-A-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (250 mg, 0.6 mmol, 81 % yield). 'H-NMR (400 MHz, DMSO-cL) 5 9.59 (d, J = 4.9 Hz, 1H), 8.83 (d, J = 4.4 Hz, 1H), 8.78 (d, J = 1.2 Hz, 1H), 8.56 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 4.4 Hz, 1H), 3.92 (s, 3H), 3.27 (t, J = 7.3 Hz, 2H), 3.01 (d, J = 4.9 Hz, 3H), 1.40-1.34 (m, 3H); ESI MS (m / z) 435.55 (MH)+. Step-8: Synthesis of 2-(Ethylsulfonyl)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-A-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (160 mg, 0.4 mmol) in dichloromethane (15 mL), m-chloroperbenzoic acid (244 mg, 0.9 mmol) was added at 0 °C. The reaction mixture was stirred at 25 °C for 16 h. After the completion of the reaction, the reaction mixture was quenched with sodium thiosulphate solution (120 mL) and extracted with dichloromethane (4x10 mL). The combined organic layers were washed with aqueous NaHCOs solution (120 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain a crude compound which was purified by flash column chromatography to obtain 2-(ethylsulfonyl)-A-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (95 mg, 0.2 mmol, 55.3 % yield) as a white solid. ’H-NMR (400 MHz, DMSO-t / 6) 8 9.31 (d, J = 4.9 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.83 (d, J = 4.4 Hz, 1H), 3.81-3.76 (m, 5H), 3.01 (d, J = 4.6 Hz, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 467.10 (MH)+1. Example-02: Synthesis 2-(Ethylsulfonyl)-N-methyl-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (Compound-23) Step-1: Synthesis of 2-(Chloromethyl)-6-(trifluoromethyl)imidazo[l,2-a]pyridine To a stirred solution of 5-(trifluoromethyl)pyridin-2-amine (13.0 g, 80.0 mmol) in ethanol (150 mL), l,3-dichloropropan-2-one (20.36 g, 160.0 mmol) was added, and the resulting reaction mixture was stirred at 90 °C for 24 h. After the completion of the reaction, the reaction mixture was poured into aqueous saturated sodium bicarbonate (400 mL) solution. The aqueous layer was extracted with ethyl acetate (2 X 200 mL). The combined organic layers were washed with brine solution (200 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain 2-(chloromethyl)-6-(trifluoromethyl)imidazo[l,2-a]pyridine (10.54 g, 44.9 mmol, 56 % yield) as a liquid. 'H-NMR (400 MHz, CHLOROFORM-t / ) 3 8.46 (td, J = 2.1, 1.1 Hz, 1H), 7.72 (d, J = 0.5 Hz, 1H), 7.67 (dd, J = 9.5, 0.7 Hz, 1H), 7.34 (dd, J = 9.5, 1.7 Hz, 1H), 4.76 (d, J = 0.5 Hz, 2H); ESI MS (m / z) 235.80 (MH)+. Step-2: Synthesis of 2-(6-(Trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)acetonitrile To a stirred solution of 2-(chloromethyl)-6-(trifluoromethyl)imidazo[l,2-a]pyridine (18.0 g, 77.0 mmol) in acetonitrile (180 mL), trimethylsilyl cyanide (15.43 mL, 115.0 mmol) and tetra butyl ammonium fluoride (115 mL, 115.0 mmol) were added. The resulting reaction mixture was stirred at 25 °C for 48 h. After the completion of the reaction, the reaction mixture was poured into water (300 mL). The aqueous layer was extracted with ethyl acetate (3 x 100 mL), the combined organic layers were washed with saturated brine solution (50 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain the desired 2-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)acetonitrile (14.2 g, 63.1 mmol, 82 % yield) as solid. 'H-NMR (400 MHz, DMSO-t / 6) 3 8.50-8.49 (m, 1H), 7.76 (d, J = 0.7 Hz, 1H), 7.67 (d, J = 9.5 Hz, 1H), 7.38 (dd, J = 9.4, 1.8 Hz, 1H), 3.96 (d, J = 0.7 Hz, 2H); ESI MS (m / z) 226.0 (MH)+. Step-3:    Synthesis of 3,3-bis(ethylthio)-2-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2- yl)acrylonitrile To a stirred solution of potassium hydroxide (7.47 g, 133 mmol) in acetonitrile (300 mL) at 25 °C, 2-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)acetonitrile (15.0 g, 66.6 mmol) was added. The resulting reaction mixture was stirred for 1 h at 25 °C and it was cooled to -5 °C followed by dropwise addition of carbon disulfide (4.0 mL, 66.6 mmol) over 10 minutes. The resulting reaction mixture was stirred for 1 h at -5 °C and then ethyl iodide (10.8 mL, 133.0 mmol) was added in a dropwise manner over 15 minutes. The reaction mixture was stirred for 2 h at 0 °C and then at 25 °C for 16 h. After the completion of the reaction, the volatiles were evaporated under reduced pressure to get a crude product which was purified by flash column chromatography to obtain 3,3-bis(ethylthio)-2-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)acrylonitrile (17.14 g, 48.0 mmol, 72 % yield) as solid. ESI MS (m / z) 358.2 (MH)+. Step-4: Synthesis of 3-(Ethylthio)-4-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)-lH-pyrazol-5-amine To a stirred solution of 3,3-bis(ethylhio)-2-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)acrylonitrile (19.0 g, 53.2 mmol) in acetonitrile (200 mL) and ethanol (200 mL) at 0 °C, hydrazine hydrate (3.9 mL, 80.0 mmol) was added in a dropwise manner. The reaction mixture was stirred at 25 °C for 1 h and then at 75 °C for 16 h. After the completion of the reaction, the solvents were evaporated under reduced pressure. Water (200 mL) was added to the residue and extracted with ethyl acetate (3 X 200 mL). The combined organic layers were washed with saturated brine solution (100 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain 3-(ethylthio)-4-(6- (trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)-lH-pyrazol-5-amine (13 g, 39.7 mmol, 74.7 % yield) as solid. ’H-NMR (400 MHz, DMSO-t / 6) 3 11.88 (s, 1H), 9.26 (s, 1H), 8.25 (s, 1H), 7.68 (d, J = 9.3 Hz, 1H), 7.42 (dd, J = 9.5, 1.7 Hz, 1H), 6.05 (s, 2H), 2.95 (d, J = 6.1 Hz, 2H), 1.27 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 328.0 (MH)+. Step-5: Synthesis of Ethyl 2-(ethylthio)-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate To a stirred solution of 3-(ethylthio)-4-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)-lH-pyrazol-5-amine (4.0 g, 12.22 mmol) in acetic acid (100 mL), ethyl (E)-4-ethoxy-2-oxobut-3-enoate (3.16 g, 18.33 mmol) was added and the resulting reaction mixture was stirred at 110 °C for 3 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C, evaporated the solvent under reduce pressure to obtain a residue. The residue was diluted with ethylacetate (100 mL). The organic layer was washed with saturated aqueous sodium bicarbonate solution (2 x 100 mL), brine solution (2 x 50 mL), dried over anhydrous sodium sulphate, filtered and evapoarted to obtain a crude product which was purified by flash column chromatography to obtain ethyl 2-(ethylthio)-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (2.0 g, 4.59 mmol, 37.6 % yield) as a powder. ESI MS (m / z) 436.3 (MH)+1. Step-6: Synthesis of 2-(Ethylthio)-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid To a stirred solution of ethyl 2-(ethylthio)-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (1.6 g, 3.67 mmol) in tetrahydrofuran (80 mL). Lithium hydroxide monohydrate (0.46 g, 11.02 mmol) in water (13 mL) was added and the resulting reaction mixture was stirred at 25 °C for 1 h. After the completion of the reaction, the reaction mixture was diluted with water (20 mL) and neutralized to pH=4 using with LON aqueous hydrochloride solution. The aqueous layer was extracted with ethyl acetate (2 x 25 mL). The combined organic layers were dried over anhydrous sodium sulphate, filtered, and evaporated under reduced pressure to obtain a crude product which was further washed with diethylether to obtain 2-(ethylthio)-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (1.272 g, 3.12 mmol, 85 % yield) as a solid. ESI MS (m / z) 407.7 (MH)+. Step-7: Synthesis of 2-(Ethylthio)- / V-methyl-3-(6-(trifluoroniethyl)iniidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (400 mg, 0.98 mmol) in A,A-dimethylformamide (6 mL), pyridine (0.63 mL, 7.86 mmol), 1-propylphosphonic anhydride (0.88 mL, 1.47 mmol) and methanamine (1.23 mL, 2.45 mmol) were added at 0 °C. The resulting reaction mixture was stirred at 25 °C for 16 h. After the completion of the reaction, the reaction mixture was poured into ice water (20 mL). The solid obtained was filtered, washed with diethyl ether (5 mL) and dried to get the desired 2-(ethylthio)-A-methyl-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (360 mg, 0.856 mmol, 87 % yield) as a solid. 'H-NMR (400 MHz, DMSO-cL) 5 9.78 (d, J = 4.8 Hz, 1H), 9.36 (s, 1 H), 8.82 (d, J = 4.4 Hz, 1H), 8.73 (s, 1H), 7.80 (d, J = 9.2 Hz, 1H), 7.57 (d, J = 4.4 Hz, 1H), 7.49-7.47 (m, 1H), 3.34-3.29 (m, 2H), 3.02 (d, J = 4.4 Hz, 3H), 1.46 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 420.9 (MH)+. Step-8: Synthesis of 2-(Ethylsulfonyl)-N-methyl-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-N-methyl-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (310 mg, 0.74 mmol) in dichloromethane (20 mL), 3-chloroperoxybenzoic acid (489 mg, 1.84 mmol) was added slowly at 0 °C. The resulting reaction mixture was stirred at 25 °C for 2 h. After the completion of the reaction, the reaction mixture was quenched with aqueous sodium thiosulphate solution (200 mL). The aqueous layer was extracted with dichloromethane (2x 50 mL). The combined organic layers were washed with aqueous saturated sodium bicarbonate solution (2 x 50 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain 2-(ethylsulfonyl)-N-methyl-3-(6-(trifluoromethyl)imidazo[l,2-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (105 mg, 0.232 mmol, 31.5 % yield) as a yellow solid. 'H-NMR (400 MHz, DMSO-< / 6) 5 9.42 (t, J = 4.8 Hz, 1H), 9.39 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.69 (d, J = 0.5 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 4.4 Hz, 1H), 7.52 (dd, J = 9.4, 1.8 Hz, 1H), 4.11 (q, J = 7.4 Hz, 2H), 2.99 (d, J = 4.6 Hz, 3H), 1.25 (q, J = 7.4 Hz, 3H); ESI MS (m / z) 453.10 (MH)+. Example-03: Synthesis of N-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide (Compound-247) Step-1: Synthesis of 5-(ethylsulfonyl)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)- lH-pyrazol-3-amine The desired 5-(ethylsulfonyl)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-3-amine (3.5 g, 9.35 mmol, 64.0 % yield) was prepared from of 5-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-3-amine (5.0 g, 14.61 mmol), using the similar procedure mentioned in step-8 of Example-1. ESI MS (m / z) 374.9 (MH)+ Step-2: Synthesis of ethyl 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate To a stirred solution of 5-(ethylsulfonyl)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-3-amine (3.5 g, 9.35 mmol) in ethanol (35 mL), ethyl-2-formyl-3-oxopropionate (1.47 mL, 11.22 mmol) was added and the resulting mixture was stirred at 80 °C for 3 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and ethanol was evaporated. The crude was diluted with ethyl acetate (50 mL), and the solid obtained was filtered, and dried under reduced pressure to obtain the desired ethyl 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate (4.1 g, 8.50 mmol, 91 % yield). 'H-NMR (400 MHz, DMSO-t / 6) 5 10.05 (d, J = 2.2 Hz, 1H), 9.17 (d, J = 2.0 Hz, 1H), 8.86 (q, J = 0.9 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.78 (q, J = 7.3 Hz, 5H), 1.38 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 483.05 (MH)+. Step-3: Synthesis of 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid To a stirred solution of ethyl 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate (3.6 g, 7.46 mmol) in 1,4-dioxane (45 mL), cone, hydrochloric acid (9.72 ml, 112 mmol) was added dropwise. The resulting mixture was stirred at 25 °C for 10 minutes then at 95 °C for 16 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and the solvents were evaporated to get a residue. The residue was diluted with ice water (250 mL) to get a white precipitate, which was filtered, washed with water and dried to obtain 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid (3.6 g, 7.92 mmol) as a mixture with it's corresponding decarboxylated product, which was not further purified and used in the next step as it is. ESI MS (m / z) 454.95 (MH)+. Step-4: Synthesis of N-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide To a stirred solution of 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid (200 mg, 0.44 mmol) in dichloromethane (4 mL) at 0 °C, cyclopropanamine (35 pL, 0.46 mmol) and pyridine (0.22 mL, 2.64 mmol) were added and for 10 minutes at 0 °C followed by the addition of 1-propanephosphonic acid cyclic anhydride (0.38 mL, 0.66 mmol). The resulting reaction mixture was warmed to 25 °C and stirred for 16 h. After the completion of the reaction, the reaction mixture was diluted with water (25 mL) and was extracted with dichloromethane (4 x 20 mL). The combined organic layers were washed with saturated brine solution (25 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get a crude product which was purified by flash chromatography to obtain A-cyclopropyl-2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide (110 mg, 0.223 mmol, 50.6 % yield). 'H-NMR (400 MHz, DMSO-A) 5 9.79 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 8.89 (d, J = 3.9 Hz, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.79-3.74 (m, 5H), 2.93-2.88 (m, 1H), 1.25 (t, J = 7.3 Hz, 3H), 0.80-0.75 (m, 2H), 0.64-0.60 (m, 2H); ESI MS (m / z) 494.25 (MH)+. Example-4: Synthesis of N-ethoxy-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide (Compound-235) Step-1: Synthesis of ethyl 2-(ethylthio)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate To a stirred solution of ethyl (Z)-2-((dimethylamino)methylene)-3-oxobutanoate (9.74 g, 52.6 mmol) in ethanol (100 mL), 3-(ethyhhio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-5-amine (9 g, 26.3 mmol) was added and the resulting mixture was stirred at 85 °C for 16 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C, the solvents were evaporated under reduced pressure to obtain a residue. The residue was triturated with water (300 mL) and the resulting solid was filtered, washed with hexane (30 mL) to obtain desired ethyl 2-(ethylthio)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate (11.0 g, 23.68 mmol, 90 % yield). ). ’H-NMR (400 MHz, CHLORFORM-d) 5 9.03 (s, 1H), 8.68 (d, J = 1.2 Hz, 1H), 8.38 (d, J = 1.2 Hz, 1H), 4.45 (q, J = 7.2 Hz, 2H), 4.03 (s, 3H), 3.35 (q, J = 3.6 Hz, 2H), 3.22 (s, 3 H), 1.51 (t, J = 7.6 Hz, 3H), 1.44 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 465.20 (MH)+. Step-2: Synthesis of ethyl 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate The desired ethyl 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate (6.5 g, 13.09 mmol, 60.8 % yield) was prepared from ethyl 2-(ethylthio)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate (10 g, 21.53 mmol), using the similar procedure mentioned in step-8 of Example-1. 'H-NMR (400 MHz, DMSO-A) 5 9.11 (s, 1H), 8.85 (q, J = 0.9 Hz, 1H), 8.63 (q, J = 0.9 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 3.81-3.75 (m, 5H), 3.19 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 497.20 (MH)+. Step-3: Synthesis of 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid To a stirred solution of ethyl ethyl 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylate (3 g, 6.04 mmol) in tetrahydrofuran (30 mL), lithium hydroxide monohydrate (0.56 g, 13.29 mmol) in water (3 mL) was added slowly at 25 °C and stirred for 3 h. After the completion of the reaction, the reaction mixture was diluted with water (5 mL) and acidified (pH=4) using 10% hydrochloric acid solution. The aqueous layer was extracted with ethyl acetate (3 x 20 mL), dried over anhydrous sodium sulphate, filtered, and evaporated under reduced pressure to obtain 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l ,5-a]pyrimidine-6-carboxylic acid (2.41 g, 5.15 mmol, 85 % yield) which was used in the next step without any further purification. 'H-NMR (400 MHz, DMSO-cL) 5 8.85 (t, J = 1.1 Hz, 1H), 8.62 (d, J = 1.8 Hz, 2H), 3.72 (s, 3H), 3.57 (q, J = 7.3 Hz, 2H), 2.61 (s, 3H), 1.22 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.95 (MH)+. Step-4: Synthesis of N-ethoxy-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide To a stirred solution of 2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxylic acid (200 mg, 0.43 mmol) in N,N-dimethylformamide (2 mL), HATU (406 mg, 1.07 mmol), DIPEA (0.37 ml, 2.14 mmol) and O-ethylhydroxylamine hydrochloride (62.5 mg, 0.64 mmol) were added at 25 °C and stirred at 60 °C for 16 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and diluted with water (50 mL). The aqueous layer was extracted with ethyl acetate (4 x 25 mL), the combined organic layers were washed with saturated brine solution (100 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain N-ethoxy-2-(ethylsulfonyl)-7-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-6-carboxamide (81 mg, 0.158 mmol, 37.1 % yield. 'H-NMR (400 MHz, DMSO-t / 6) 5 8.81 (d, J = 1.2 Hz, 1H), 8.57 (d, J = 1.5 Hz, 1H), 8.06 (s, 1H), 4.11 (q, J = 7.0 Hz, 2H), 3.74 (s, 3H), 3.65-3.57 (m, 2H), 2.18 (s, 3H), 1.25-1.18 (m, 6H); ESI MS (m / z) 512.00 (MH)+. Example-5: Synthesis of N-ethyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (Compound-297) Step-1: Synthesis of 2-cyano-N-(5-(methylamino)-2-(trifluoromethyl)pyridin-4-yl)acetamide To a stirred solution of N3-methyl-6-(trifluoromethyl)pyridine-3,4-diamine (40 g, 209 mmol) in dichloromethane (400 mL) at 0 °C, under nitrogen, 2-cyanoacetic acid (44.5 g, 523 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (64.2 g, 335 mmol) were added followed by the addition of A,A-diisopropylethylamine (110 mL, 628 mmol). The resulting reaction mixture was stirred at 25 °C for 24 h under nitrogen. After the completion of the reaction, the reaction mixture was concentrated to obtain a residue which was diluted with water (1000 mL). The aqueous layer was extracted with dichloromethane (3 x 300 mL), the combined organic layers were washed with brine solution (800 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain the crude 2-cyano-N-(5-(methylamino)-2-(trifluoromethyl)pyridin-4-yl)acetamide (40 g, 155 mmol, 74.0 % yield), which further used in next step without purification. ESI MS (m / z) 259.05 (MH)+. Step-2: Synthesis of 2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)acetonitrile A stirred solution of 2-cyano-A-(5-(methylamino)-2-(trifluoromethyl)pyridin-4-yl)acetamide (40 g, 155 mmol) in acetic acid (400 mL) was stirred at 110 °C for 3 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C, and the solvent was evaporated under reduced pressure. The residue was diluted with water (800 mL) and the aqueous layer was extracted with ethyl acetate (3 x 300 mL). The combined organic layers were washed with aqueous sodium bicarbonate solution (800 mL), saturated brine solution (800 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain the crude compound which was purified by flash column chromatography to obtain the desired 2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)acetonitrile (30 g, 125 mmol, 81 % yield). 'H-NMR (400 MHz, DMSO-A) 5 9.10 (s, 1H), 8.17 (s, 1H), 4.68 (s, 2H), 3.91 (s, 3H); ESI MS (m / z) 240.90 (MH)+ Step-3: Synthesis of 3,3-bis(ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)acrylonitrile To a stirred solution of KOH (22.53 g, 341 mmol) in acetonitrile (550 mL) at 0 °C, 2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)acetonitrile (41 g, 171 mmol) was added. The resulting reaction mixture was stirred for 1 h at 25 °C and it was cooled to -5 °C followed by dropwise addition of carbon disulfide (11.35 mL, 188 mmol). The reaction mixture was stirred for 1 h at -5 °C, followed by the addition of ethyl iodide (27.4 mL, 341 mmol) at 0 °C. The reaction mixture was stirred for 2 h at 0 °C and then at 25 °C for 16 h. After the completion of the reaction, the volatiles were evaporated under reduced pressure. The residue was diluted with water (800 mL) and the aqueous layer was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with saturated brine solution (800 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain the crude compound which was purified by flash column chromatography to obtain the desired 3,3-bis(ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)acrylonitrile (51 g, 137 mmol, 80 % yield). 'H-NMR (400 MHz, DMSO-cL) 9.20 (s, 1H), 8.24 (s, 1H), 3.97 (s, 3H), 3.24 (q, J = 7.3 Hz, 2H), 2.80 (q, J = 7.4 Hz, 2H), 1.36 (t, J = 7.5 Hz, 3H), 1.13 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 372.90 (MH)+. Step-4: Synthesis of 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-lH-pyrazol-5-amine To a stirred solution of 3,3-bis(ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)acrylonitrile (25 g, 67.1 mmol) in ethanol (250 mL) and acetonitrile (125 mL) at 0 °C, hydrazine hydrate (3.95 mL, 81 mmol) was added and the resulting reaction mixture was stirred for 1-1.5 h. After the completion of the reaction, the reaction mixture was poured into ice-cold water (1.5 L). The resulting yellow solid was filtered and dried. The yellow crude compound was purified by flash column chromatography to obtain the desired 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-lH-pyrazol-5-amine (13 g, 38.0 mmol, 56.6 % yield). 'H-NMR (400 MHz, DMSO-A) 8 12.01 (s, 1H), 9.03 (s, 1H), 8.07 (s, 1H), 5.73 (s, 2H), 3.84 (s, 3H), 2.87 (q, J = 7.3 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 343.15 (MH)+ Step-5: Synthesis of ethyl 2-(ethylthio)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate To a stirred solution of 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-lH-pyrazol-5-amine (9 g, 26.3 mmol) in ethanol (90 mL), ethyl (Z)-4-ethoxy-3-methyl-2-oxobut-3-enoate (7.34 g, 39.4 mmol) was added at 25 °C. The resulting reaction mixture was stirred at 85 °C for 4-5 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C, poured into water (100 mL) and extracted with ethyl acetate (4 x 50 mL). The combined organic layers were dried over anhydrous sodium sulphate, filtered and evaporated to obtain the crude compound which was purified by flash column chromatography to obtain ethyl 2-(ethylthio)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (8.2 g, 17.65 mmol, 67.2 % yield); ’H-NMR (400 MHz, DMSO-t / 6) 8 9.14 (s, 1H), 8.75 (s, 1H), 8.19 (s, 1H), 4.58 (q, J = 6.8 Hz, 2H), 4.01 (s, 3H), 3.15 (q, J = 7.2 Hz, 2H), 2.37 (s, 3H), 1.40 (t, J = 6.8 Hz, 3H), 1.35 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 465.5 (MH)+ Step-6: Synthesis of ethyl 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate The desired ethyl 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (8.75 g, 17.62 mmol, 82 % yield) was prepared from ethyl 2-(ethylthio)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (10 g, 21.53 mmol), using the similar procedure mentioned in step-8 of Example-1. 'H-NMR (400 MHz, DMSO-t / e) 8 9.22 (s, 1H), 8.91 (s, 1H), 8.26 (d, J = 1.0 Hz, 1H), 4.62 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 3.70 (q, J = 7.4 Hz, 2H), 2.45 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 497.15 (MH)+ Step-7: Synthesis of 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-iniidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid The desired 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (1.6 g, 3.42 mmol, 56.5 % yield) was prepared from ethyl 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (3 g, 6.04 mmol), using the similar procedure mentioned in step-6 of Example-1. 'H-NMR (400 MHz, DMSO-A) 5 9.22 (s, 1H), 8.89 (s, 1H), 8.26 (d, J = 0.6 Hz, 1H), 3.89 (s, 3H), 3.71 (q, J = 7.4 Hz, 2H), 2.44 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.85 (MH)+ Step-8: Synthesis of N-ethyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (300 mg, 0.64 mmol) in N,N-dimethylformamide (3 mL), pyridine (0.26 ml, 3.20 mmol), PyBOP (500 mg, 0.96 mmol) were added at 25 °C followed by the addition of ethanamine hydrochloride (54.8 mg, 0.67 mmol). The resulting reaction mixture was stirred at 25 °C for 16 h. After the completion of the reaction, the reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (4 x 20 mL). The combined organic layers were washed with saturated brine solution (25 mL), dried over anhydrous sodium sulphate, filtered and concentrated to obtain the crude compound which was purified using flash column chromatography to obtain the desired product A-ethyl-2-(ethylsulfonyl)-6-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-c]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (65 mg, 0.131 mmol, 20.48 % yield). ’H-NMR (400 MHz, DMSO-t / 6) 5 9.23 (s, 1H), 9.10 (t, J = 5.4 Hz, 1H), 8.88 (s, 1H), 8.26 (s, 1H), 3.89 (s, 3H), 3.68 (q, J = 7.4 Hz, 2H), 3.46-3.40 (m, 2H), 2.38 (s, 3H), 1.22 (dt, J = 17.0, 7.3 Hz, 6H); ESI MS (m / z) 496.20 (MH)+. Example-6: Synthesis of         2-(ethylsulfonyl)-N,N-dimethyl-3-(6-(2,2,3,3,3- pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (Compound-26) Step-2 c2F5. Step-3 Step-1: Synthesis of 3-methyl-6-(2,2,3,3,3-pentafluoropropoxy)pyridazine To a stirred solution of 3-chloro-6-methylpyridazine (15 g, 117 mmol) in A,A-dimethylformamide (200 mL), 2,2,3,3,3-pentafluoropropan-l-ol (26.3 g, 175 mmol) and NaH (55% by wt; 7.00 g, 175 mmol) were added at 0 °C. The resulting reaction mixture was stirred at 80 °C for 14 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and quenched with water (300 mL). The aqueous layer was extracted with ethyl acetate (3 x 500 mL), the combined organic layers were washed with saturated brine solution (500 mL), dried over anhydrous sulphate, filtered and concentrated under reduced pressure to obtain the crude compound which was purified by flash column chromatography to obtain 3-methyl-6-(2,2,3,3,3-pentafluoropropoxy)pyridazine (19 g, 78.0 mmol, 67.2 % yield). 1H-NMR (400 MHz, CHLOROFORM-t / ) 5 7.31 (d, J = 9.2 Hz, 1H), 7.01 (d, J = 9.2 Hz, 1H), 5.02-4.95 (m, 2H), 2.64 (s, 3H); ESI MS (m / z) 242.95 (MH)+. Step-2: Synthesis of 3-(chloromethyl)-6-(2,2,3,3,3-pentafluoropropoxy)pyridazine To a strried solution of 3-methyl-6-(2,2,3,3,3-pentafluoropropoxy)pyridazine (5 g, 20.65 mmol) in chloroform (50 mL) at 65 °C, l,3,5-trichloro-[l,3,5]triazinane-2,4,6-trione (3.36 g, 14.45 mmol) was added. The reaction mixture was stirred at 65 °C for 1 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and diluted with dichloromethane (250 mL). The organic layer was washed with an aqueous solution of IN NaOH (250 mL), saturated brine solution (200 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain the crude compound which was purified by flash column chromatography to obtain 3-(chloromethyl)-6-(2,2,3,3,3-pentafluoropropoxy)pyridazine (40 g, 145 mmol, 62.5 % yield). 'H-NMR (400 MHz, CHLOROFORM-t / ) 5 7.68 (d, J = 9.2 Hz, 1H), 7.16 (d, J = 9.2 Hz, 1H), 5.06-4.99 (m, 2H), 4.82 (s, 2H); GC MS (m / z) 275.9. Step-3: 2-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)acetonitrile To a stirred solution of 3-(chloromethyl)-6-(2,2,3,3,3-pentafluoropropoxy)pyridazine (35 g, 127 mmol) in acetonitrile (700 mL), trimethylsilyl cyanide (25.4 mL, 190 mmol) and TBAF (190 mL, 190 mmol) were added at 0 °C. The reaction mixture was stirred at 25 °C for 14 h. After the completion of the reaction, the reaction mixture was poured into water (1000 mL) and extracted with ethyl acetate (2 x 2000 mL). The combined organic layers were washed with saturated brine solution (1500 mL), dried over anhydrous sodium sulphate, filtered and concentrated to obtain a crude product which was purified by flash column chromatography to obtain 2-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)acetonitrile (20.5 g, 77 mmol, 60.6 % yield). 'H-NMR (400 MHz, DMSO-A) 5 7.73 (d, J = 9.2 Hz, 1H), 7.45 (d, J = 9.2 Hz, 1H), 5.32-5.25 (m, 2H), 4.36 (s, 2H); ESI MS (m / z) 267.5 (MH)+. Step-4:    Synthesis of 3,3-bis(ethylthio)-2-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3- yl)acrylonitrile The desired 3,3-bis(ethylthio)-2-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)acrylonitrile (21 g, 52.6 mmol, 70.2 % yield) was prepared from 2-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)acetonitrile (20 g, 74.9 mmol), using the similar procedure mentioned in step-3 of Example-1. 'H-NMR (400 MHz, CHLOROFORM-t / ) 5 7.80 (d, J = 9.6 Hz, 1H), 7.17 (d, J = 9.6 Hz, 1H), 5.11-5.04 (m, 2H), 3.13 (q, J = 7.6 Hz, 2H), 3.02 (q, J = 7.2 Hz, 2H), 2.80 (q, J = 7.4 Hz, 2H), 1.42 (t, J = 7.6 Hz, 3H), 1.28 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 399.65 (MH)+. Step-5: 3-(ethylthio)-4-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)-lH-pyrazol-5-amine The desired 3-(ethylthio)-4-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)-lH-pyrazol-5-amine (16 g, 43.3 mmol, 87   % yield) was prepared from 3,3-bis(ethylthio)-2-(6-(2,2,3,3,3- pentafluoropropoxy)pyridazin-3-yl)acrylonitrile (20 g, 50.1 mmol), using the similar procedure mentioned in step-4 of Example-1. ESI MS (m / z) 369.55 (MH)+. Step-6: ethyl 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate The desired ethyl 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (3.4 g, 7.12 mmol, 49.0 % yield) was prepared from 3-(ethylthio)-4-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)-lH-pyrazol-5-amine (4.29 g, 11.62 mmol), using the similar procedure mentioned in step-5 of Example-l.'H-NMR (400 MHz, CHLOROFRM-<7) 5 8.21 (d, J = 9.2 Hz, 12H), 8.58 (d, J = 4.4 Hz, 1H), 7.26 (d, J = 4.4 Hz, 1H), 7.18 (d, J = 9.2 Hz, 1H), 5.12-5.06 (m, 2H), 4.58 (q, J = 6.8 Hz, 2H), 3.33 (q, J = 7.6 Hz, 2H), 1.53-1.47 (m, 6H); ESI MS (m / z) 478.3 (MH)+. Step-7:            2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5- a]pyrimidine-7-carboxylic acid To a stirred solution of ethyl 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (3.5 g, 7.33 mmol) in ethanol (50 mL), lithium hydroxide (1.76 g, 73.3 mmol) in water (50.0 ml) was added and stirred at 25 °C for 1.5 h. After the completion of the reaction, the solvents were evaporated and the residue obtained was acidified using 6 N aqueous HC1 solution and extracted with ethylacetate (2 x 50 mL). The combined organic layers were washed with brine solution (2 x 50 mL), dried over anhydrous sodium sulphate, filtered and evapoarated under reduced pressure to obtain 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (2.8 g, 6.23 mmol, 85 % yield). 'H-NMR (400 MHz, CHLOROFORM-d) 8.83 (d, J = 9.2 Hz, 1H), 8.80 (d, J = 4.4 Hz, 1H), 7.76 (d, J = 4.4 Hz, 1H), 7.24 (d, J = 9.2 Hz, 1H), 5.14-5.07 (m, 2 H), 3.23 (q, J = 7.6 Hz, 2H), 1.54 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 450.5 (MH)+. Step-8:             2-(ethylthio)-N,N-dimethyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (500 mg, 1.113 mmol) in A, A-dimethylformamide (5 mL), pyridine (0.9 mL, 11.13 mmol), 1-propylphosphonic anhydride (1.0 mL, 1.669 mmol) and dimethylamine hydrochloride (100 mg, 1.224 mmol) were added at 0 °C. The reaction mixture was stirred for 16 h at 25 °C. After the completion of the reaction, the reaction mixture was poured into ice water. The resulting solid was filtered and washed with water, diethyl ether and dried to obtain the desired 2-(ethylthio)-A,A-dimethyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7- carboxamide (250 mg, 0.524 mmol, 47.2 % yield). ’H-NMR (400 MHz, CHLOROFORM-t / ) 8.82 (d, J = 9.2 Hz, 1H), 8.57 (d, J = 4.4 Hz, 1H), 7.18 (d, J = 9.2 Hz, 1H), 6.88 (d, J = 4.4 Hz, 1H), 5.09 (t, J = 12.8 Hz, 2H), 3.28-3.22 (m, 5 H), 2.92 (s, 1H), 1.46 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 477.5 (MH)+. Step-9:         2-(ethylsulfonyl)-N,N-dimethyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3- yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-A,A-dimethyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (200 mg, 0.420 mmol) in dichloromethane (10 mL), mCPBA (217 mg, 0.88 mmol) was added at 25 °C. The reaction mixture was stirred for 4 h at 25 °C. After the completion of the reaction, the reaction mixture was diluted with dichloromethane (15 mL), washed with aqueous saturated sodium thiosulfate solution (25 mL), aqueous IN NaOH (10 mL), dried over anhydrous sodium sulphate, filtered and concentrated to obtain the crude compound which was purified by using flash column chromatography to obtain 2-(ethylsulfonyl)-A,A-dimethyl-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (105 mg, 0.207 mmol, 49.2 % yield). ’H-NMR (400 MHz, DMSO- de) 5 8.91 (d, J = 4.4 Hz, 1H), 8.22 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 7.55 (d, J = 4.2 Hz, 1H), 5.36 (t, J = 13.3 Hz, 2H), 3.80 (q, J = 7.3 Hz, 2H), 3.13 (s, 3H), 2.90 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 509.00 (MH)+. Example-7: Synthesis of N-cyclopropyl-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5- a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide                      (Compound-228) Step-1: l,2-diamino-5-(trifluoromethyl)pyridin-l-ium diphenylphosphinate To a stirred solution of 5-(trifluoromethyl)pyridin-2-amine (30 g, 185 mmol) in dichloromethane (500 mL), (aminooxy)diphenylphosphine oxide (43.2 g, 185 mmol) was added at 25 °C. The resulting reaction mixture was stirred at 25 °C for 18 h. After the completion of the reaction, the reaction mixture was diluted with hexane (250 mL) and the resulting white precipitate was filtered, washed with diethyl ether (200 mL), and dried to obtain l,2-diamino-5-(trifluoromethyl)pyridin-l-ium diphenylphosphinate (44 g, 111 mmol, 60.1 % yield) as off white solid.; ESI MS (m / z) 178.10 (MH)+. Step-2:       2-(ethylthio)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5- a]pyrimidin-7(4H)-one To a stirred solution of 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylic acid (20 g, 84 mmol) and l,2-diamino-5-(trifluoromethyl)pyridin-l-ium diphenylphosphinate (33.0 g, 84 mmol) in pyridine (300 mL), l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (24.04 g, 125 mmol) and lH-l,2,3-benzotriazol-l-ol hydrate (14.31 g, 84 mmol) were added. The resulting reaction mixture was stirred at 85 °C for 16 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and solvents were evaporated. The residue was diluted with water (IL) and extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with IN HC1 solution (500 mL), dried over anhydrous sodium sulphate, filtered and concentrated to obtain a crude product which was purified by flash column chromatography to obtain 2-(ethylthio)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one (10 g, 26.3 mmol, 31.5 % yield). ’H-NMR (400 MHz, DMSO-t / 6) 3 11.93 (brs, 1H), 9.60 (d, J = 1.2 Hz, 1H), 7.98 (d, J = 1.2 Hz, 2H), 7.85 (d, J = 6.0 Hz, 1H), 5.89 (d, J = 3.2 Hz, 1H), 3.24 (q, J = 7.6 Hz, 2H), 1.39 (t, J = 7.6Hz, 3H); ESI MS (m / z) 380.9 (MH)+. Step-3: Synthesis of 2-(7-chloro-2-(ethylthio)pyrazolo[l,5-a]pyrimidin-3-yl)-6-(trifluoromethyl)-[1,2,4] triazolo[ 1,5-a] pyridine To a stirred solution of 2-(ethylthio)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one (20 g, 84 mmol) in toluene (100 mL) and acetonitrile (100 mL), POCk (24.5 mL, 263 mmol) was added at 25 °C. The reaction mixture was stirred at 100 °C for 12 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and poured into ice-water (IL) and extracted with ethyl acetate (2 x 500 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (2 x 500 mL), dried over anhydrous sodium sulphate, filtered and concentrated to obtain a crude compound which was purified by flash column chromatography to obtain 2-(7-chloro-2-(ethylthio)pyrazolo[l,5-a]pyrimidin-3-yl)-6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridine (7 g, 17.55 mmol, 66.8 % yield). 'H-NMR (400 MHz, DMSO-t / e) 5 9.74 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 4.4 Hz, 1H), 8.06 (d, J = 9.6 Hz, 1H), 7.94 (dd, J = 9.6 Hz, 2.0 Hz, 1H), 7.50 (d, J = 4.4 HZ, 1H), 3.17 (q, J = 9.6 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 398.85 (MH)+ Step-4:     Synthesis of 2-(7-chloro-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidin-3-yl)-6- (trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridine The desired 2-(7-chloro-2-(ethylsulfonyl)pyrazolo[l ,5-a]pyrimidin-3-yl)-6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridine (12.5 g, 29.0 mmol, 96 % yield) was prepared from 2-(7-chloro-2-(ethylthio)pyrazolo[l ,5-a]pyrimidin-3-yl)-6-(trifluoromethyl)-[l ,2,4]triazolo[l ,5-a]pyridine (12 g, 30.1 mmol), using the similar procedure mentioned in step-8 of Example-1. 'H-NMR (400 MHz, CHLOROKRNLd) 5 9.09 (s, 1H), 8.78 (d, J = 4.8 Hz, 1H), 7.98 (d, J = 9.6 Hz, 1H), 7.73 (dd, J = 9.6 Hz, 2.0 Hz, 1H), 7.33 (d, J = 4.4 HZ, 1H), 3.97 (q, J = 9.6 Hz, 2H), 1.52 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 431.1 (MH)+ Step-5: Synthesis of 3-(ethylsulfonyl)-4-(6-(trifhioromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)-lH-pyrazol-5-amine To a stirred solution of 2-(7-chloro-2-(ethylsulfonyl)pyrazolo[l,5-a]pyrimidin-3-yl)-6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridine (12 g, 27.9 mmol) in / V, / V-dimcthylfbrmamidc (180 mL), Al,A2-dimethylethane-l,2-diamine (30.0 mL, 279 mmol) was added at 25 °C. The resulting reaction mixture was stirred at 25 °C for 12 h. After the completion of the reaction, the reaction mixture was poured into ice-cold water (250 mL). The precipitated solid product was filtered, washed with water (1 L) followed by hexane (200 mL) and dried to obtain 3-(ethylsulfonyl)-4-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)-lH-pyrazol-5-amine (10 g, 27.8 mmol, 100 % yield). 'H-NMR (400 MHz, DMSO-t / 6) 5 12.85 (brs, 1H), 9.61 (s, 1H), 7.99-7.92 (m, 2H), 6.44 (s, 2H), 3.82 (q, J = 7.2 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H).; ESI MS (m / z) 361.05 (MH)+ Step-6:       ethyl 2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2- yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate The desired ethyl 2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (6.6 g, 14.09 mmol, 52.9 % yield) was prepared from 3-(ethylsulfonyl)-4-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)-lH-pyrazol-5-amine (9.6 g, 26.6 mmol), using the similar procedure mentioned in step-5 of Example-l.'H-NMR (400 MHz, DMSO-< / 6) 5 9.82 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.14 (d, J = 9.2 Hz, 1H), 8.04-8.01 (m, 1H), 7.86 (d, J = 4.4 Hz, 1H), 4.52 (q, J = 7.2 Hz, 2H), 3.89 (q, J = 7.2 Hz, 2H), 1.85 (t, J = 6.8 Hz, 3H), 1.28 (t, J = 7.6 Hz, 3H).; ESI MS (m / z) 469.05 (MH)+ Step-7: 2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid To a stirred solution of ethyl 2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylate (800 mg, 1.71 mmol) in tetrahydrofuran (10 mL), lithium hydroxide, monohydrate (143 mg, 3.42 mmol) in water (10.0 mL) was added at 0 °C. The resulting reaction mixture was stirred at 0 °C for 15 minutes. After the completion of the reaction, the reaction mixture was acidified with 2N aqueous HC1 solution (pH 2-3) and the volatiles were evaporated. The solid obtained was filtered, washed with 50% ethyl acetate in hexane (50 ml) and dried to obtain 2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (700 mg, 1.590 mmol, 93 % yield). ESI MS (m / z) 440.85 (MH)+ Step-8: Ar-cyclopropyl-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (150 mg, 0.341 mmol) in A,A-dimethylformamide (2 mL), pyridine (0.14 mL, 1.70 mmol), cyclopropanamine (38.9 mg, 0.681 mmol) and 1-propylphosphonic anhydride (0.31 mL, 0.511 mmol) were added at 25 °C. The resulting reaction mixture was stirred at 25 °C for 16 h. After the completion of the reaction, the reaction mixture was quenched with water (25 mL) and the precipitated solid product was filtered, washed with water (100 mL) followed by 20% ethyl acetate in hexane (100 mL) and dried to obtain / V-cyclopropyl-2-(ethylsulfonyl)-3-(6-(trifluoromethyl)-[l,2,4]triazolo[l,5-a]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (100 mg, 0.209 mmol, 61.2 % yield). 'H-NMR (400 MHz, DMSO-t / e) 5 9.82 (d, J = 0.9 Hz, 1H), 9.45 (d, J = 4.3 Hz, 1H), 8.98 (d, J = 4.3 Hz, 1H), 8.15-8.11 (m, 1H), 8.03 (dd,J = 9.5,1.8 Hz, 1H), 7.74 (d, J = 4.0 Hz, 1H), 3.97-3.88 (m, 2H), 3.03-2.98 (m, 1H), 1.29 (t, J = 7.3 Hz, 3H), 0.86 (td, J = 7.0, 5.1 Hz, 2H), 0.65-0.61 (m, 2H); ESI MS (m / z) 480.05 (MH)+ Example-8: Synthesis of 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylic acid Step-1: Synthesis of ethyl 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylate A mixture of ethyl 5-amino-3-(ethylthio)-lH-pyrazole-4-carboxylate (25 g, 116 mmol) and methyl 3,3-dimethoxypropanoate (19.76 mL, 139 mmol) in acetic acid (250 mL) was stirred at 110 °C for 18 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and acetic acid was removed under reduced pressure. The residue was diluted with cold water (IL) to obtain a light yellow precipitate which was filtered and washed with water (1 L), hexane (500 mL) and dried to obtain ethyl 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylate (30 g, 112 mmol, 97 % yield). ESI MS (m / z) 268.0 (MH)+ Step-2: Synthesis of 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylic acid To a stirred solution of ethyl 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylate (20 g, 74.8 mmol) in ethanol (250 mL), sodium hydroxide (29.9 g, 748 mmol) in water (250 mL) was added at 25 °C. The resulting reaction mixture was stirred at 70 °C for 16 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C. The solvents were evaporated to get a residue which was acidified with cone HC1 ( pH= 1).,The resulting white precipitate was filtered and dried to obtain 2-(ethylthio)-7-oxo-4,7-dihydropyrazolo[l,5-a]pyrimidine-3-carboxylic acid (15.5 g, 64.8 mmol, 87 % yield). ESI MS (m / z) 239.85 (MH)+. Example-9:    Synthesis of 2-(ethylsulfonimidoyl)-N-methoxy-N-methyl-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (Compound-293) Step-1: Synthesis of 2-(ethylthio)-N-methoxy-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxylic acid (1.2 g, 2.84 mmol) in A,A-dimethylformamide (10 mL), pyridine (1.84 mL, 22.73 mmol), HATU (2.160 g, 5.68 mmol) and N,O-dimethylhydroxylamine hydrochloride (0.291 g, 2.98 mmol) were added at 25 °C. The resulting reaction mixture was stirred for 16 h at 25 °C. After the completion of the reaction, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with saturated brine solution (50 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain the desired 2-(ethylthio)-A-methoxy-A-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (600 mg, 1.289 mmol, 45.4 % yield). 'H-NMR (400 MHz, DMSO-^M) 5 8.79 (d, J = 4.4 Hz, 1H), 8.77 (d, J = 1.2 Hz, 1H), 8.54 (d, J = 1.2 Hz, 1H), 7.44 (d, J = 4.4 Hz, 1H), 2.96 (s, 3H), 3.59 (s, 3H), 3.42 (s, 3H), 3.08 (q, J = 6.8 Hz, 2H), 1.34 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 465.5 (MH)+. Step-2:      Synthesis of 2-(ethylsulfonimidoyl)-N-methoxy-N-methyl-3-(3-methyl-6- (trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide To a stirred solution of 2-(ethylthio)-A-methoxy-A-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (500 mg, 1.07 mmol) in methanol (20 mL), iodobenzene diacetate (1038 mg, 3.22 mmol) was added followed by carbamic acid ammonium salt (335 mg, 4.30 mmol) at 0 °C. The resulting reaction mixture was stirred at 25 °C for 5 h. After the completion of the reaction, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with saturated brine solution (50 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain the desired           2-(ethylsulfonimidoyl)-A-methoxy-A-methyl-3-(3-methyl-6-(trifluoromethyl)-3H- imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidine-7-carboxamide (270 mg, 0.544 mmol, 50.6 % yield). ’H-NMR (400 MHz, DMSO-t / 6) 5 8.92 (d, J = 4.2 Hz, 1H), 8.84 (s, 1H), 8.61 (s, 1H), 7.70 (d, J = 3.9 Hz, 1H), 4.86 (s, 1H), 3.80 (s, 3H), 3.62 (s, 3H), 3.58-3.49 (m, 2H), 3.44 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 497.05 (MH)+. Example-10: Synthesis of 2-(ethylsulfonyl)-N-isopropoxy-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide (Compound 181) Step-1: Synthesis of tert-butyl 2-cyano-2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acetate To a stirred solution of tert-butyl cyanoacetate (14.33 g, 101 mmol) in / V, / V-dimcthylformamidc (200 mL), sodium hydride (60% by wt.; 4.06 g, 101 mmol) was added slowly at 0 °C, and the resulting mixture was stirred at 0 °C for 10 minutes followed by the addition of 5-bromo-2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidine (WO2021165834) (18 g, 67.7 mmol) and the resulting mixture was stirred at 25 °C for 14 h. After the completion of the reaction, the reaction mixture was poured slowly into water (IL). The aqueous layer was extracted with ethyl acetate (4 x 250 mL) and the combined organic layers were washed with saturated brine solution (250 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was purified using flash column cromatography to obtain tert-butyl 2-cyano-2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acetate (15 g, 46.0 mmol, 67.9 % yield).1H-NMR (400 MHz, DMSO-cL) 5 13.00 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 6.84 (s, 1H), 6.71 (d, J = 8.4 Hz, 1H), 3.89 (s, 1H), 1.51 (s, 9H); ESI MS (m / z) 324.85 (MH). Step-2: Synthesis of 2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acetonitrile To a stirred solution of tert-butyl 2-cyano-2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acetate (13 g, 39.8 mmol) in acetonitrile (130 mL), p-toluenesulfonic acid monohydrate (7.73 g, 39.8 mmol) was added and the resulting mixture was stirred at 80 °C for 3 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and poured into water (250 mL). The aqueous layer was extracted with ethyl acetate (2 x 200 mL) and the combined organic layers were washed with satuarted aqueous NaHCOs solution (200 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain desired 2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acetonitrile (7.3 g, 32.3 mmol, 81 % yield). ’H-NMR (400 MHz, CHLOROFORM-t / ) 5 8.77 (d, J = 7.2 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 6.97 (s, 1H), 4.03 (s, 2H); ESI MS (m / z) 224.95 (MH). Step-3: Synthesis of 3,3-bis(ethylthio)-2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acrylonitrile To a solution of potassium hydroxide (4.47 g, 80 mmol) in acetonitrile (150 mL), added 2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acetonitrile (9 g, 39.8 mmol) at 0 °C and the resulting mixture was stirred for 1 h at 25 °C. Then the reaction mixture was cooled to -5 °C and added dropwise, carbon disulfide (2.4 mL, 39.8 mmol) over 10 minutes. The resulted mixture was stirred for 1 h at -5 °C before the addition of ethyl iodie (6.43 mL, 80 mmol). The resulting reaction mixture was stirred for 2 h at 0 °C and then at 25 °C for 16 h. After the completion of the reaction, the reaction mixture was diluted with water (250 mL). Aqueous layer was extracted with ethyl acetate (2 x 250 mL) and the combined organic layers were washed with saturated brine solution (200 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain 3,3-bis(ethylthio)-2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acrylonitrile (11g, 30.7 mmol, 77 % yield) as solid. 'H-NMR (400 MHz, DMSO-A) 5 8.67 (d, J = 7.6 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.00 (s, 1H), 3.19 (q, J = 7.2 Hz, 2H), 3.08 (d, J = 7.2 Hz, 2H), 1.43 (t, J = 7.6 Hz, 3H), 1.32 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 358.95 (MH)+ Step-4: Synthesis of 3-(ethylthio)-4-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)-lH-pyrazol-5-amine To a stirred solution of 3,3-bis(ethylthio)-2-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)acrylonitrile (9 g, 25.1 mmol) in acetonitrile (90 mL) and ethanol (90 mL), hydrazine hydrate (1.37 mL, 27.6 mmol) was added dropwise at 0 °C and the resulting mixture was stirred at 25 °C for 1 h and then stirred at 75 °C for 14 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C and poured into water (IL). Aqueous layer was extracted with ethyl acetate (4 x 200 mL) and the combined organic layers were washed with saturated brine solution (250 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was washed with a solution of 20% ethylacetate in hexane to obatin the desired 3-(ethylthio)-4-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)-lH-pyrazol-5-amine (6.9 g, 21.02 mmol, 84 % yield) as solid. ’H-NMR (400 MHz, DMSO-t / 6) 5 12.09 (s, 1H), 9.02 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 6.94-6.89 (m, 3H), 3.04 (q, J = 6.8 Hz, 2H), 1.32 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 329.00 (MH)+. Step-5: Synthesis of ethyl 2-(ethylthio)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylate To a stirred solution of 3-(ethylthio)-4-(2-(trifluoromethyl)pyrazolo[l,5-a]pyrimidin-5-yl)-lH-pyrazol-5-amine (8 g, 24.37 mmol) in acetic acid (50 mL). ethyl (E)-4-ethoxy-2-oxobut-3-enoate (8.39 g, 48.7 mmol) was added at 25 °C and the reaction mixture was stirred at 100 °C for 4 h. After the completion of the reaction, the reaction mixture was cooled to 25 °C then poured into water (500 mL). The aqueous layer was extracted with ethyl acetate (4 x 200 mL), and the combined organic layers were washed with saturated brine solution (250 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain the desired ethyl 2-(ethyhhio)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylate (5.6 g, 12.83 mmol, 52.7 % yield) as solid.. ’H-NMR (400 MHz, DMSO-t / 6) 5 8.67-8.64 (m, 2H), 8.49 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 4.4 Hz, 1H), 6.95 (s, 1H), 4.59 (q, J = 7.2 Hz, 2H), 3.33 (q, J = 7.2 Hz, 2H), 1.57-1.49 (m, 6H); ESI MS (m / z) 437.10 (MH)+. Step-6: Synthesis of ethyl 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine] -7-carboxylate The desired ethyl 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylate (4.2 g, 8.97 mmol, 93 % yield) was prepared from of ethyl 2-(ethylthio)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylate (4.2 g, 9.62 mmol), using the similar procedure mentioned in step-8 of Example-1. 'H-NMR (400 MHz, DM SO-cT) 5 9.38 (dd, J = 7.3, 0.7 Hz, 1H), 9.06 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 7.3 Hz, 1H), 7.88 (d, J = 4.2 Hz, 1H), 7.33 (s, 1H), 4.53 (q, J = 7.1 Hz, 2H), 3.92 (q, J = 7.4 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.32 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 468.90 (MH)+ Step-7: Synthesis of 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylic acid The desired 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylic acid (3.5 g, 7.95 mmol, 93 % yield) was prepared from of ethyl 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylate (4 g, 8.54 mmol), using the similar procedure mentioned in step-6 of Example-1. 'H-NMR (400 MHz, DMSO-A) 5 9.36 (dd, J = 7.5, 0.8 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.01 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 4.3 Hz, 1H), 7.31 (s, 1H), 3.94 (q, J = 7.4 Hz, 2H), 1.33-1.29 (m, 3H); ESI MS (m / z) 440.85 (MH)+ Step-8: Synthesis of 2-(ethylsulfonyl)-N-isopropoxy-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine] -7-carboxamide The desired 2-(ethylsulfonyl)-N-isopropoxy-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxamide (90 mg, 0.181 mmol, 39.8 % yield) was prepared from of 2-(ethylsulfonyl)-2'-(trifluoromethyl)-[3,5'-bipyrazolo[l,5-a]pyrimidine]-7-carboxylic acid (200 mg, 0.454 mmol), using the similar procedure mentioned in step-7 of Example-1. 'H-NMR (400 MHz, DM SO-cT) 5 12.00 (s, 1H), 9.39 (dd, J = 7.5, 0.8 Hz, 1H), 9.05 (d, J = 4.3 Hz, 1H), 8.00 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 4.3 Hz, 1H), 7.33 (s, 1H), 4.32-4.26 (m, 1H), 3.99-3.91 (m, 2H), 1.37-1.26 (m, 9H); ESI MS (m / z) 498.15 (MH)+. Table-A: Representative compounds of the present disclosure were prepared according to the suitable methods as described in the respective schemes and chemistry examples. Compound Number Structure Analytical Data 1 1 O 1 1 * J f z-z ° 'H-NMR (400 MHz, DMSO-t / 6) 5 8.98 (d, J = 4.2 Hz, 1H), 8.85 (q, J = 0.9 Hz, 1H), 8.63 (dd, J = 2.1, 0.6 Hz, 1H), 7.93-7.90 (m, 1H), 4.54 (q, J = 7.1 Hz, 2H), 3.78 (d, J = 7.1 Hz, 3H), 3.71 (q, J = 7.3 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.32-1.22 (m, 4H); ESI MS (m / z) 482.55 (MH)+ 2 \ ZI O= / o / " T / o 1 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.31 (d, J = 4.9 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.83 (d, J = 4.4 Hz, 1H), 3.813.76 (m, 5H), 3.01 (d, J = 4.6 Hz, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 467.55 (MH)+ 3 F ’H-NMR (400 MHz, DMSO-t / 6) 5 9.71 (t, J = 6.1 Hz, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.86-8.86 (m, 1H), 8.648.64 (m, 1H), 7.86 (d, J = 4.4 Hz, 1H), 6.28 (tt, J = 55.3, 3.4 Hz, 1H), 3.96 (tdd, J = 16.3, 6.0, 3.4 Hz, 2H), 3.84-3.73 (m, 5H), 1.32-1.21 (m, 4H); ESI MS (m / z) 517.90 (MH)+ 4 f\xAu 'H-NMR (400 MHz, DMSO-t / 6) 5 9.38 (t, J = 5.4 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.86 (dd, J = 2.1, 0.6 Hz, 1H), 8.64 (t, J = 1.1 Hz, 1H), 7.81 (d, J = 4.2 Hz, 1H), 3.81-3.74 (m, 5H), 3.52-3.45 (m, 2H), 1.29-1.16 (m, 7H); ESI MS (m / z) 481.55 (MH)+ 5 ■ / ^Z>^Z 1 O / 1 " J / Yn ° / ^o o I ’H-NMR (400 MHz, DMSO-t / 6) 5 8.94 (d, J = 4.2 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.63-8.63 (m, 1H), 7.79 (d, J = 4.2 Hz, 1H), 3.78 (s, 3H), 3.72 (q, J = 7.3 Hz, 2H), 1.27-1.22 (m, 4H); ESI MS (m / z) 454.55 (MH)+ 6 ■ / -z^z 1 o I 1 " J ° / o IZ ’H-NMR (400 MHz, DMSO-t / 6) 5 9.39 (d, J = 4.4 Hz, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.77 (d, J = 4.2 Hz, 1H), 3.783.71 (m, 5H), 3.02 (td, J = 7.3, 4.1 Hz, 1H), 1.27 (t, J = 7.3 Hz, 3H), 0.87 (td, J = 7.1, 5.1 Hz, 2H), 0.66-0.62 (m, 2H); ESI MS (m / z) 494.12 (MH)+. 7 f\x:4u 'H-NMR (400 MHz, DMSO-t / 6) 5 9.50 (t, J = 5.5 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 4.2 Hz, 1H), 3.793.74 (m, 5H), 3.40-3.37 (m, 2H), 1.28 (t, J = 7.3 Hz, 3H), 0.55-0.50 (m, 2H), 0.37-0.33 (m, 2H); ESI MS (m / z) 508.13 (MH)+. 8 -Zx^z 1 O / 1 " J Yen ° Ao IZ y 'H-NMR (400 MHz, DMSO-t / 6) 5 9.74 (t, J = 5.4 Hz, 1H), 8.99 (d, J = 4.4 Hz, 1H), 8.86 (t, J = 0.9 Hz, 1H), 8.64-8.63 (m, 1H), 7.85 (d, J = 4.2 Hz, 1H), 4.30 (q, J = 2.7 Hz, 2H), 3.82-3.67 (m, 5H), 3.32-3.31 (m, 2H), 1.29-1.22 (m, 3H); ESI MS (m / z) 492.10 (MH)+. 9 r- F ’H-NMR (400 MHz, DMSO-t / 6) 5 9.45 (t, J = 5.9 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.86 (dd, J = 2.1, 0.6 Hz, 1H), 8.64-8.64 (m, 1H), 7.84 (d, J = 4.4 Hz, 1H), 3.793.73 (m, 5H), 3.32 (d, J = 6.1 Hz, 2H), 1.97-1.87 (m, 2H), 1.25 (q, J = 7.7 Hz, 3H), 1.04-1.01 (m, 6H); ESI MS (m / z) 510.15 (MH)+. 10 I O 1 1 w J ° / ^o J 'H-NMR (400 MHz, DMSO-t / 6) 5 8.97 (d, J = 4.2 Hz, 1H), 8.86 (q, J = 0.9 Hz, 1H), 8.63 (dd, J = 2.1, 0.6 Hz, 1H), 7.76 (d, J = 4.2 Hz, 1H), 4.73 (dd, J = 22.7, 12.0 Hz, 4H), 3.80-3.74 (m, 5H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 530.10 (MH)+. 11 1 O 1 1 " J ZYn ° / =0 "Z \ 'H-NMR (400 MHz, DMSO-t / 6) 5 8.94 (d, J = 4.2 Hz, 1H), 8.85 (dd, J = 2.1,0.6 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 7.62 (d, J = 4.2 Hz, 1H), 3.83 (s, 3H), 3.75 (q, J = 7.3 Hz, 2H), 3.15 (s, 3H), 2.94 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 482.12 (MH)+. 12 f\iAu 'H-NMR (400 MHz, DMSO-t / 6) 5 9.53 (t, J = 5.7 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 4.2 Hz, 1H), 6.035.94 (m, 1H), 5.46 (dd, J = 17.4, 1.5 Hz, 1H), 5.22 (dd, J = 10.5, 1.5 Hz, 1H), 4.12 (t, J = 5.1 Hz, 2H), 3.843.73 (m, 5H), 1.25 (q, J = 7.6 Hz, 3H); ESI MS (m / z) 494.12 (MH)+. 13 E f        "Z\-0 f\Au f N^> H--SF ’H-NMR (400 MHz, DMSO-t / 6) 5 9.63 (t, J = 5.8 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.83 (d, J = 4.3 Hz, 1H), 3.803.71 (m, 7H), 2.73-2.61 (m, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 550.11 (MH)+. 14 F            ''ZZq'^-O f\Am ' nJ x^.—     n    / \ F F 'H-NMR (400 MHz, DMSO-t / 6) 5 9.92 (t, J = 6.3 Hz, 1H), 9.00 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.85 (d, J = 4.3 Hz, 1H), 4.434.34 (m, 2H), 3.75 (q, J = 7.5 Hz, 5H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 536.09 (MH)+. 15 F         "-'s'0 F F 'H-NMR (400 MHz, DMSO-t / 6) 5 9.93 (t, J = 6.4 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.86 (q, J = 0.9 Hz, 1H), 8.64-8.64 (m, 1H), 7.85 (d, J = 4.2 Hz, 1H), 4.44 (td, J = 15.5, 6.4 Hz, 2H), 3.78-3.72 (m, 5H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 586.09 (MH)+. 16 - F ^¢¢0 F\xHU ’H-NMR (400 MHz, DMSO-t / 6) 5 8.95 (d, J = 4.2 Hz, 1H), 8.86-8.85 (m, 1H), 8.63-8.63 (m, 1H), 7.70 (d, J = 4.2 Hz, 1H), 5.61-5.44 (m, 1H), 4.63-4.45 (m, 2H), 4.37-4.26 (m, 2H), 3.80-3.79 (m, 3H), 3.75 (td, J = 7.4, 1.9 Hz, 2H), 1.25 (q, J = 7.1 Hz, 3H); ESI MS (m / z)512.11 (MH)+. 17 ' NH* ’H-NMR (400 MHz, DMSO-t / 6) 5 8.99 (d, J = 4.2 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.79 (d, J = 21.8 Hz, 2H), 8.64 (d, J = 1.5 Hz, 1H), 7.85 (d, J = 4.2 Hz, 1H), 3.843.76 (m, 5H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 454.09 (MH)+. 18 1 o I 1 " J ° Ao IZ^ ’H-NMR (400 MHz, DMSO-A) 5 9.54 (s, 1H), 8.96 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.77 (d, J = 4.4 Hz, 1H), 3.77-3.71 (m, 5H), 1.49 (s, 3H), 1.30-1.22 (m, 3H), 0.87-0.81 (m, 2H), 0.80-0.75 (m, 2H); ESI MS (m / z) 507.7 (MH)+. 19 _ F ' -CrV9 ’H-NMR (400 MHz, DMSO-t / 6) 5 12.29 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.80 (d, J = 4.4 Hz, 1H), 3.86 (s, 3H), 3.79-3.74 (m, 5H), 1.29-1.22 (m, 3H); ESI MS (m / z) 484.0 (MH)+. 20 '\«4v ' n^J^cn ’H-NMR (400 MHz, DMSO-t / 6) 5 9.91 (t, J = 5.5 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.93 (d, J = 4.2 Hz, 1H), 4.62 (d, J = 5.6 Hz, 2H), 3.84-3.76 (m, 5H), 1.29-1.22 (m, 3H); ESI MS (m / z) 493.05 (MH)+. 21 F 'H-NMR (400 MHz, DMSO-t / 6) 5 11.37 (s, 1H), 9.05 (d, J = 4.2 Hz, 1H), 8.87 (t, J = 1.0 Hz, 1H), 8.65 (d, J = 1.5 Hz, 1H), 7.93 (d, J = 4.2 Hz, 1H), 7.76 (dd, J = 8.6, 1.0 Hz, 2H), 7.49-7.45 (m, 2H), 7.26-7.22 (m, 1H), 3.82 (s, 3H), 3.76 (q, J = 7.3 Hz, 2H), 1.28 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 530.05 22 ZI O^ / o rz\)> / "      1 / o 1 ’H-NMR (400 MHz, DMSO- de) 8 10.09 (s, 1H), 9.00 (d, J = 4.4Hz, 1H), 8.86 (dd, J = 2.1,0.6 Hz, 1H), 8.648.63 (m, 1H), 7.84 (d, J = 4.2 Hz, 1H), 3.78-3.73 (m, 5H), 1.76-1.68 (m, 2H), 1.46-1.38 (m, 2H), 1.31-1.24 (m, 3H); ESI MS (m / z) 519.0 (MH)+. 23 z A 1 O 1 1 "J f z-z ° Ao IZ \ 'H-NMR (400 MHz, DMSO-t / 6) 8 9.42 (t, J = 4.8 Hz, 1H), 9.39 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.69 (d, J = 0.5 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 4.4 Hz, 1H), 7.52 (dd,J = 9.4,1.8 Hz, 1H),4.11 (q, J = 7.4 Hz, 2H), 2.99 (d, J = 4.6 Hz, 3H), 1.25 (q, J = 7.4 Hz, 3H); ESI MS (m / z) 453.10 24 CM I z O^ / z-z O. H \ ? ^J'o 1 '1 X o LL? ’H-NMR (400 MHz, DMSO-t / 6) 8 8.97 (d, J = 4.3 Hz, 1H), 8.87 (s, 1H), 8.74 (s, 1H), 8.22 (d, J = 9.2 Hz, 1H), 7.81 (d, J = 4.3 Hz, 1H), 7.61 (d, J = 9.2 Hz, 1H), 5.37 (dd, J = 13.8, 12.8 Hz, 2H), 3.85 (q, J = 7.4 Hz, 2H), 1.29-1.24 (m, 3H); ESI MS (m / z) 481.35 (MH)+ 25 I Z-^ O^Z z-z o. J \ / ) w^x^^z ^s° 1 K^Z II X o LL? 'H-NMR (400 MHz, DMSO-t / 6) 8 9.35 (d, J = 4.6 Hz, 1H), 8.96 (d, J = 4.2 Hz, 1H), 8.21 (d, J = 9.3 Hz, 1H), 7.78 (d, J = 4.2 Hz, 1H), 7.60 (d, J = 9.3 Hz, 1H), 5.37 (t, J = 13.7 Hz, 2H), 3.85 (q, J = 7.4 Hz, 2H), 2.99 (d, J = 4.6 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 495.10 (MH)+ 26 o ^S'° c a zo-<y-<h o FsC-?—' n=n VnvJ( F 'H-NMR (400 MHz, DMSO- de) 5 8.91 (d, J = 4.4 Hz, 1H), 8.22 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 7.55 (d, J = 4.2 Hz, 1H), 5.36 (t, J = 13.3 Hz, 2H), 3.80 (q, J = 7.3 Hz, 2H), 3.13 (s, 3H), 2.90 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 509.00 (MH)+ 27 F      ^0*0 ’H-NMR (400 MHz, DMSO-t / 6) 5 8.94 (d, J = 4.4 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 7.65 (d, J = 4.2 Hz, 1H), 3.87 (d, J = 14.4 Hz, 1H), 3.83 (s, 3H), 3.78-3.65 (m, 5H), 3.59 (t, J = 4.8 Hz, 2H), 3.37 (d, J = 3.4 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 524.1 (MH)+. 28 'Xi:4v. v n^nA ’H-NMR (400 MHz, DMSO- de) 8 9.31 (d, J = 7.3 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 4.18 (q, J = 6.8 Hz, 1H), 3.78-3.71 (m, 5H), 1.30-1.22 (m, 9H); ESI MS (m / z) 496.2 (MH)+. 29 z 1 0 1 ^^z-z 0 z \ ’H-NMR (400 MHz, DMSO-A) 8 9.39 (s, 1H), 8.92 (d, J = 4.2 Hz, 1H), 8.66 (d, J = 0.5 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.51 (dt, J = 7.6, 1.8 Hz, 2H), 4.05 (q, J = 7.3 Hz, 2H), 3.13 (s, 3H), 2.89 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 467.45 (MH)+. 30 T 0 / 1 w J n " Y_z-z' 0 ^0 ’H-NMR (400 MHz, DMSO-t / 6) 8 9.37 (d, J = 4.4 Hz, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.76 (d, J = 4.2 Hz, 1H), 3.803.71 (m, 5H), 2.73 (td, J = 7.5, 3.9 Hz, 1H), 1.27 (t, J = 7.5 Hz, 3H), 1.18 (t, J = 4.8 Hz, 1H), 1.15-1.11 (m, 3H), 0.82-0.77 (m, 1H), 0.69-0.65 (m, 1H); ESI MS (m / z) 508.45 (MH)+. 31 1- f < ' nJOaCF3 ’H-NMR (400 MHz, DMSO- de) 8 9.82 (d, J = 8.9 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.80 (d, J = 4.3 Hz, 1H), 4.99 (d, J = 8.3 Hz, 1H), 3.79 (s, 3H), 3.71 (q, J = 7.3 Hz, 2H), 1.42 (d, J = 6.7 Hz, 3H), 1.27 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 550.15 (MH)+. 32 f ' / N 'H-NMR (400 MHz, DMSO-t / 6) 8 8.93 (t, J = 4.2 Hz, 1H), 8.85 (d, J = 1.7 Hz, 1H), 8.62 (d, J = 1.8 Hz, 1H), 7.62 (dd, J = 4.3, 0.9 Hz, 1H), 3.83 (d, J = 3.7 Hz, 3H), 3.73 (q, J = 7.3 Hz, 2H), 3.12 (s, 2H), 2.91 (s, 1H), 1.26-1.18 (m, 5H), 1.12-1.06 (m, 3H); ESI MS (m / z) 496.5 (MH)+. 33 ■3' 1 0 / 1 " J ^^z-z 0 Yo IZ^ 'H-NMR (400 MHz, DMSO- de) 8 9.61 (d, J = 7.3 Hz, 1H), 8.98 (d, J = 4.0 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.78 (d, J = 4.3 Hz, 1H), 4.51 (q, J = 7.9 Hz, 1H), 3.75 (q, J = 7.7 Hz, 5H), 2.41-2.33 (m, 2H), 2.09-1.98 (m, 2H), 1.82-1.75 (m, 2H), 1.29 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 507.5 (MH)+. 34 F 'H-NMR (400 MHz, DMSO-t / 6) 5 9.41 (t, J = 5.5 Hz, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.86-8.86 (m, 1H), 8.648.64 (m, 1H), 7.82 (d, J = 4.2 Hz, 1H), 3.78 (s, 3H), 3.75 (t, J = 7.5 Hz, 2H), 3.43 (dd, J = 12.6, 6.7 Hz, 2H), 1.63 (td, J = 14.2, 7.3 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H), 1.01 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 495.5 (MH)+. 35 X o^ / z-z ox J! A yo I f II X o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.35 (d, J = 4.9 Hz, 1H), 8.95 (d, J = 4.2 Hz, 1H), 8.67 (dd, J = 23.7, 1.5 Hz, 2H), 7.76 (d, J = 4.2 Hz, 1H), 5.27-5.20 (m, 2H), 3.79 (q, J = 7.3 Hz, 2H), 2.99 (d, J = 4.9 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 495.40 (MH)+ 36 'H-NMR (400 MHz, DMSO- de) 5 8.94 (d, J = 4.2 Hz, 1H), 8.65 (dd, J = 16.5, 1.3 Hz, 2H), 7.82 (d, J = 4.2 Hz, 1H), 5.27-5.20 (m, 2H), 4.52 (q, J = 7.1 Hz, 2H), 3.71 (q, J = 7.4 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 510.40 (MH)+ 37 \ z^ o^ / z-z Q. / / \    / / ^'O I X o ’H-NMR (400 MHz, DMSO- de) 5 8.90 (d, J = 4.2 Hz, 1H), 8.70 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.53 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.8 Hz, 2H), 3.73 (q, J = 7.4 Hz, 2H), 3.13 (s, 3H), 2.89 (s, 3H), 1.23 (q, J = 7.2 Hz, 3H); ESI MS (m / z) 508.50 (MH)+ 38 y z 1 ° 1 / Yyf {^z-z ° Ao \ 'H-NMR (400 MHz, DMSO-t / 6) 5 8.92 (t, J = 4.0 Hz, 2H), 8.71 (s, 1H), 8.13 (s, 1H), 7.52 (d, J = 4.2 Hz, 1H), 7.25 (dd, J = 7.2, 1.8 Hz, 1H), 4.07 (q, J = 7.3 Hz, 2H), 3.13 (s, 3H), 2.89 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 466.95 (MH)+ 39 zx 0A ZZ } A / "z ^ah Z^ / £ O LJ_ LL? ’H-NMR (400 MHz, DMSO-A) 5 9.45 (s, 1H), 8.95 (d, J = 4.4 Hz, 1H), 8.72 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.77 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.6 Hz, 2H), 3.75 (q, J = 7.3 Hz, 2H), 1.46 (s, 9H), 1.28 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 537.45 (MH)+ 40 8 -S 0 )=N o F,>ozyvA F F         N^J < 'H-NMR (400 MHz, DMSO- de) 5 9.42 (t, J = 5.5 Hz, 1H), 8.95 (d, J = 4.3 Hz, 1H), 8.71 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.75 (d, J = 4.0 Hz, 1H), 5.23 (dd, J = 13.8, 13.1 Hz, 2H), 3.77 (q, J = 7.3 Hz, 2H), 3.49-3.43 (m, 2H), 1.26 (t, J = 7.3 Hz, 3H), 1.21 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 508.50 (MH)+ 41 Mny ’H-NMR (400 MHz, DMSO- de) 5 9.45 (d, J = 4.3 Hz, 1H), 8.94 (d, J = 4.3 Hz, 1H), 8.71 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.71 (d, J = 4.3 Hz, 1H), 5.275.17 (m, 2H), 3.75 (q, J = 7.3 Hz, 2H), 3.00 (qd, J = 7.5, 3.7 Hz, 1H), 1.26 (t, J = 7.5 Hz, 3H), 0.89-0.79 (m, 2H), 0.68-0.60 (m, 2H); ESI MS (m / z) 520.70 (MH)+ 42 1 O 1 1 " J f z-z ° / «o IZ 6 “'O o ’H-NMR (400 MHz, DMSO- d6) 8 10.09 (d, J = 5.4 Hz, 1H), 9.01 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.82 (d, J = 4.4 Hz, 1H), 4.82-4.73 (m, 3H), 4.25-4.22 (m, 2H), 3.78 (s, 3H), 3.74 (t, J = 7.3 Hz, 2H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 557.4 (MH)+. 43 K 0 0 \ hN O V F3C>^ j Mw F F °^N J J H 'H-NMR (400 MHz, DMSO-t / 6) 5 9.57 (t, J = 5.5 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 8.71 (d, J = 1.2 Hz, 1H), 8.65 (d, J = 1.5 Hz, 1H), 7.78 (d, J = 4.3 Hz, 1H), 5.24 (t, J = 13.8 Hz, 2H), 3.78 (q, J = 7.3 Hz, 2H), 3.36 (t, J = 6.3 Hz, 2H), 1.27 (t, J = 7.3 Hz, 3H), 1.09 (s, 1H), 0.54-0.49 (m, 2H), 0.33 (q, J = 5.0 Hz, 2H); ESI MS (m / z) 535.40 (MH)+ 44 T| y z « J s' \ Co Hx'° / =° —Z\__ 'H-NMR (400 MHz, DMSO- d6) 8 8.87 (t, J = 4.4 Hz, 1H), 8.70 (d, J = 1.2 Hz, 1H), 8.58 (d, J = 1.5 Hz, 1H), 7.48 (t, J = 4.3 Hz, 1H), 5.24-5.17 (m, 2H), 3.70-3.59 (m, 3H), 3.20 (q, J = 7.0 Hz, 1H), 3.11 (s, 2H), 2.86 (s, 1H), 1.29-1.18 (m, 4H), 1.10 (t, J = 7.0 Hz, 2H); ESI MS (m / z) 522.50 (MH)+ 45 _ 0 o \=N  9 / UvVy 'H-NMR (400 MHz, DMSO- d6) 8 9.95 (s, 1H), 8.92 (d, J = 4.3 Hz, 1H), 7.98 (d, J = 0.6 Hz, 1H), 7.84-7.80 (m, 2H), 7.22 (d, J = 5.2 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 4.40 (q, J = 9.6 Hz, 2H), 3.72 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 602.35 (MH)+ 46 'H-NMR (400 MHz, DMSO-t / 6) 8 9.57 (t, J = 5.4 Hz, 1H), 8.91 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 1.0 Hz, 1H), 7.83-7.81 (m, 2H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 3.74 (q, J = 7.4 Hz, 2H), 3.40-3.37 (m, 2H), 1.26 (t, J = 7.3 Hz, 3H), 1.15-1.08 (m, 1H), 0.550.50 (m, 2H), 0.36-0.33 (m, 2H); ESI MS (m / z) 574.00 (MH)+ 47 Y X z O^Z o J 'Z-^Zz / '    * O Um LL 'H-NMR (400 MHz, DMSO-t / 6) 8 9.44 (d, J = 4.2 Hz, 1H), 8.90 (d, J = 4.2 Hz, 1H), 7.97-7.95 (m, 1H), 7.81 (dd, J = 5.0, 0.9 Hz, 1H), 7.74 (d, J = 4.2 Hz, 1H), 7.21 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.7 Hz, 2H), 3.71 (q, J = 7.3 Hz, 2H), 3.02 (qd, J = 7.5, 3.6 Hz, 1H), 1.25 (t, J = 7.5 Hz, 3H), 0.87 (td, J = 7.1, 5.1 Hz, 2H), 0.650.61 (m, 2H); ESI MS (m / z) 560.05 (MH)+ 48 v F3C       -- N 0 / =^   0 'H-NMR (400 MHz, DMSO-t / 6) 8 8.91 (d, J = 4.3 Hz, 1H), 8.68 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.70 (d, J = 4.3 Hz, 1H), 5.23 (dd, J = 14.2, 13.3 Hz, 2H), 3.72 (q, J = 7.3 Hz, 3H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 481.65 (MH)+ 49 f3c                          9 I >—J7           J 4     r y^N ’H-NMR (400 MHz, DMSO-t / 6) 5 8.89 (d, J = 4.2 Hz, 1H), 8.71 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.54 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.4 Hz, 2H), 3.71 (s, 2H), 3.58 (d, J = 6.8 Hz, 2H), 3.19 (s, 2H), 1.291.20 (m, 6H), 1.06 (t, J = 7.0 Hz, 3H); ESI MS (m / z) 536.90 (MH)+ 50 ° \ PA £ o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 8.93 (d, J = 4.2 Hz, 1H), 8.70 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.68 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.8 Hz, 2H), 4.70 (q, J = 13.0 Hz, 4H), 3.76 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 556.80 (MH)+ 51 O=Y^ Z-Zf} & o ^-LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.45 (d, J = 8.6 Hz, 1H), 8.96 (d, J = 4.2 Hz, 1H), 8.72 (d, J = 1.2 Hz, 1H), 8.65 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 5.275.20 (m, 2H), 4.00 (q, J = 6.8 Hz, 1H), 3.80-3.70 (m, 2H), 1.84 (dt, J = 18.8, 6.8 Hz, 1H), 1.25 (t, J = 7.3 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H), 0.99 (dd, J = 9.8, 6.8 Hz, 6H); ESI MS (m / z) 550.80 (MH)+ 52 F ’H-NMR (400 MHz, DMSO-t / 6) 8 10.10 (d, J = 6.6 Hz, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.80 (d, J = 4.2 Hz, 1H), 5.14 (q, J = 7.1 Hz, 1H), 4.90 (t, J = 7.1 Hz, 2H), 4.59 (t, J = 6.5 Hz, 2H), 3.79-3.73 (m, 6H), 1.28 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 510.0 (MH)+. 53 i- f ■X4Yu ’H-NMR (400 MHz, DMSO- de) 8 9.95 (d, J = 7.3 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.86 (s, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.78 (d, J = 4.2 Hz, 1H), 5.31 (q, J = 8.2 Hz, 1H), 3.78-3.73 (m, 5H), 3.54-3.49 (m, 2H), 3.443.39 (m, 2H), 1.28 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 525.4 (MH)+. 54 Yx4v ’H-NMR (400 MHz, DMSO- de) 8 8.99 (d, J = 4.2 Hz, 1H), 8.86 (s, 1H), 8.63 (s, 1H), 7.73 (d, J = 3.9 Hz, 1H), 3.82 (s, 3H), 3.76 (d, J = 7.3 Hz, 2H), 3.13 (s, 3H), 2.83 (s, 1H), 1.26-1.20 (m, 3H), 0.57 (s, 2H), 0.44 (d, J = 5.6 Hz, 2H); ESI MS (m / z) 507.9 (MH)+. 55 J1 -n o y^-z zO^ / o y^z-z Ao z I ’H-NMR (400 MHz, DMSO-t / 6) 8 9.42 (t, J = 5.5 Hz, 1H), 8.91 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.81 (dd, J = 5.0, 0.9 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 7.22 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.3 Hz, 2H), 3.74 (q, J = 7.4 Hz, 2H), 3.52-3.45 (m, 2H), 1.27-1.21 (m, 6H); ESI MS (m / z) 547.45 (MH)+ 56 1 o / 1 " J ° Yo ’H-NMR (400 MHz, DMSO- de) 8 8.93 (d, J = 4.2 Hz, 1H), 8.85 (q, J = 0.9 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 4.2 Hz, 1H), 3.83 (s, 3H), 3.75 (d, J = 17.9 Hz, 2H), 3.60 (q, J = 7.0 Hz, 2H), 3.24 (d, J = 6.1 Hz, 2H), 1.27-1.20 (m, 6H), 1.09 (t, J = 7.0 Hz, 3H); ESI MS (m / z) 509.5 (MH)+. 57 1 o 1 1 w J / “O IZ ’H-NMR (400 MHz, DMSO- de) 5 9.82 (t, J = 6.0 Hz, 1H), 8.99 (d, J = 4.0 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.8 Hz, 1H), 7.84 (d, J = 4.3 Hz, 1H), 7.52 (d, J = 7.6 Hz, 2H), 7.40-7.37 (m, 2H), 7.32-7.28 (m, 1H), 4.71 (d, J = 5.8 Hz, 2H), 3.79-3.72 (m, 5H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 543.5 (MH)+. 58 i- F                    ' 'H-NMR (400 MHz, DMSO- de) 5 8.97 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.77 (d, J = 4.3 Hz, 1H), 3.89-3.79 (m, 3H), 3.73 (q, J = 7.3 Hz, 2H), 3.63 (d, J = 11.3 Hz, 3H), 3.45 (s, 3H), 1.29-1.21 (m, 3H); ESI MS (m / z) 497.4 (MH)+. 59 JP m o Az o < '° # z z ^=° O X 'H-NMR (400 MHz, DMSO-t / 6) 5 8.92 (d, J = 4.2 Hz, 1H), 8.19 (d, J = 9.3 Hz, 1H), 7.74 (d, J = 4.2 Hz, 1H), 7.59 (d, J = 9.0 Hz, 1H), 5.36 (t, J = 13.6 Hz, 2H), 3.79 (q, J = 7.4 Hz, 2H), 1.28-1.22 (m, 3H); ESI MS (m / z) 481.90 (MH)+ 60 0^° F3<\       / 7-^          ° 'H-NMR (400 MHz, DMSO- de) 5 8.92 (d, J = 4.2 Hz, 1H), 8.21 (d, J = 9.3 Hz, 1H), 7.64 (d, J = 4.2 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 5.59-5.41 (m, 1H), 5.36 (t, J = 13.4 Hz, 2H), 4.61-4.40 (m, 2H), 4.35-4.24 (m, 2H), 3.85-3.79 (m, 2H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 539.15 (MH)+ 61 F ? / - N NH vJH '—  0 'H-NMR (400 MHz, DMSO-t / 6) 5 9.57 (t, J = 5.5 Hz, 1H), 8.97 (d, J = 4.0 Hz, 1H), 8.22 (d, J = 9.2 Hz, 1H), 7.80 (d, J = 4.3 Hz, 1H), 7.61 (d, J = 9.2 Hz, 1H), 5.405.34 (m, 2H), 3.83 (q, J = 7.3 Hz, 2H), 3.38-3.31 (m, 2H), 1.28 (t, J = 7.3 Hz, 3H), 1.12-1.07 (m, 1H), 0.540.50 (m, 2H), 0.34 (td, J = 5.3, 3.9 Hz, 2H); ESI MS (m / z) 534.95 (MH)+ 62 o= / o rO .co r          I o X 1 ( U X o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 8.95-8.92 (m, 1H), 8.23-8.17 (m, 1H), 7.67-7.57 (m, 2H), 5.37 (dd, J = 13.8, 12.8 Hz, 2H), 4.79 (s, 1H), 3.83-3.75 (m, 2H), 3.21 (s, 1H), 3.00 (s, 2H), 2.51 (d, J = 1.8 Hz, 1H), 2.45 (d, J = 1.8 Hz, 1H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 533.95 (MH)+ 63 ,Co ° V F                  N F3c4— / N=N V'NxrA / F                                l ° 'H-NMR (400 MHz, DMSO-t / 6) 5 8.94 (d, J = 4.3 Hz, 1H), 8.24 (d, J = 9.2 Hz, 1H), 7.69 (d, J = 4.3 Hz, 1H), 7.60 (d, J = 9.2 Hz, 1H), 5.36 (t, J = 13.4 Hz, 2H), 3.79 (q, J = 7.3 Hz, 2H), 3.59 (s, 3H), 3.44 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 525.20 (MH)+ 64 _v° F3C. F     o* \      _ F\ / F ’H-NMR (400 MHz, DMSO-t / 6) 5 9.75 (t, J = 5.9 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.81 (d, J = 4.2 Hz, 1H), 7.61 (d, J = 9.3 Hz, 1H), 6.27 (tt, J = 55.2, 3.4 Hz, 1H), 5.37 (t, J = 13.8 Hz, 2H), 3.94 (tdd, J = 16.3, 6.0, 3.4 Hz, 2H), 3.82 (q, J = 7.3 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 544.80 (MH)+ 65 ZI o= / o rQ -CO r " i o X 1 J 11? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.96 (d, J = 7.6 Hz, 1H), 8.97 (d, J = 4.3 Hz, 1H), 8.22 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 4.3 Hz, 1H), 7.61 (d, J = 9.2 Hz, 1H), 5.415.33 (m, 2H), 5.30 (t, J = 7.9 Hz, 1H), 3.83 (q, J = 7.3 Hz, 2H), 3.49 (td, J = 8.4, 1.4 Hz, 2H), 3.41 (td, J = 8.2,1.4Hz, 2H), 1.29 (t, J = 7.3 Hz, 3H); ESIMS (m / z) 553.25 (MH)+ 66 ’H-NMR (400 MHz, DMSO-t / 6) 5 8.94 (d, J = 4.3 Hz, 1H), 8.21 (d, J = 9.2 Hz, 1H), 7.70 (d, J = 4.3 Hz, 1H), 7.60 (d, J = 9.2 Hz, 1H), 5.37 (t, J = 13.6 Hz, 2H), 4.71 (q, J = 12.1 Hz, 4H), 3.83 (q, J = 7.3 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 557.10 (MH)+ 67 x° ’H-NMR (400 MHz, DMSO- de) 8 8.89 (d, J = 4.4 Hz, 1H), 8.23 (d, J = 9.0 Hz, 1H), 7.60 (d, J = 9.3 Hz, 1H), 7.55 (d, J = 4.2 Hz, 1H), 5.36 (t, J = 13.3 Hz, 2H), 3.79 (s, 2H), 3.58 (q, J = 7.0 Hz, 2H), 3.19 (s, 2H), 1.251.21 (m, 6H), 1.06 (t, J = 7.0 Hz, 3H); ESI MS (m / z) 537.40 (MH)+ 68 ^ZI o=( o rd w / A / yz C o T 1 Z \ " X LL? ’H-NMR (400 MHz, DMSO- de) 8 9.68 (d, J = 7.6 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 8.23 (d, J = 9.2 Hz, 1H), 7.74 (d, J = 4.3 Hz, 1H), 7.61 (dd, J = 9.2, 3.4 Hz, 1H), 5.37 (dd, J = 13.8, 12.8 Hz, 2H), 4.50 (q, J = 7.8 Hz, 1H), 3.83 (q, J = 7.4 Hz, 2H), 2.40-2.31 (m, 2H), 2.102.00 (m, 2H), 1.81-1.73 (m, 2H), 1.29 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 535.25 69 ~~Mo 0 V F. 0—P F3cM n=nV nvA  I , F    MM I ’H-NMR (400 MHz, DMSO-t / 6) 8 9.62 (t, J = 5.6 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.23 (d, J = 9.3 Hz, 1H), 7.84 (d, J = 4.4 Hz, 1H), 7.62 (d, J = 9.3 Hz, 1H), 5.37 (t, J = 13.6 Hz, 2H), 3.83 (q, J = 7.4 Hz, 2H), 3.28 (s, 2H), 1.25 (t, J = 7.3 Hz, 3H), 1.02 (s, 9H); ESI MS (m / z) 551.15 (MH)+ 70 F\ XYa n O F3C-)--n=n        __U CN F                      B 'H-NMR (400 MHz, DMSO-t / 6) 8 9.92 (t, J = 5.6 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.18 (d, J = 9.0 Hz, 1H), 7.86 (d, J = 4.2 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 5.37 (t, J = 13.8 Hz, 2H), 4.60 (d, J = 5.6 Hz, 2H), 3.85 (q, J = 7.4 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 520.05 (MH)+ 71 Mu ’H-NMR (400 MHz, DMSO- de) 8 9.31 (d, J = 4.9 Hz, 1H), 9.23 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.27 (d, J = 0.7 Hz, 1H), 7.83 (d, J = 4.4 Hz, 1H), 3.88 (s, 3H), 3.78 (q, J = 7.3 Hz, 2H), 3.01 (d, J = 4.9 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.1 (MH)+. 72 1 O / / / \^ u " y^z-z ° Mo IZ 'H-NMR (400 MHz, DMSO- de) 8 9.37 (t, J = 5.5 Hz, 1H), 9.23 (s, 1H), 8.99-8.96 (m, 1H), 8.28-8.25 (m, 1H), 7.82 (d, J = 4.4 Hz, 1H), 3.89 (d, J = 4.9 Hz, 3H), 3.82-3.70 (m, 2H), 3.52-3.45 (m, 2H), 1.29-1.21 (m, 6H); ESI MS (m / z) 482.0 (MH)+. 73 oS o 1 z> / £ O u. LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 8.90 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 1.0 Hz, 1H), 7.86-7.84 (m, 2H), 7.20 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.3 Hz, 2H), 4.54 (q, J = 7.1 Hz, 2H), 3.70 (q, J = 7.4 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 549.55 (MH)+ 74 (Xo °     1 n^?hn-A 'H-NMR (400 MHz, DMSO- de) 8 9.47 (dd, J = 31.5, 4.3 Hz, 1H), 8.96 (q, J = 4.4 Hz, 1H), 8.26-8.21 (m, 1H), 7.76 (dd, J = 33.0, 4.3 Hz, 1H), 7.65-7.59 (m, 1H), 5.43-5.33 (m, 2H), 3.81 (q, J = 7.4 Hz, 2H), 2.742.71 (m, 1H), 1.29-1.22 (m, 3H), 1.14 (dd, J = 22.8, 5.3 Hz, 3H), 1.04 (t, J = 8.3 Hz, 1H), 0.80-0.76 (m, 1H), 0.66 (dd, J = 12.5, 5.5 Hz, 1H); ESI MS (m / z) 535.25 (MH)+ 75 «Zg^O F                    0 F3C-)-^  N=N         y p. F                      h cn 'H-NMR (400 MHz, DMSO- de) 8 10.09 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.21 (d, J = 9.3 Hz, 1H), 7.78 (d, J = 4.2 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 5.37 (t, J = 13.8 Hz, 2H), 3.82 (q, J = 7.3 Hz, 2H), 1.72 (dd, J = 8.2, 5.5 Hz, 2H), 1.38 (dd, J = 8.2, 5.7 Hz, 2H), 1.28 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 546.25 (MH)+ 76 T ° 1 1 " j ^_z-zz ° X) IZ ’H-NMR (400 MHz, DMSO- de) 8 9.74 (t, J = 5.5 Hz, 1H), 9.23 (s, 1H), 8.99 (d, J = 4.4 Hz, 1H), 8.27 (d, J = 1.0 Hz, 1H), 7.85 (d, J = 4.2 Hz, 1H), 4.30 (q, J = 2.7 Hz, 2H), 3.88 (s, 3H), 3.77 (q, J = 7.3 Hz, 2H), 2.69 (d, J = 24.2 Hz, 1H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 492.0 (MH)+. 77 \          h yCFa F ’H-NMR (400 MHz, DMSO- de) 8 9.94 (t, J = 6.4 Hz, 1H), 9.24 (s, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.85 (d, J = 4.4 Hz, 1H), 4.44 (td, J = 15.4, 6.4 Hz, 2H), 3.89 (s, 3H), 3.74 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 586.1 (MH)+. 78 F      ^S'° ■7x4u ' Njn^ 'H-NMR (400 MHz, DMSO- de) 8 9.41 (t, J = 5.6 Hz, 1H), 9.24 (s, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.82 (d, J = 4.2 Hz, 1H), 3.89 (s, 3H), 3.75 (q, J = 7.4 Hz, 2H), 3.43 (dd, J = 12.6, 6.7 Hz, 2H), 1.65-1.58 (m, 2H), 1.26 (t, J = 7.5 Hz, 3H), 1.01 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 496.1 (MH)+. 79 zx o=v r " t / o 1 z^z" ’H-NMR (400 MHz, DMSO- de) 8 9.40 (d, J = 4.4 Hz, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.77 (d, J = 4.2 Hz, 1H), 3.88 (s, 3H), 3.73 (q, J = 7.4 Hz, 2H), 3.02 (td, J = 7.3, 4.2 Hz, 1H), 1.28-1.22 (m, 3H), 0.87 (td, J = 7.1, 5.1 Hz, 2H), 0.65-0.62 (m, 2H); ESI MS (m / z) 494.1 (MH)+. 80 1 □ 1 1 " J ° / ^o xz w ’H-NMR (400 MHz, DMSO- de) 8 9.91 (t, J = 6.4 Hz, 1H), 9.23 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.27 (d, J = 1.0 Hz, 1H), 7.86 (d, J = 4.4 Hz, 1H), 4.43-4.34 (m, 2H), 3.92 (d, J = 25.9 Hz, 3H), 3.74 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 536.0 (MH)+. 81 i- f 'H-NMR (400 MHz, DMSO- d6) 5 9.23 (s, 1H), 8.93 (d, J = 4.4 Hz, 1H), 8.26 (d, J = 0.7 Hz, 1H), 7.63 (d, J = 4.4 Hz, 1H), 3.94 (s, 3H), 3.74 (t, J = 7.5 Hz, 2H), 3.60 (q, J = 7.1 Hz, 2H), 3.25 (t, J = 6.5 Hz, 2H), 1.24 (q, J = 7.3 Hz, 6H), 1.12-1.06 (m, 3H); ESI MS (m / z) 510.3 (MH)+. 82 I   O / 1 " J ( Z-Z ° Ao IZ } Z. 'H-NMR (400 MHz, DMSO- d6) 5 9.93 (t, J = 5.6 Hz, 1H), 9.23 (s, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.27-8.26 (m, 1H), 7.93 (d, J = 4.2 Hz, 1H), 4.62 (d, J = 5.6 Hz, 2H), 3.88 (d, J = 4.2 Hz, 3H), 3.80 (q, J = 7.3 Hz, 2H), 1.27-1.22 (m, 3H); ESI MS (m / z) 493.0 (MH)+. 83 FsXo5V^ / nh^ ’H-NMR (400 MHz, DMSO-t / 6) 5 8.93 (d, J = 4.2 Hz, 1H), 8.88 (s, 1H), 8.80 (s, 1H), 7.99 (d, J = 0.7 Hz, 1H), 7.86-7.83 (m, 2H), 7.23 (d, J = 5.1 Hz, 1H), 5.35 (t, J = 13.3 Hz, 2H), 3.77 (q, J = 7.3 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 520.20 (MH)+ 84 V1 j l 0 }=N o FxAyvy ’H-NMR (400 MHz, DMSO- d6) 5 9.34 (d, J = 4.9 Hz, 1H), 8.91 (d, J = 4.3 Hz, 1H), 7.97 (d, J = 0.9 Hz, 1H), 7.82-7.79 (m, 2H), 7.21 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 3.75 (q, J = 7.3 Hz, 2H), 3.01 (d, J = 4.9 Hz, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 534.10 (MH)+ 85 °'J 'xAAy. 'H-NMR (400 MHz, DMSO-t / 6) 5 8.87 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 1.0 Hz, 1H), 7.86 (dd, J = 5.0, 0.9 Hz, 1H), 7.77 (d, J = 4.2 Hz, 1H), 7.20 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 3.71 (q, J = 7.4 Hz, 2H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 521.05 (MH)+ 86 ^-¾¼ 'H-NMR (400 MHz, DMSO-t / 6) 5 8.89 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.86-7.85 (m, 1H), 7.71 (d, J = 4.2 Hz, 1H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 4.77-4.65 (m, 4H), 3.74 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 596.20 (MH)+ 87 1 O / 1 "A / /       n " \_z-z ° AO ~z w ’H-NMR (400 MHz, DMSO- d6) 5 8.95 (q, J = 4.0 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.64 (dd, J = 36.4,4.3 Hz, 1H), 4.58-4.34 (m, 2H), 3.83 (d, J = 2.8 Hz, 3H), 3.71 (q, J = 7.3 Hz, 2H), 3.17 (d, J = 77.3 Hz, 3H), 1.24 (td, J = 7.3, 3.1 Hz, 3H); ESI MS (m / z) 550.2 (MH)+. 88 f3c     n-^ ? J cV^O^ / 0=^ F F     V-N 1 h     II .V / ^N N\ H ’H-NMR (400 MHz, DMSO-t / 6) 5 8.91 (d, J = 4.0 Hz, 1H), 7.97 (d, J = 0.6 Hz, 1H), 7.83-7.79 (m, 2H), 7.22 (d, J = 5.2 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 4.31 (d, J = 2.4 Hz, 2H), 3.75 (q, J = 7.4 Hz, 2H), 1.87 (s, 1H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 558.20 (MH)+ 89 \ / / \ J u 'r z O 1 z^ / J O u. LL? ’H-NMR (400 MHz, DMSO- dd) 8 8.87 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 1.0 Hz, 1H), 7.88 (dd, J = 5.1, 1.0 Hz, 1H), 7.65 (d, J = 4.2 Hz, 1H), 7.22 (d, J = 5.1 Hz, 1H), 5.52 (dtd, J = 60.2, 6.0, 3.0 Hz, 1H), 5.33 (t, J = 13.3 Hz, 2H), 4.63-4.41 (m, 2H), 4.35-4.26 (m, 2H), 3.793.69 (m, 2H), 1.23 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 578.25 (MH)+ 90 f3c                o / F F    \-N I h     II X— / ^N ^<7 v> N. / 1 ' N'x H CN ’H-NMR (400 MHz, DMSO- dd) 8 10.10 (s, 1H), 8.92 (d, J = 4.4 Hz, 1H), 7.97 (d, J = 1.0 Hz, 1H), 7.80-7.79 (m, 2H), 7.22 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 3.72 (q, J = 7.3 Hz, 2H), 1.74 (dd, J = 8.1, 5.6 Hz, 2H), 1.39 (dd, J = 8.4, 5.7 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 585.25 (MH)+ 91 z <a O^ZI --,  Z-z'^ n       z O J. ^Z^z Z^ / J £ O u. LL? 'H-NMR (400 MHz, DMSO- / / 6) 8 9.93 (s, 1H), 8.93 (d, J = 4.4 Hz, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.89 (d, J = 4.4 Hz, 1H), 7.79 (dd, J = 5.0, 0.9 Hz, 1H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.3 Hz, 2H), 4.62 (d, J = 3.4 Hz, 2H), 3.77 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 559.20 (MH)+ 92 0^0 $ "z^z 1 ° 1 1   1' J ° ? ° 'H-NMR (400 MHz, DMSO- / / 6) 8 8.94 (d, J = 4.2 Hz, 1H), 7.86 (d, J = 4.2 Hz, 1H), 7.81 (d, J = 0.5 Hz, 1H), 7.75 (d, J = 0.5 Hz, 1H), 4.54 (q, J = 7.2 Hz, 2H), 3.723.67 (m, 5H), 1.41 (t, J = 7.1 Hz, 3H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 494.20 (MH)+ 93 >CWj 'H-NMR (400 MHz, DMSO- / / 6) 8 8.91 (d, J = 4.2 Hz, 1H), 7.82 (s, 1H), 7.77 (d, J = 4.2 Hz, 1H), 7.75 (s, 1H), 3.73-3.68 (m, 5H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 465.80 (MH)+ 94 / ^o z z M ’H-NMR (400 MHz, DMSO- / / 6) 8 8.95 (d, J = 4.3 Hz, 1H), 8.85 (s, 1H), 8.76 (s, 1H), 7.82 (d, J = 4.3 Hz, 2H), 7.75 (s, 1H), 3.77 (q, J = 7.3 Hz, 2H), 3.68 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 464.90 (MH)+ 95 T o / 1 * J ° / ^o IZ z ’H-NMR (400 MHz, DMSO- dd) 8 10.20 (s, 1H), 9.23 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.26 (s, 1H), 7.83 (d, J = 3.4 Hz, 1H), 3.87 (s, 3H), 3.74 (q, J = 7.4 Hz, 2H), 1.73 (s, 2H), 1.40 (s, 2H), 1.27 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 519.0 (MH)+. 96 "z^z 1 O 1 1 " J / , \ / / " \^z.--z. ° 7=0 IZ cA GJ 'H-NMR (400 MHz, DMSO- dd) 8 9.86 (d, J = 9.0 Hz, 1H), 9.24 (s, 1H), 8.99 (d, J = 4.4 Hz, 1H), 8.27 (s, 1H), 7.80 (d, J = 4.2 Hz, 1H), 5.01-4.94 (m, 1H), 3.92 (d, J = 23.0 Hz, 3H), 3.70 (q, J = 7.3 Hz, 2H), 1.42 (d, J = 7.1 Hz, 3H), 1.27 (t, J = 7.3 Hz, 3H);ESI MS (m / z) 550.1 (MH)+. 97 \ 0== / / " I 1 o 1 £ ’H-NMR (400 MHz, DMSO- A) 5 9.23 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.26 (d, J = 1.0 Hz, 1H), 7.62 (d, J = 4.2 Hz, 1H), 3.93 (s, 3H), 3.74 (q, J = 7.3 Hz, 2H), 3.13 (d, J = 14.2 Hz, 3H), 2.94 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 482.2 (MH)+. 98 -n O 1 O Z        " r\ \^Z-Z ’H-NMR (400 MHz, DMSO-A) 5 9.45 (d, J = 8.1 Hz, 1H), 8.91 (d, J = 4.4 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.82-7.79 (m, 2H), 7.22 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 3.76-3.69 (m, 3H), 1.31-1.22 (m, 6H), 1.07-1.01 (m, 1H), 0.54-0.36 (m, 4H); ESI MS (m / z) 588.10 (MH)+ 99 F3C.      ,N^\ ° J =>OoA / 0^ F 'F u VN L h T ,\__An N VlN'__n \\ H-- 'H-NMR (400 MHz, DMSO-A) 5 9.58 (t, J = 5.6 Hz, 1H), 8.92 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.83-7.81 (m, 2H), 7.22 (d, J = 5.1 Hz, 1H), 6.03-5.94 (m, 1H), 5.45 (dd, J = 17.4, 1.5 Hz, 1H), 5.33 (t, J = 13.7 Hz, 2H), 5.21 (dd, J = 10.3, 1.5 Hz, 1H), 4.12 (t, J = 5.3 Hz, 2H), 3.73 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 560.05 (MH)+ 100 F3C _        ° J F F u     N V h      II ,\—Z*N < -z \x i 0 N   / N\^   / nx / / nA H x ’H-NMR (400 MHz, DMSO-A) 5 9.38 (d, J = 7.3 Hz, 1H), 8.90 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.81 (dd, J = 5.0, 0.9 Hz, 1H), 7.78 (d, J = 4.4 Hz, 1H), 7.22 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.7 Hz, 2H), 4.19 (dt, J = 20.5, 6.5 Hz, 1H), 3.76-3.68 (m, 2H), 1.27 (d, J = 6.4 Hz, 9H); ESI MS (m / z) 562.10 (MH)+ 101 F3C. _          9 / / o=s F F        N L h     IT .v / ^N n vnx_y NE      N'°\ 'H-NMR (400 MHz, DMSO-A) 5 12.30 (s, 1H), 8.89 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.84-7.83 (m, 1H), 7.74 (d, J = 3.9 Hz, 1H), 7.21 (d, J = 5.1 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 3.85 (s, 3H), 3.73 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 550.15 (MH)+ 102 J1 y / O z      " _n zT>^\--w'0 r \ / / \ k^z-z c? ’H-NMR (400 MHz, DMSO-A) 5 9.51 (t, J = 5.5 Hz, 1H), 8.91 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.82 (dd, J = 5.0, 0.9 Hz, 2H), 7.22 (d, J = 4.9 Hz, 1H), 5.37-5.30 (m, 2H), 3.73 (q, J = 7.3 Hz, 2H), 3.50 (t, J = 6.2 Hz, 2H), 2.61 (dd, J = 14.9, 6.8 Hz, 1H), 2.102.03 (m, 2H), 1.93-1.79 (m, 4H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 588.05 (MH)+ 103 f3c       n-\. 9 / .>OoA / 0=^ F F u \-N   \ ,V_Z*N vp? n-^.f H K F CF3 ’H-NMR (400 MHz, DMSO-A) 5 9.97 (t, J = 6.4 Hz, 1H), 8.93 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.83-7.82 (m, 2H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.7 Hz, 2H), 4.49-4.40 (m, 2H), 3.72 (q, J = 7.4 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 652.10 (MH)+ 104 ^?s-° ’H-NMR (400 MHz, DMSO-t / 6) 5 9.40 (t, J = 5.3 Hz, 1H), 8.94 (d, J = 4.2 Hz, 1H), 7.82 (s, 1H), 7.78 (d, J = 4.2 Hz, 1H), 7.75 (s, 1H), 3.75 (q, J = 7.4 Hz, 2H), 3.68 (s, 3H), 3.51-3.44 (m, 2H), 1.23 (dd, J = 15.9, 7.3 Hz, 6H); ESI MS (m / z) 493.20 (MH)+ 105 '         H^CF3 ’H-NMR (400 MHz, DMSO- de) 5 9.92 (t, J = 6.4 Hz, 1H), 8.95 (d, J = 4.2 Hz, 1H), 7.83-7.82 (m, 2H), 7.75 (s, 1H), 4.43-4.34 (m, 2H), 3.73 (q, J = 7.4 Hz, 2H), 3.68 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 547.20 (MH)+ 106 0^0 1 O 1 1 " J ° I ’H-NMR (400 MHz, DMSO-t / 6) 5 9.73 (t, J = 6.0 Hz, 1H), 8.96 (d, J = 4.4 Hz, 1H), 7.83 (d, J = 4.9 Hz, 2H), 7.75 (s, 1H), 6.28 (tt, J = 55.3, 3.3 Hz, 1H), 4.03-3.90 (m, 2H), 3.77-3.71 (m, 2H), 3.68 (s, 3H), 1.26-1.22 (m, 3H); ESI MS (m / z) 529.20 (MH)+ 107 >ca% F ' n'^^xb^cf3 F ’H-NMR (400 MHz, DMSO-t / 6) 5 9.95 (t, J = 6.4 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 7.82-7.81 (m, 2H), 7.75 (s, 1H), 4.43 (td, J = 15.5, 6.3 Hz, 2H), 3.76-3.70 (m, 2H), 3.69 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 597.35 (MH)+ 108 >oaHu ’H-NMR (400 MHz, DMSO-t / 6) 5 9.94 (d, J = 7.6 Hz, 1H), 8.95 (d, J = 4.2 Hz, 1H), 7.83 (s, 1H), 7.76-7.73 (m, 2H), 5.31 (q, J = 8.1 Hz, 1H), 3.74 (q, J = 7.3 Hz, 2H), 3.68 (s, 3H), 3.53-3.48 (m, 2H), 3.42 (dd, J = 9.5, 8.1 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 537.10 (MH)+ 109 '        !Pcn ’H-NMR (400 MHz, DMSO-t / 6) 5 9.91 (t, J = 5.7 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 7.89 (d, J = 4.3 Hz, 1H), 7.82 (s, 1H), 7.75 (s, 1H), 4.62 (d, J = 5.8 Hz, 2H), 3.78 (q, J = 7.3 Hz, 2H), 3.67 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 504.10 (MH)+ 110 05 U v X           H CN ’H-NMR (400 MHz, DMSO-t / 6) 5 10.09 (s, 1H), 8.95 (d, J = 4.3 Hz, 1H), 7.82-7.80 (m, 2H), 7.74 (d, J = 3.1 Hz, 1H), 3.73 (q, J = 7.4 Hz, 2H), 3.67 (s, 3H), 1.73 (dd, J = 8.4, 5.7 Hz, 2H), 1.39 (dd, J = 8.3, 5.8 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 530.10 (MH)+ 111 0^0 $ 1 O 1 1 " J ° \ o / ’H-NMR (400 MHz, DMSO-t / 6) 5 12.28 (s, 1H), 8.94 (d, J = 4.3 Hz, 1H), 7.82 (s, 1H), 7.76 (t, J = 4.0 Hz, 2H), 3.85 (s, 3H), 3.74 (q, J = 7.4 Hz, 2H), 3.68 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 495.10 (MH)+ 112 5s'° \ n J^h \ F F ’H-NMR (400 MHz, DMSO-t / 6) 5 8.92 (d, J = 4.3 Hz, 1H), 7.82 (s, 1H), 7.75 (s, 1H), 7.72 (d, J = 4.3 Hz, 1H), 4.72 (q, J = 11.6 Hz, 4H), 3.74 (q, J = 7.3 Hz, 2H), 3.70 (s, 3H), 1.25-1.22 (m, 3H); ESI MS (m / z) 541.05 (MH)+ 113 i- F 'H-NMR (400 MHz, DMSO- d6) 5 12.16 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.86 (s, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 4.08 (q, J = 7.1 Hz, 2H), 3.75 (q, J = 7.4 Hz, 5H), 1.28 (dt, J = 19.9,7.2 Hz,6H); ESI MS (m / z) 498.0 (MH)+. 114 O' \ N o ftuyjX ’H-NMR (400 MHz, DMSO-t / 6) 5 8.85 (t, J = 4.4 Hz, 1H), 7.97-7.94 (m, 2H), 7.57 (dd, J = 4.3, 1.6 Hz, 1H), 7.22 (dd, J = 5.0, 0.9 Hz, 1H), 5.37-5.30 (m, 2H), 3.743.61 (m, 3H), 3.24 (q, J = 6.9 Hz, 1H), 3.00 (d, J = 89.3 Hz, 3H), 1.25-1.09 (m, 6H); ESI MS (m / z) 562.30 (MH)+ 115 Os^zl z-z'x \ / / \ / ) u w ?r z o J. zy £ O u-11? 'H-NMR (400 MHz, DMSO-A) 5 9.49 (s, 1H), 8.91 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 1.0 Hz, 1H), 7.83 (d, J = 4.2 Hz, 1H), 7.79 (dd, J = 5.0, 0.9 Hz, 1H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 3.72 (q, J = 7.4 Hz, 2H), 1.47 (s, 9H), 1.27 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 576.30 (MH)+ 116 O^1 "■■, z-z'X \ Ji \ J u u >r z O 1 z^ / 7 £ O U- LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.53 (t, J = 5.7 Hz, 1H), 8.91 (d, J = 4.3 Hz, 1H), 7.98 (d, J = 0.9 Hz, 1H), 7.82 (dt, J = 4.9, 1.1 Hz, 2H), 7.22 (d, J = 5.2 Hz, 1H), 5.33 (t, J = 13.6 Hz, 2H), 3.73 (q, J = 7.4 Hz, 2H), 3.33 (d, J = 6.1 Hz, 2H), 1.92 (t, J = 6.7 Hz, 1H), 1.24 (t, J = 7.5 Hz, 3H), 1.01 (d, J = 6.7 Hz, 6H); ESI MS (m / z) 576.35 (MH)+ 117 F3C _         ? / cV'o^ / 0=^ F p u \^N   \ r      II ,\_ / *N sry^ H 'H-NMR (400 MHz, DMSO-t / 6) 5 9.81 (d, J = 6.6 Hz, 1H), 8.92 (d, J = 4.4 Hz, 1H), 7.97 (d, J = 0.7 Hz, 1H), 7.83 (dd, J = 5.0, 0.9 Hz, 1H), 7.76 (d, J = 4.4 Hz, 1H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 4.41 (dd, J = 8.4, 6.5 Hz, 1H), 3.72 (q, J = 7.4 Hz, 2H), 3.203.09 (m, 2H), 2.74 (ddd, J = 28.9, 15.0, 6.5 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 610.00 (MH)+ 118 n O Az z^zj 1 O zT^r^X^w-0 Z \ / / \ lz-z 'H-NMR (400 MHz, DMSO-A) 5 9.60 (s, 1H), 8.89 (d, J = 4.3 Hz, 1H), 7.97 (s, 1H), 7.79 (dd, J = 5.0, 0.8 Hz, 1H), 7.76 (d, J = 4.0 Hz, 1H), 7.21 (d, J = 5.2 Hz, 1H), 5.33 (t, J = 13.8 Hz, 2H), 3.71 (q, J = 7.4 Hz, 2H), 1.49 (s, 3H), 1.26 (t, J = 7.5 Hz, 3H), 0.87-0.82 (m, 2H), 0.80-0.75 (m, 2H); ESI MS (m / z) 574.00 (MH)+ 119 F3C _  ,N^\ ° J / o=y F F U \^N   \ IT \__ / ^N v^yyj , H CF3 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.86 (d, J = 8.8 Hz, 1H), 8.92 (d, J = 4.2 Hz, 1H), 7.98 (d, J = 0.7 Hz, 1H), 7.82 (dd, J = 5.0, 0.9 Hz, 1H), 7.78 (d, J = 4.4 Hz, 1H), 7.22 (d, J = 4.9 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 4.99 (dd, J = 15.8, 7.2 Hz, 1H), 3.68 (q, J = 7.3 Hz, 2H), 1.42 (t, J = 6.8 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 615.95 (MH)+ 120 T o 1 1 w J ° / =0 IZ / ’H-NMR (400 MHz, DMSO- de) 5 12.22 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.77 (d, J = 4.2 Hz, 1H), 6.12-6.02 (m, 1H), 5.48 (d, J = 17.4 Hz, 1H), 5.37 (d, J = 10.8 Hz, 1H), 4.55 (d, J = 6.1 Hz, 2H), 3.78-3.73 (m, 5H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 510.2 (MH)+. 121 'H-NMR (400 MHz, DMSO- de) 5 12.26 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.55 (d, J = 6.4 Hz, 2H), 7.46-7.38 (m, 3H), 5.07 (s, 2H), 3.78 (s, 3H), 3.73 (q, J = 7.3 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS(m / z) 560.3 (MH)+. 122 ^-¾¼ ’H-NMR (400 MHz, DMSO- de) 5 11.64 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 3.80 (s, 3H), 3.77-3.70 (m, 2H), 1.35 (s, 9H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 526.2 123 ’H-NMR (400 MHz, DMSO-t / 6) 5 11.65 (s, 1H), 8.90 (d, J = 4.3 Hz, 1H), 7.97 (d, J = 0.9 Hz, 1H), 7.84 (dd, J = 4.9, 0.9 Hz, 1H), 7.76 (d, J = 4.3 Hz, 1H), 7.22 (d, J = 5.2 Hz, 1H), 5.33 (t, J = 13.4 Hz, 2H), 3.70 (q, J = 7.4 Hz, 2H), 1.35 (s, 9H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 592.15 124 / =o IZ \ ’H-NMR (400 MHz, DMSO-t / 6) 5 9.33 (d, J = 4.4 Hz, 1H), 8.94 (d, J = 4.4 Hz, 1H), 7.82 (s, 1H), 7.79 (d, J = 4.2 Hz, 1H), 7.75 (s, 1H), 3.76 (q, J = 7.3 Hz, 2H), 3.67 (s, 3H), 3.00 (d, J = 4.9 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 479.15 (MH)+ 125 _ F 'W<v x___n / 'H-NMR (400 MHz, DMSO- de) 5 12.00 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.77 (d, J = 1.2 Hz, 1H), 8.35 (d, J = 1.5 Hz, 1H), 8.22 (d, J = 4.2 Hz, 1H), 4.46-4.40 (m, 1H), 3.92 (s, 3H), 3.79 (q, J = 7.4 Hz, 2H), 1.47-1.38 (m, 9H); ESI MS (m / z) 512.2 (MH)+. 126 lx o=v ° / f-zv^ r " 1 ° 1 o o^o 'H-NMR (400 MHz, DMSO-t / 6) 5 9.42 (d, J = 4.4 Hz, 1H), 8.93 (d, J = 4.4 Hz, 1H), 7.82 (s, 1H), 7.75-7.73 (m, 2H), 3.72 (q, J = 7.4 Hz, 2H), 3.67 (s, 3H), 3.02 (d, J = 4.2 Hz, 1H), 1.24 (t, J = 7.3 Hz, 3H), 0.88-0.84 (m, 2H), 0.64-0.62 (m, 2H); ESI MS (m / z) 505.05 (MH)+ 127 1V° >CWj ’H-NMR (400 MHz, DMSO-A) 5 9.75 (s, 1H), 8.95 (d, J = 4.2 Hz, 1H), 7.82 (d, J = 4.4 Hz, 2H), 7.75 (d, J = 0.5 Hz, 1H), 4.30 (q, J = 2.7 Hz, 2H), 3.75 (q, J = 7.4 Hz, 2H), 3.67 (s, 3H), 1.24 (t, J = 7.3 Hz, 4H); ESI MS (m / z) 503.00 (MH)+ 128 ^Hu° X        h'0^ x^-—    n 'H-NMR (400 MHz, DMSO-t / 6) 5 12.15 (s, 1H), 8.93 (d, J = 4.3 Hz, 1H), 7.83 (s, 1H), 7.76 (d, J = 4.0 Hz, 2H), 4.08 (q, J = 7.0 Hz, 2H), 3.73 (q, J = 7.3 Hz, 2H), 3.68 (s, 3H), 1.30 (t, J = 7.0 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 509.20 (MH)+ 129 T o / 1 J ° IZ \ o o^ / 'H-NMR (400 MHz, DMSO- de) 5 12.25 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 5.16 (s, 1H), 4.03-3.97 (m, 1H), 3.83-3.72 (m, 5H), 3.62 (d,J= 11.7 Hz, 1H), 1.80-1.75 (m, 3H), 1.62-1.59 (m, 3H), 1.281.23 (m, 3H); ESI MS (m / z) 554.0 (MH)+. 130 O'S'0 >CQKU y X       NH^ 'H-NMR (400 MHz, DMSO-A) 5 9.57 (s, 1H), 8.92 (d, J = 4.3 Hz, 1H), 7.82 (s, 1H), 7.74 (d, J = 4.6 Hz, 2H), 3.72 (q, J = 7.4 Hz, 2H), 3.67 (s, 3H), 1.48 (s, 3H), 1.25 (t, J = 7.3 Hz, 3H), 0.86-0.83 (m, 2H), 0.770.74 (m, 2H); ESI MS (m / z) 519.05 ESI MS (m / z) 509.20 (MH)+ (MH)+ 131 F 0 ' tny 'H-NMR (400 MHz, DMSO- de) 5 912.14 (s, 1H), 9.24 (s, 1H), 8.97 (d, J = 4.0 Hz, 1H), 8.27 (s, 1H), 7.78 (d, J = 4.3 Hz, 1H), 4.30 (t, J = 6.1 Hz, 1H), 3.89 (s, 3H), 3.73 (q, J = 7.3 Hz, 2H), 1.31-1.20 (m, 9H); ESI MS (m / z) 512.0 (MH)+. 132 & 1 O 1 1 " J ° Xo IZ V 'H-NMR (400 MHz, DMSO- de) 5 12.27 (s, 1H), 9.24 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.77 (d, J = 4.2 Hz, 1H), 6.12-6.02 (m, 1H), 5.50-5.35 (m, 2H), 4.55 (d, J = 6.1 Hz, 2H), 3.94-3.89 (m, 3H), 3.75 (q, J = 7.3 Hz, 2H), 1.27-1.20 (m, 3H); ESI MS (m / z) 510.0 (MH)+. 133 1$ T o / 1 " J ° / =0 IZ \ ’H-NMR (400 MHz, DMSO- de) 5 11.64 (s, 1H), 9.24 (s, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.27 (s, 1H), 7.80 (d, J = 4.2 Hz, 1H), 3.90 (s, 3H), 3.73 (q, J = 7.4 Hz, 2H), 1.35 (s, 9H), 1.26 (t, J = 7.5 Hz, 3H), 1.21-1.12 (m, 1H); ESI MS (m / z) 526.2 (MH)+. 134 - F       "ZVo Wb kty“ ’H-NMR (400 MHz, DMSO- de) 5 12.26 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.787.76 (m, 1H), 7.59 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 5.06 (s, 2H), 3.88 (s, 3H), 3.73 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 594.0 (MH)+. 135 F                ' W-o 'H-NMR (400 MHz, DMSO- de) 5 12.33 (s, 1H), 9.23 (s, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.76 (d, J = 3.9 Hz, 1H), 7.61 (s, 1H), 7.52 (d, J = 3.9 Hz, 1H), 7.48-7.45 (m, 2H), 5.08 (s, 2H), 3.89 (d, J = 8.8 Hz, 3H), 3.73 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 594.2 (MH)+. 136 i- F Ax^u =^n ' N\J H x__-n ’H-NMR (400 MHz, DMSO- de) 5 12.36 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.29-8.24 (m, 1H), 7.78-7.70 (m, 2H), 7.55-7.52 (m, 1H), 7.45-7.39 (m, 2H), 5.14 (d, J = 48.9 Hz, 2H), 3.89 (d, J = 9.5 Hz, 3H), 3.72 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 594.2 (MH)+. 137 F Ar^U \ nJsMJ ’H-NMR (400 MHz, DMSO- d6) 5 12.21 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.43 (d, J = 7.8 Hz, 2H), 7.24-7.20 (m, 2H), 5.02 (s, 2H), 3.90 (d, J = 15.4 Hz, 3H), 3.73 (q, J = 7.3 Hz, 2H), 2.32-2.27 (m, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 574.1 138 F        ~^S'° 'H-NMR (400 MHz, DMSO- d6) 5 12.26 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.32 (t, J = 6.1 Hz, 3H), 7.20 (d, J = 6.6 Hz, 1H), 5.03 (s, 2H), 3.88 (s, 3H), 3.72 (q, J = 7.4 Hz, 2H), 2.34 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 574.2 (MH)+. 139 tf' 1 o 1 1 " J ° 7=0 ZZ b ’H-NMR (400 MHz, DMSO- d6) 5 12.27 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.28 (d, J = 5.1 Hz, 1H), 7.75 (d, J = 3.9 Hz, 1H), 7.46-7.41 (m, 1H), 7.327.21 (m, 3H), 5.10 (s, 2H), 3.88 (s, 3H), 3.76-3.69 (m, 2H), 2.47 (s, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 574.2 (MH)+. 140 FAc Au 0 '   n        — ’H-NMR (400 MHz, DMSO- d6) 5 12.24 (s, 1H), 9.23 (s, 1H), 8.98-8.93 (m, 1H), 8.28 (d, J = 12.7 Hz, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.61 (dd, J = 8.6, 5.6 Hz, 2H), 7.25 (t, J = 8.8 Hz, 2H), 5.05 (s, 2H), 3.90 (d, J = 14.7 Hz, 3H), 3.73 (q, J = 7.4 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 578.3 141 F        "-S'0 ’H-NMR (400 MHz, DMSO- de) 5 12.31 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.77 (d, J = 4.2 Hz, 1H), 7.48 (dd, J = 13.9, 8.1 Hz, 1H), 7.407.37 (m, 2H), 7.24 (d, J = 8.3 Hz, 1H), 5.09 (s, 2H), 3.88 (s, 3H), 3.72 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 578.3 142 % Au \ 4J a AJ ’H-NMR (400 MHz, DMSO- de) 5 12.32 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.27 (d, J = 5.9 Hz, 1H), 7.73 (d, J = 4.2 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.30-7.25 (m, 2H), 5.14 (s, 2H), 3.89 (d, J = 8.6 Hz, 3H), 3.73 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 578.0 (MH)+. 143 r- F AAu 0 r. \ vYAJ ’H-NMR (400 MHz, DMSO- de) 5 12.26 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.3 Hz, 1H), 8.26 (s, 1H), 7.76 (d, J = 4.0 Hz, 1H), 7.56-7.54 (m, 2H), 7.46-7.37 (m, 3H), 5.08 (d, J = 4.9 Hz, 2H), 3.91-3.85 (m, 3H), 3.75-3.67 (m, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 560.0 (MH)+. 144 r- F Wwi ’H-NMR (400 MHz, DMSO- d6) 5 12.32 (s, 1H), 8.97 (d, J = 3.9 Hz, 1H), 8.86 (s, 1H), 8.63 (s, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.61 (s, 1H), 7.52 (d, J = 4.6 Hz, 1H), 7.46 (d, J = 4.2 Hz, 2H), 5.09 (s, 2H), 3.77 (s, 3H), 3.72 (t, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 594.0 (MH)+. 145 p F 0        ?Me 'H-NMR (400 MHz, DMSO- d6) 5 12.26 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.7 Hz, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.11-7.09 (m, 2H), 6.96-6.94 (m, 1H), 5.05 (s, 2H), 3.78 (d, J = 1.5 Hz, 6H), 3.74-3.69 (m, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 590.2 (MH)+. 146 f\x:4u rr^ 'H-NMR (400 MHz, DMSO- d6) 5 12.17 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.86 (s, 1H), 8.64 (s, 1H), 7.76 (d, J = 4.2 Hz, 1H), 7.48 (d, J = 8.6 Hz, 2H), 6.98 (d, J = 8.6 Hz, 2H), 4.99 (s, 2H), 3.77 (d, J = 4.9 Hz, 6H), 3.74 (d, J = 7.1 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 590.2 (MH)+. 147 F      "^*0 ^8y.._ N<^ H M ’H-NMR (400 MHz, DMSO- d6) 5 12.26 (s, 1H), 8.98 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.80 (d, J = 4.3 Hz, 1H), 7.38-7.30 (m, 4H), 7.23 (t, J = 7.0 Hz, 1H), 4.26 (t, J = 6.9 Hz, 2H), 3.83-3.71 (m, 5H), 3.06 (t, J = 6.9 Hz, 2H), 1.27-1.20 (m, 3H); ESI MS (m / z) 574.0 148 Mnh ^,S 'H-NMR (400 MHz, DMSO- d6) 5 8.95 (d, J = 4.2 Hz, 2H), 8.84 (t, J = 1.0 Hz, 1H), 8.79 (s, 1H), 8.63-8.63 (m, 1H), 7.83 (d, J = 4.2 Hz, 1H), 4.99 (s, 1H), 3.77 (s, 3H), 3.60 (q, J = 7.3 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 452.8 149 ~~A     £HF2 F         Js-N~ / F<        O'5.  \ x V °" ’H-NMR (400 MHz, DMSO- d6) 5 9.03 (d, J = 4.4 Hz, 1H), 8.87-8.85 (m, 1H), 8.68-8.63 (m, 1H), 7.97-7.95 (m, 1H), 5.99-5.72 (m, 1H), 4.23-4.11 (m, 2H), 4.07 (s, 3H), 3.78-3.71 (m, 3H), 1.36-1.29 (m, 3H); ESI MS (m / z) 546.1 (MH)+. 150 0 x 'H-NMR (400 MHz, DMSO- d6) 5 9.05 (d, J = 4.4 Hz, 1H), 8.87 (t, J = 1.1 Hz, 1H), 8.64-8.64 (m, 1H), 7.997.97 (m, 1H), 4.30 (qd, J = 7.3, 2.4 Hz, 2H), 4.05 (d, J = 8.1 Hz, 3H), 3.74 (s, 3H), 1.37 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 563.8 (MH)+. 151 0.^ i- F        ' Mn Mu 'H-NMR (400 MHz, DMSO- d6) 5 8.99 (d, J = 4.2 Hz, 1H), 8.86 (dd, J = 2.1,0.6 Hz, 1H), 8.66 (d, J = 1.5 Hz, 1H), 7.92 (d, J = 4.4 Hz, 1H), 4.07 (s, 3H), 3.91-3.85 (m, 2H), 3.71 (s, 3H), 1.46 (d, J = 10.3 Hz, 3H), 1.28 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 509.9 (MH)+. 152 ’H-NMR (400 MHz, DMSO-A) 5 9.63 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.87 (d, J = 4.2 Hz, 1H), 3.78-3.73 (m, 5H), 3.64 (t, J = 5.1 Hz, 2H), 3.57 (t, J = 4.9 Hz, 2H), 3.34 (s, 3H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 512.2 (MH)+ 153 o?s=° ' Nx J x—n      X— 'H-NMR (400 MHz, DMSO- de) 5 9.62 (t, J = 5.6 Hz, 1H), 8.99 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.85 (d, J = 4.4 Hz, 1H), 3.78 (dd, J = 14.4, 7.6 Hz, 5H), 3.67 (q, J = 6.4 Hz, 2H), 2.79 (t, J = 6.7 Hz, 2H), 2.62 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H), 1.22 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 542.00 (MH)+ 154 'H-NMR (400 MHz, DMSO- de) 5 9.43 (t, J = 5.6 Hz, 1H), 8.98 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.82 (d, J = 4.4 Hz, 1H), 3.783.74 (m, 5H), 3.54-3.48 (m, 4H), 3.28 (s, 3H), 1.84 (t, J = 6.5 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 526.05 (MH)+ 155 ^s=° ' Nk\ J x—n      X 'H-NMR (400 MHz, DMSO-t / 6) 5 9.62-9.60 (m, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.7 Hz, 1H), 7.85 (d, J = 4.2 Hz, 1H), 3.81-3.75 (m, 5H), 3.69 (q, J = 6.4 Hz, 2H), 2.76 (t, J = 6.7 Hz, 2H), 2.15 (s, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 528.00 (MH)+ 156 ' N. J / N^ / OH x—   n / ’H-NMR (400 MHz, DMSO-t / 6) 5 9.61 (t, J = 5.6 Hz, 1H), 8.99 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.91 (d, J = 4.2 Hz, 1H), 3.783.74 (m, 5H), 3.42 (d, J = 5.6 Hz, 2H), 1.27-1.23 (m, 9H); ESI MS (m / z) 526.05 (MH)+ 157 5s"0 FWu ' nU MV n / \ F ’H-NMR (400 MHz, DMSO-t / 6) 5 9.74 (t, J = 6.1 Hz, 1H), 9.00 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.85 (d, J = 4.3 Hz, 1H), 3.97 (td, J = 13.9, 6.2 Hz, 2H), 3.79 (s, 3H), 3.74 (q, J = 7.3 Hz, 2H), 1.77 (t, J = 19.1 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 532.25 158 Wn ' N« JI x-—H       X 'H-NMR (400 MHz, DMSO-t / 6) 5 9.63-9.60 (m, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.86 (q, J = 0.9 Hz, 1H), 8.64 (t, J = 1.1 Hz, 1H), 7.89 (d, J = 4.3 Hz, 1H), 3.76 (q, J = 7.5 Hz, 5H), 3.68-3.57 (m, 2H), 3.43 (dt, J = 13.3, 5.6 Hz, 1H), 3.34 (s,3H), 1.29-1.25 (m, 3H), 1.21-1.18 (m, 3H); ESI MS (m / z) 526.10 (MH)+ 159 ’Wk? ' nk\ JI x—n / ’H-NMR (400 MHz, DMSO-t / 6) 5 9.58 (t, J = 5.5 Hz, 1H), 8.99 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.89 (d, J = 4.2 Hz, 1H), 4.98 (d, J = 4.6 Hz, 1H), 3.91-3.83 (m, 1H), 3.81-3.71 (m, 5H), 3.49 (dt, J = 13.0, 5.4 Hz, 1H), 3.41-3.34 (m, 1H), 1.26 (t, J = 7.3 Hz, 3H), 1.18 (d, J = 6.4 Hz, 3H); ESI MS (m / z) 512.05 (MH)+ 160 ZI O " JI A ' / /  "  T /   o I z^z" & o LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 9.75-9.72 (m, 1H), 9.00 (t, J = 3.8 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.648.64 (m, 1H), 7.88 (d, J = 4.4 Hz, 1H), 5.03-4.97 (m, 1H), 4.62-4.53 (m, 2H), 3.84-3.72 (m, 4H), 3.60 (dt, J = 14.3, 4.3 Hz, 1H), 2.89 (d, J = 8.3 Hz, 1H), 2.72-2.56 (m, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 524.00 (MH)+ 161 'H-NMR (400 MHz, DMSO-d6) 8 9.95 (d, J = 6.7 Hz, 1H), 9.23 (s, 1H), 9.00 (d, J = 4.3 Hz, 1H), 8.27 (d, J = 0.9 Hz, 1H), 7.86 (d, J = 4.3 Hz, 1H), 5.17 (td, J = 8.8, 6.8 Hz, 1H), 4.79 (t, J = 8.4 Hz, 1H), 4.20 (t, J = 9.0 Hz, 1H), 3.88 (s, 3H), 3.76 (q, J = 7.3 Hz, 2H), 3.653.53 (m, 2H), 1.26 (t, J = 7.3 Hz, 3H), 1.17 (t, J = 7.0 Hz, 3H); ESI MS (m / z) 567.20 162 'Yir-Qt O °v ) 'H-NMR (400 MHz, DMSO- de) 8 9.95 (d, J = 6.6 Hz, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.86 (d, J = 4.2 Hz, 1H), 5.17 (dd, J = 15.5, 8.9 Hz, 1H), 4.79 (t, J = 8.6 Hz, 1H), 4.20 (t, J = 9.0 Hz, 1H), 3.80-3.74 (m, 5H), 3.67-3.51 (m, 2H), 1.27 (t, J = 7.5 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 567.30 (MH)+ 163 ’H-NMR (400 MHz, DMSO-t / 6) 8 12.30 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.26 (d, J = 0.7 Hz, 1H), 7.80-7.76 (m, 1H), 3.87 (d, J = 9.8 Hz, 6H), 3.76 (q, J = 7.3 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 484.10 (MH)+ 164 "?s-0 0* \ ^xrHu 0 'H-NMR (400 MHz, DMSO-t / 6) 8 12.18 (s, 1H), 9.23 (s, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.26 (s, 1H), 7.79 (d, J = 4.2 Hz, 1H), 4.08 (q, J = 7.0 Hz, 2H), 3.89 (s, 3H), 3.82-3.72 (m, 2H), 1.33-1.21 (m, 6H); ESI MS (m / z) 498.05 (MH)+ 165 oP o |OsfX Z~^J% / / \ / 1 o z-z >O o 'H-NMR (400 MHz, DMSO-t / 6) 8 9.38 (dd, J = 7.3, 0.7 Hz, 1H), 9.06 (d, J = 4.2 Hz, 1H), 7.97 (d, J = 7.3 Hz, 1H), 7.88 (d, J = 4.2 Hz, 1H), 7.33 (s, 1H), 4.53 (q, J = 7.1 Hz, 2H), 3.92 (q, J = 7.4 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.32 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 468.90 (MH)+ 166 > f# W! J v X            H CN 'H-NMR (400 MHz, DMSO-A) 8 9.90 (s, 1H), 9.24 (s, 1H), 9.00 (dd, J = 10.3, 4.2 Hz, 1H), 8.27 (s, 1H), 7.88 (d, J = 4.2 Hz, 1H), 3.88 (s, 3H), 3.79-3.70 (m, 2H), 1.79 (s, 6H), 1.29 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 521.10 (MH)+ 167 ? )s*o ’H-NMR (400 MHz, DMSO-t / 6) 5 9.22 (s, 1H), 8.94 (d, J = 4.0 Hz, 1H), 8.25 (s, 1H), 7.70 (d, J = 4.3 Hz, 1H), 3.88 (s, 3H), 3.70 (q, J = 7.3 Hz, 2H), 3.61 (s, 6H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 529.90 (MH)+ 168 O ft I z^VX r o V- / =0 o I ’H-NMR (400 MHz, DMSO-t / 6) 5 9.36 (dd, J = 7.5, 0.8 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.01 (d, J = 7.3 Hz, 1H), 7.68 (d, J = 4.3 Hz, 1H), 7.31 (s, 1H), 3.94 (q, J = 7.4 Hz, 2H), 1.33-1.29 (m, 3H); ESI MS (m / z) 440.85 (MH)+ 169 F,cxiy?MN^cF \ N^J / H     CF3 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.62 (d, J = 3.4 Hz, 1H), 9.24 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.27 (s, 1H), 7.77 (d, J = 4.2 Hz, 1H), 3.88 (s, 3H), 3.75 (q, J = 7.3 Hz, 2H), 3.37 (t, J = 4.3 Hz, 1H), 2.23 (s, 1H), 1.401.37 (m, 1H), 1.33-1.24 (m, 4H);ESIMS (m / z) 562.20 (MH)+ 170 CM X z CW z-z CL / / \ / / I ‘A o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.40-9.38 (m, 1H), 9.07 (d, J = 4.3 Hz, 1H), 8.86 (s, 1H), 8.76 (s, 1H), 8.02 (d, J = 7.3 Hz, 1H), 7.85 (d, J = 4.0 Hz, 1H), 7.34 (s, 1H), 4.00 (dd, J = 14.5, 6.9 Hz, 2H), 1.33-1.28 (m, 3H); ESI MS (m / z) 437.90 (MH)- 171 X z^<-1 O^ / NJ ^V)—z / "       1 / O   1 o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.46 (d, J = 4.4 Hz, 1H), 9.38 (d, J = 6.8 Hz, 1H), 9.06 (d, J = 4.2 Hz, 1H), 8.03 (d, J = 7.3 Hz, 1H), 7.78 (d, J = 4.4 Hz, 1H), 7.33 (s, 1H), 3.97 (q, J = 7.4 Hz, 2H), 3.01 (q, J = 3.7 Hz, 1H), 1.32 (t, J = 7.5 Hz, 3H), 0.89-0.84 (m, 2H), 0.650.61 (m, 2H); ESI MS (m / z) 480.00 (MH)+ 172 f3c ’H-NMR (400 MHz, DMSO-d,,) 5 9.90 (s, 1H), 9.39 (dd, J = 7.5, 0.8 Hz, 1H), 9.08 (d, J = 4.3 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.89 (d, J = 4.3 Hz, 1H), 7.34 (s, 1H), 4.61 (d, J = 5.5 Hz, 2H), 3.98 (q, J = 7.4 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 478.90 (MH)+ 173 \ o N^\ Xj N7 ’H-NMR (400 MHz, DMSO-d,,) 5 9.22 (s, 1H), 8.93 (d, J = 4.2 Hz, 1H), 8.26 (s, 1H), 7.70 (d, J = 4.4 Hz, 1H), 3.89 (s, 3H), 3.76-3.68 (m, 4H), 3.57 (s, 3H), 1.44 (t, J = 7.3 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 543.90 (MH)+ 174 f3c^Y-n °" k° XXw x—    n / /  \ 0 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.86 (t, J = 5.6 Hz, 1H), 9.23 (s, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.27 (s, 1H), 7.91 (d, J = 4.2 Hz, 1H), 4.35 (d, J = 5.6 Hz, 2H), 3.88 (s, 3H), 3.80 (q, J = 7.4 Hz, 2H), 3.73 (s, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 525.90 (MH)+ 175 J1 o ft, HT'b <1 / =° oZ 1 z ’H-NMR (400 MHz, DMSO-t / 6) 5 10.10 (s, 1H), 9.38 (d, J = 7.3 Hz, 1H), 9.08 (d, J = 4.2 Hz, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.83 (d, J = 4.2 Hz, 1H), 7.33 (s, 1H), 3.95 (q, J = 7.3 Hz, 2H), 1.73 (dd, J = 8.3, 5.6 Hz, 2H), 1.39 (dd, J = 8.3, 5.6 Hz, 2H), 1.35-1.30 (m, 3H); ESI MS (m / z) 504.90 (MH)+ 176 FoC                          1 3                        CN ’H-NMR (400 MHz, DMSO-t / 6) 5 9.66 (d, J = 5.6 Hz, 1H), 9.39 (d, J = 7.6 Hz, 1H), 9.07 (d, J = 4.2 Hz, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.80 (d, J = 4.4 Hz, 1H), 7.33 (s, 1H), 3.97 (q, J = 7.3 Hz, 2H), 3.72 (q, J = 6.4 Hz, 2H), 2.87 (t, J = 6.5 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 492.90 (MH)+ 177 4 N \ n4 / o ’H-NMR (400 MHz, DMSO-t / 6) 5 9.87 (t, J = 5.4 Hz, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.86 (s, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.91 (d, J = 4.2 Hz, 1H), 4.35 (d, J = 5.6 Hz, 2H), 3.82 (t, J = 7.3 Hz, 2H), 3.78 (s, 3H), 3.73 (s, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 526.15 (MH)+ 178 f3c^            CFs ’H-NMR (400 MHz, DMSO-t / 6) 5 9.93 (t, J = 6.2 Hz, 1H), 9.39 (d, J = 7.3 Hz, 1H), 9.08 (d, J = 4.2 Hz, 1H), 8.00 (d, J = 7.3 Hz, 1H), 7.84 (d, J = 4.2 Hz, 1H), 7.33 (s, 1H), 4.41-4.33 (m, 2H), 3.94 (q, J = 7.4 Hz, 2H), 1.31 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 521.90 (MH)+ 179 o4 n-QrA" F3C' ’H-NMR (400 MHz, DMSO-t / 6) 5 12.22 (s, 1H), 9.38 (d, J = 7.3 Hz, 1H), 9.05 (d, J = 4.2 Hz, 1H), 7.99 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 4.2 Hz, 1H), 7.33 (s, 1H), 6.11-6.01 (m, 1H), 5.48 (d, J = 17.1 Hz, 1H), 5.36 (d, J = 9.8 Hz, 1H), 4.54 (d, J = 6.1 Hz, 2H), 3.96 (q, J = 7.3 Hz, 2H), 1.32 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 495.95 (MH)+ 180 ^yyN uNnh \—     n II x~--' 0 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.84 (t, J = 5.6 Hz, 1H), 9.23 (s, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.27 (d, J = 0.7 Hz, 1H), 7.90 (d, J = 4.2 Hz, 1H), 4.33 (d, J = 5.9 Hz, 2H), 4.20 (q, J = 7.1 Hz, 2H), 3.88 (s, 3H), 3.80 (q, J = 7.4 Hz, 2H), 1.28-1.19 (m, 6H); ESI MS (m / z) 540.25 (MH)+ 181 ~V ° \ / ^\L /    0 N'NJrAr<V II / z N            II N N^J H [ F3C                                ' ’H-NMR (400 MHz, DMSO-t / 6) 5 12.00 (s, 1H), 9.39 (dd, J = 7.5,0.8 Hz, 1H), 9.05 (d, J = 4.3 Hz, 1H), 8.00 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 4.3 Hz, 1H), 7.33 (s, 1H), 4.32-4.26 (m, 1H), 3.99-3.91 (m, 2H), 1.37-1.26 (m, 9H); ESI MS (m / z) 498.15 (MH)+ 182 A / =4 / =0 m-N 7 AN\A JMN Md f3c ’H-NMR (400 MHz, DMSO-t / 6) 5 12.29 (s, 1H), 9.38 (dd, J = 7.5, 0.9 Hz, 1H), 9.05 (d, J = 4.2 Hz, 1H), 7.99 (d, J = 7.3 Hz, 1H), 7.77 (d, J = 4.2 Hz, 1H), 7.33 (s, 1H), 3.96 (q, J = 7.4 Hz, 2H), 3.85 (s, 3H), 1.32 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 470.00 (MH)+ 183 / XZ X \ o w Ji ✓L ^co^x^^z / " T / o 1 z^z^ & o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.89 (t, J = 5.3 Hz, 1H), 9.24 (s, 1H), 9.01 (d, J = 4.4 Hz, 1H), 8.27 (d, J = 0.7 Hz, 1H), 8.07 (t, J = 4.5 Hz, 1H), 7.93 (d, J = 4.4 Hz, 1H), 4.14 (d, J = 5.4 Hz, 2H), 3.88 (s, 3H), 3.873.78 (m, 2H), 2.68 (d, J = 4.6 Hz, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 525.00 (MH)+ 184 oz O;= / Z:L o 4' JI J___ / / "      1 / o   I 0 o LL? 'H-NMR (400 MHz, DMSO-Z,) 5 9.92 (s, 1H), 9.23 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.25 (d, J = 9.5 Hz, 1H), 7.80 (d, J = 4.2 Hz, 1H), 3.88 (S, 3H), 3.75 (q, J = 7.4 Hz, 2H), 3.69 (s, 3H), 1.61-1.54 (m, 2H), 1.331.22 (m, 5H); ESI MS (m / z) 551.90 (MH)+ 185 IZ^ ,o Z^' X \ o w Ji ✓V ^W^X^^Z r t / o 1 z^z^ 0 o LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 9.89 (t, J = 4.9 Hz, 1H), 9.23 (s, 1H), 9.00 (d, J = 4.4 Hz, 1H), 8.27 (d, J = 0.7 Hz, 1H), 7.93 (d, J = 4.4 Hz, lH),7.85(s, 1H),4.11 (d, J = 5.1 Hz, 2H), 3.90-3.84 (m, 5H), 1.31 (d, J = 8.3 Hz, 9H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 567.15 (MH)+ 186 ■•xiAy-' ’H-NMR (400 MHz, DMSO-t / 6) 5 9.33 (d, J = 7.1 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.53 (s, 1H), 7.86 (d, J = 4.2 Hz, 1H), 7.59 (dd, J = 7.3, 2.0 Hz, 1H), 4.52 (q, J = 7.1 Hz, 2H), 3.89 (q, J = 7.3 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.29 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 469.15 (MH)+ 187 O J °A ' zV—Z^N n^^<dh 'H-NMR (400 MHz, DMSO-t / 6) 5 9.33 (d, J = 7.3 Hz, 1H), 8.96 (d, J = 4.3 Hz, 1H), 8.53 (s, 1H), 7.78 (d, J = 4.0 Hz, 1H), 7.59 (dd, J = 7.2, 2.0 Hz, 1H), 3.92 (t, J = 7.3 Hz, 2H), 1.29-1.26 (m, 3H); ESI MS (m / z) 441.10 (MH)+ 188 o / " J F3C.         O=S b^X^N I 1 J~N N / ^N'0'- H ’H-NMR (400 MHz, DMSO-t / 6) 5 12.28 (s, 1H), 9.33 (d, J = 7.0 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.53 (t, J = 0.9 Hz, 1H), 7.75 (d, J = 4.3 Hz, 1H), 7.60 (dd, J = 7.2, 2.0 Hz, 1H), 3.94 (q, J = 7.4 Hz, 2H), 3.85 (s, 3H), 1.29 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 470.15 (MH)+ 189 JP o fs z— / 4Jz / o r \ / / \ Xzz-Z !Z^° b ( 'H-NMR (400 MHz, DMSO-t / 6) 5 12.15 (s, 1H), 9.33 (d, J = 7.1 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.54 (s, 1H), 7.75 (d, J = 4.2 Hz, 1H), 7.60 (dd, J = 7.2, 1.8 Hz, 1H), 4.07 (q, J = 7.0 Hz, 2H), 3.93 (q, J = 7.3 Hz, 2H), 1.32-1.26 (m, 6H); ESI MS (m / z) 483.90 (MH)+ 190 CM X °^z __, z-z ~\ \ J r ? " T 1 ° 1 zX 0 o LL? ’H-NMR (400 MHz, DMSO-Z,) 5 9.23 (s, 1H), 8.95 (d, J = 4.4 Hz, 2H), 8.79 (s, 1H), 8.26 (d, J = 1.0 Hz, 1H), 7.83 (d, J = 4.2 Hz, 1H), 4.98 (s, 1H), 3.87 (s, 3H), 3.59 (q, J = 7.3 Hz, 2H), 1.25-1.21 (m, 3H); ESI MS (m / z) 453.05 (MH)+ 191 £ / P z z=\ Pz-z / > o LL? 'H-NMR (400 MHz, DMSO-A) 5 9.28 (s, 1H), 9.08 (d, J = 4.3 Hz, 1H), 8.86 (s, 1H), 8.72 (s, 1H), 8.30 (d, J = 0.9 Hz, 1H), 7.94 (d, J = 4.3 Hz, 1H), 4.38-4.32 (m, 2H), 3.98 (s, 3H), 1.38 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 478.25 (MH)+ 192 "AsO 0. / Osi? 'H-NMR (400 MHz, DMSO-t / 6) 5 10.14 (t, J = 4.4 Hz, 1H), 9.25 (d, J = 10.8 Hz, 1H), 8.99 (q, J = 4.5 Hz, 1H), 8.29-8.27 (m, 1H), 7.98 (d, J = 4.4 Hz, 1H), 4.494.36 (m, 2H), 3.94-3.85 (m, 5H), 3.03 (s, 3H), 2.93 (S, 3H), 1.28-1.21 (m, 3H); ESI MS (m / z) 538.95 (MH)+ 193 \ aku o Xj" x 'H-NMR (400 MHz, DMSO-t / 6) 5 12.27 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.69 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.72 (d, J = 4.2 Hz, 1H), 5.27-5.20 (m, 2H), 3.84 (s, 3H), 3.76 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 510.85 (MH)+ 194 \ ZI CW \M-z W 1 ° A o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 12.14 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.69 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.71 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.9 Hz, 2H), 4.06 (q, J = 7.0 Hz, 2H), 3.75 (q, J = 7.4 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 524.90 (MH)+ 195 ’H-NMR (400 MHz, DMSO-t / 6) 5 8.93 (d, J = 4.2 Hz, 1H), 8.73 (s, 1H), 8.63 (d, J = 1.2 Hz, 1H), 7.68 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.7 Hz, 2H), 3.72 (q, J = 7.3 Hz, 2H), 3.59 (s, 3H), 3.43 (s, 3H), 1.21 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 524.95 (MH)+ 196 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.76 (t, J = 5.4 Hz, 1H), 8.96 (d, J = 4.4 Hz, 1H), 8.70 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.78 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.7 Hz, 2H), 4.28 (q, J = 2.7 Hz, 2H), 3.78 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 518.85 (MH)+ 197 O, y-o X V z % o co LL ’H-NMR (400 MHz, DMSO-t / 6) 5 10.06 (d, J = 2.0 Hz, 1H), 9.24 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.27 (d, J = 0.7 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 3.78 (q, J = 7.4 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 482.90 (MH)+ 198 TV x4nU ^7-7 N ^jV1^ 'H-NMR (400 MHz, DMSO-t / 6) 5 12.20 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.69 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.69 (d, J = 4.2 Hz, 1H), 6.10-6.00 (m, 1H), 5.47 (dd, J = 17.2, 1.6 Hz, 1H), 5.37-5.34 (m, 1H), 5.23 (t, J = 13.3 Hz, 2H), 4.53 (d, J = 6.1 Hz, 2H), 3.76 (q, J = 7.4 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 536.90 (MH)+ 199 f, H       t F3c4-- /                  \7 F                        H CF3 ’H-NMR (400 MHz, DMSO-A) 5 9.96 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.70 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.69 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.8 Hz, 2H), 3.72 (q, J = 7.4 Hz, 2H), 1.46-1.43 (m, 2H), 1.27 (t, J = 7.3 Hz, 5H); ESI MS (m / z) 588.95 (MH)+ 200 N-a F. O—^  ?—<\ N p f3c>^     yNu „ F            H y 'H-NMR (400 MHz, DMSO-t / 6) 5 11.98 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.70 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.2 Hz, 1H), 7.71 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.7 Hz, 2H), 4.28 (t, J = 6.2 Hz, 1H), 3.74 (q, J = 7.3 Hz, 2H), 1.29 (d, J = 6.1 Hz, 6H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 539.15 (MH)+ 201 o zj o ) z \ wx o-4 ° 'H-NMR (400 MHz, DMSO-t / 6) 5 10.05 (d, J = 2.2 Hz, 1H), 9.17 (d, J = 2.0 Hz, 1H), 8.86 (q, J = 0.9 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 3.78 (q, J = 7.3 Hz, 5H), 1.38 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 483.05 (MH)+ 202 O 7 Z'Z o=\ o z ’H-NMR (400 MHz, DMSO-t / 6) 5 10.06 (s, 1H), 9.16 (s, 1H), 8.35 (s, 1H), 8.18 (d, J = 0.7 Hz, 1H), 3.87 (s, 3H), 3.69 (q, J = 7.4 Hz, 2H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 454.85 (MH)+ 203 "XiHu \ N^jf NH2 'H-NMR (400 MHz, DMSO-A) 5 9.23 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.79 (d, J = 19.3 Hz, 2H), 8.27 (d, J = 1.0 Hz, 1H), 7.85 (d, J = 4.2 Hz, 1H), 3.89 (s, 3H), 3.78 (q, J = 7.3 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 453.90 (MH)+ 204 o / "  / F3C.         O=S 1     / ^N 1, N.      N'"X H 'H-NMR (400 MHz, DMSO-A) 5 9.45 (s, 1H), 9.33 (d, J = 7.1 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.53 (s, 1H), 7.80 (d, J = 4.2 Hz, 1H), 7.59 (dd, J = 7.1, 2.0 Hz, 1H), 3.93 (q, J = 7.3 Hz, 2H), 1.46 (s, 9H), 1.31 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 496.00 (MH)+ 205 1 o zi O= / o 'w^s^"z r " T / o 1 X o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 12.19 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.69 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.71 (d, J = 4.2 Hz, 1H), 5.27-5.20 (m, 2H), 3.85 (d, J = 7.3 Hz, 2H), 3.75 (q, J = 7.3 Hz, 2H), 1.26-1.21 (m, 4H), 0.61-0.56 (m, 2H), 0.37-0.33 (m, 2H); ESI MS (m / z) 550.90 (MH)+ 206 \ ZI O=Z O w JI S' / w 1 / o 1 K^z 1 o LL? 'H-NMR (400 MHz, DMSO-t / 6) 8 12.17 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.69 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.70 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.7 Hz, 2H), 3.80 (d, J = 6.8 Hz, 2H), 3.75 (q, J = 7.3 Hz, 2H), 2.05 (q, J = 6.7 Hz, 1H), 1.25 (t, J = 7.3 Hz, 3H), 0.98-0.39 (m, 6H); ESI MS (m / z) 552.95 (MH)+ 207 n Xj n i ’H-NMR (400 MHz, DMSO-t / 6) 5 8.90 (d, J = 4.2 Hz, 1H), 8.70 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.60 (d, J = 4.2 Hz, 1H), 5.23 (t, J = 13.9 Hz, 2H), 4.45 (dd, J = 14.4, 6.6 Hz, 2H), 4.27-4.23 (m, 1H), 3.99 (d, J = 9.0 Hz, 2H), 3.79-3.73 (m, 2H), 3.63-3.57 (m, 1H), 1.24 (t, J = 7.5 Hz, 3H), 1.09 (d, J = 6.1 Hz, 3H), 1.04 (d, J = 6.1 Hz, 3H); ESI MS (m / z) 579.40 (MH)+ 208 J? °^ZI o       A " -J! X / ° i X o LL? ’H-NMR (400 MHz, DMSO-A) 5 9.91 (s, 1H), 8.97 (d, J = 4.4 Hz, 1H), 8.72 (d, J = 1.5 Hz, 1H), 8.65 (d, J = 1.5 Hz, 1H), 7.78 (d, J = 4.4 Hz, 1H), 5.24 (t, J = 13.8 Hz, 2H), 4.77 (d, J = 6.4 Hz, 2H), 4.49 (d, J = 6.6 Hz, 2H), 3.78 (q, J = 7.3 Hz, 2H), 1.71 (s, 3H), 1.28 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 551.05 (MH)+ 209 z (° CWZI X / Z~z / J o=” y^zz O 4 & o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.91 (t, J = 5.7 Hz, 1H), 9.83 (s, 1H), 9.01 (d, J = 4.3 Hz, 1H), 8.15 (d, J = 9.2 Hz, 1H), 8.03 (dd, J = 9.5, 1.8 Hz, 1H), 7.86 (d, J = 4.3 Hz, 1H), 4.61 (d, J = 5.5 Hz, 2H), 3.95 (q, J = 7.3 Hz, 2H), 1.29 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 479.15 (MH)+ 210 O J F3C.___    O=S I I \V_ / ^N Nx #N'°\ H ’H-NMR (400 MHz, DMSO-t / 6) 5 12.27 (s, 1H), 9.83 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 9.3 Hz, 1H), 8.03 (dd, J = 9.4, 1.6 Hz, 1H), 7.75 (d, J = 4.2 Hz, 1H), 3.94 (q, J = 7.3 Hz, 2H), 3.85 (s, 3H), 1.29 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 470.15 (MH)+ 211 w"* O "z^z T o / 1 " J ° \ I <y z z ’H-NMR (400 MHz, DMSO-t / 6) 5 10.62 (d, J = 7.6 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.86 (d, J = 4.3 Hz, 1H), 5.35 (d, J = 7.9 Hz, 1H), 3.80-3.72 (m, 5H), 1.26 (t, J = 7.3 Hz, 3H), 1.18 (s, 9H); ESI MS (m / z) 470.15 (MH)+ 212 z OVZI X z-zZ) o--rUv ° J H O c> LL? ’H-NMR (400 MHz, DMSO-A) 5 9.97 (s, 1H), 9.83 (d, J = 0.7 Hz, 1H), 9.02 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 9.3 Hz, 1H), 8.03 (dd, J = 9.4, 1.8 Hz, 1H), 7.85 (d, J = 4.2 Hz, 1H), 3.93 (q, J = 7.4 Hz, 2H), 1.79 (s, 6H), 1.31 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 507.30 (MH)+ 213 O / ” -J F3C.         O=S V^N'N  L X-X / /     V? N. ll N Vc H CF3 ’H-NMR (400 MHz, DMSO-A) 5 9.97 (s, 1H), 9.82 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.14 (d, J = 9.3 Hz, 1H), 8.03 (dd, J = 9.3, 1.7 Hz, 1H), 7.73 (d, J = 4.2 Hz, 1H), 3.89 (q, J = 7.3 Hz, 2H), 1.47-1.44 (m, 2H), 1.29 (t, J = 7.3 Hz, 5H); ESI MS (m / z) 548.25 (MH)+ 214 O / " -J F3C.         O=S Y^n-n I Nx nY —J   H CF3 ’H-NMR (400 MHz, DMSO-A) 5 9.83 (s, 1H), 9.75 (s, 1H), 9.00 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 9.0 Hz, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 4.2 Hz, 1H), 3.91 (q, J = 7.3 Hz, 2H), 1.69 (s, 6H), 1.29 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 550.15 (MH)+ 215 "X o I w J 0-¾ 'N'\An 0 H V ’H-NMR (400 MHz, DMSOA) 5 9.83 (s, 1H), 9.43 (d, J = 7.6 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 9.5 Hz, 1H), 8.03 (dd, J = 9.3, 1.7 Hz, 1H), 7.77 (d, J = 4.2 Hz, 1H), 3.96-3.90 (m, 2H), 3.71 (q, J = 7.3 Hz, 1H), 1.32-1.28 (m, 5H), 1.05-0.99 (m, 1H), 0.53-0.34 (m, 4H); ESI MS (m / z) 508.25 (MH)+ 216 F3C^ x ri '> oX'X2 o 1 z^z L \ o ’H-NMR (400 MHz, DMSOA) 5 9.83 (s, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 9.5 Hz, 1H), 8.03 (dd, J = 9.4, 1.6 Hz, 1H), 7.73 (d, J = 4.2 Hz, 1H), 3.92 (q, J = 7.4 Hz, 2H), 3.60 (s, 3H), 3.44 (s, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 484.15 (MH)+ 217 FsCx^ 1 o Z-kV"!' / / \ / / \ V 0 JM^^F H .-A F cf3 ’H-NMR (400 MHz, DMSOA) 5 9.97 (t, J = 6.4 Hz, 1H), 9.83 (s, 1H), 9.01 (d, J = 4.3 Hz, 1H), 8.15 (d, J = 9.5 Hz, 1H), 8.03 (dd, J = 9.3, 1.7 Hz, 1H), 7.80 (d, J = 4.3 Hz, 1H), 4.42 (td, J = 15.4, 6.2 Hz, 2H), 3.92 (q, J = 7.3 Hz, 2H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 572.15 (MH)+ 218 F3C^ Nc "ZVo HN'^ ’H-NMR (400 MHz, DMSOA) 5 10.62 (d, J = 6.4 Hz, 1H), 9.24 (s, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.27 (d, J = 0.7 Hz, 1H), 7.86 (d, J = 4.2 Hz, 1H), 5.35 (d, J = 6.4 Hz, 1H), 3.91 (s, 3H), 3.78-3.71 (m, 2H), 1.28-1.13 (m, 12H); ESI MS (m / z) 525.10 (MH)+ 219 F3CV^ o / " J O=S n-n V 1 k—< N "Si An o n^cn ’H-NMR (400 MHz, DMSOA) 5 9.83 (s, 1H), 9.68 (t, J = 6.0 Hz, 1H), 9.00 (d, J = 4.0 Hz, 1H), 8.15 (d, J = 9.5 Hz, 1H), 8.03 (dd, J = 9.3, 1.7 Hz, 1H), 7.77 (d, J = 4.3 Hz, 1H), 3.93 (q, J = 7.4 Hz, 2H), 3.72 (q, J = 6.2 Hz, 2H), 2.89-2.86 (m, 2H), 1.28 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 493.00 (MH)+ 220 F’X o 1 w J 0-¾ An □ H ’H-NMR (400 MHz, DMSOA) 5 12.18 (s, 1H), 9.83 (s, 1H), 8.98 (d, J = 4.0 Hz, 1H), 8.15 (d, J = 9.5 Hz, 1H), 8.03 (d, J = 9.5 Hz, 1H), 7.74 (d, J = 4.0 Hz, 1H), 3.94 (q, J = 7.3 Hz, 2H), 3.86 (d, J = 7.3 Hz, 2H), 1.301.22 (m, 4H), 0.59 (dd, J = 12.4, 5.7 Hz, 2H), 0.36 (d, J = 5.2 Hz, 2H); ESI MS (m / z) 509.85 (MH)+ 221 "X "Is'0 9 kCF3 N'O H ’H-NMR (400 MHz, DMSOA) 5 12.86 (s, 1H), 8.98 (d, J = 4.0 Hz, 1H), 8.88-8.85 (m, 1H), 8.64 (t, J = 1.1 Hz, 1H), 7.75 (d, J = 4.0 Hz, 1H), 4.73 (q, J = 9.0 Hz, 2H), 3.80-3.72 (m, 5H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 551.90 (MH)+ 222 ^S'° £-¾ 9 ^CF3 N'O H ’H-NMR (400 MHz, DMSOA) 5 12.86 (s, 1H), 9.24 (s, 1H), 8.99 (d, J = 4.0 Hz, 1H), 8.27 (s, 1H), 7.80 (d, J = 17.7 Hz, 1H), 4.75 (q, J = 9.0 Hz, 2H), 3.88 (S, 3H), 3.74 (q, J = 7.3 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 551.85 (MH)+ 223 --\ zO ,S' 0    A -AW ’H-NMR (400 MHz, DMSOA) 5 9.21 (s, 1H), 8.96 (s, 1H), 8.25 (d, J = 0.7 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.74 (q, J = 7.3 Hz, 2H), 3.11-3.05 (m, 1H), 1.89 (dt, J = 8.9, 3.2 Hz, 2H), 1.40-1.34 (m, 5H), 1.27-1.24 (m, 3H); ESI MS (m / z) 523.35 (MH)+ 224 --\ zO X 0    A ’H-NMR (400 MHz, DMSOA) 5 8.96 (s, 1H), 8.84 (d, J = 1.5 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 3.79-3.71 (m, 5H), 3.13-3.06 (m, 1H), 1.90 (dt, J = 8.9, 3.2 Hz, 2H), 1.40-1.34 (m, 5H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 523.15 (MH)+ 225 ----ZXO A o' y=N WoW 0 ’H-NMR (400 MHz, DMSOA) 5 9.11 (s, 1H), 8.85 (q, J = 0.9 Hz, 1H), 8.63 (q, J = 0.9 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 3.81-3.75 (m, 5H), 3.19 (s, 3H), 1.38 (t, J = 7.0 Hz, 3H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 497.20 (MH)+ 226 --\ <0 A AX 0 ’H-NMR (400 MHz, DMSOA) 5 8.85 (q, J = 0.9 Hz, 1H), 8.62 (t, J = 1.1 Hz, 1H), 8.57 (s, 1H), 3.73 (s, 3H), 3.58 (q, J = 7.4 Hz, 2H), 3.41-3.36 (m, 1H), 1.22 (t, J = 7.3 Hz, 3H), 1.04-1.02 (m, 4H); ESI MS (m / z) 494.90 (MH)+ 227 OxAjAy ’H-NMR (400 MHz, DMSOA) 5 11.65 (s, 1H), 9.84 (s, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.15 (d, J = 9.3 Hz, 1H), 8.03 (dd, J = 9.3, 1.7 Hz, 1H), 7.76 (d, J = 4.2 Hz, 1H), 3.93 (q, J = 7.4 Hz, 2H), 1.34 (s, 9H), 1.27 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 512.00 (MH)+ 228 o / F3C.        °A I / i xvAn A J / ' N-O 'H-NMR (400 MHz, DMSOA) 5 9.82 (d, J = 0.9 Hz, 1H), 9.45 (d, J = 4.3 Hz, 1H), 8.98 (d, J = 4.3 Hz, 1H), 8.15-8.11 (m, 1H), 8.03 (dd, J = 9.5, 1.8 Hz, 1H), 7.74 (d, J = 4.0 Hz, 1H), 3.97-3.88 (m, 2H), 3.03-2.98 (m, 1H), 1.29 (t, J = 7.3 Hz, 3H), 0.86 (td, J = 7.0, 5.1 Hz, 2H), 0.65-0.61 (m, 2H); ESI MS (m / z) 480.05 (MH)+ 229 •—\ zO A ° A W<W 0 'H-NMR (400 MHz, DMSOA) 5 8.85 (t, J = 1.1 Hz, 1H), 8.62 (d, J = 1.8 Hz, 2H), 3.72 (s, 3H), 3.57 (q, J = 7.3 Hz, 2H), 2.61 (s, 3H), 1.22 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.95 (MH)+ 230 8 <° 'S' 0 An WO o 'H-NMR (400 MHz, DMSOA) 5 12.27 (s, 1H), 8.82 (d, J = 1.5 Hz, 1H), 8.77 (s, 1H), 8.58 (d, J = 1.5 Hz, 1H), 3.79 (s, 3H), 3.73 (q, J = 7.4 Hz, 2H), 3.35 (q, J = 3.7 Hz, lH),2.83(s,3H), 1.23 (t, J = 7.3 Hz, 3H), 1.111.04 (m, 2H), 1.03-0.96 (m, 2H); ESI MS (m / z) 507.85 (MH)+ 231 o w Z— / W / O Z^zAA° iz-z nA w v 'H-NMR (400 MHz, DMSOA) 5 9.97 (s, 1H), 9.33 (d, J = 7.0 Hz, 1H), 8.99 (d, J = 4.3 Hz, 1H), 8.53 (s, 1H), 7.73 (d, J = 4.3 Hz, 1H), 7.59 (dd, J = 7.2, 1.7 Hz, 1H), 3.89 (q, J = 7.3 Hz, 2H), 1.47-1.39 (m, 2H), 1.29 (t, J = 7.3 Hz, 3H), 1.22-1.13 (m, 2H); ESI MS (m / z) 548.00 (MH)+ 232 ,z-z ( o 1 o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.45 (d, J = 4.0 Hz, 1H), 9.33 (d, J = 7.3 Hz, 1H), 8.98 (d, J = 4.3 Hz, 1H), 8.53 (s, 1H), 7.74 (d, J = 4.0 Hz, 1H), 7.59 (dd, J = 7.3, 1.8 Hz, 1H), 3.94 (q, J = 7.3 Hz, 2H), 3.01 (td, J = 7.4, 3.9 Hz, 1H), 1.29 (t, J = 7.5 Hz, 3H), 0.88-0.84 (m, 2H), 0.65-0.61 (m, 2H); ESI MS (m / z) 479.80 (MH)+ 233 O / ll__I F3C.         O=S V^r^N  1 1 y~y^N p N H \ ’H-NMR (400 MHz, DMSO-t / 6) 5 9.33 (d, J = 7.1 Hz, 1H), 8.97 (d, J = 4.2 Hz, 1H), 8.53 (s, 1H), 7.73 (d, J = 4.2 Hz, 1H), 7.59 (dd, J = 7.1, 1.7 Hz, 1H), 4.31-4.25 (m, 1H), 3.92 (q, J = 7.3 Hz, 2H), 1.30-1.23 (m, 9H); ESI MS (m / z) 498.15 (MH)+ 234 o z— / zCz 1 O z^=k Y° r A / / \ \_z-z Yo IZ b V 'H-NMR (400 MHz, DMSO-t / 6) 5 12.17 (s, 1H), 9.33 (d, J = 6.8 Hz, 1H), 8.98 (d, J = 4.2 Hz, 1H), 8.53 (s, 1H), 7.74 (d, J = 4.2 Hz, 1H), 7.61-7.59 (m, 1H), 3.93 (q, J = 7.3 Hz, 2H), 3.81 (d, J = 6.6 Hz, 2H), 2.07 (t, J = 6.7 Hz, 1H), 1.28 (t, J = 7.3 Hz, 3H), 0.97 (d, J = 6.8 Hz, 6H); ESI MS (m / z) 512.00 (MH)+ 235 X Y / (Y Q LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 8.81 (d, J = 1.2 Hz, 1H), 8.57 (d,J= 1.5 Hz, 1H), 8.06 (s, 1H),4.11 (q,J = 7.0 Hz, 2H), 3.74 (s, 3H), 3.65-3.57 (m, 2H), 2.18 (s, 3H), 1.25-1.18 (m, 6H); ESI MS (m / z) 512.00 (MH)+ 236 > " m< .x ' N<Y< ’H-NMR (400 MHz, CHLOROFORM-t / ) 5 8.73 (q, J = 0.9 Hz, 1H), 8.67 (s, 1H), 8.33 (d, J = 1.5 Hz, 1H), 4.67 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 3.61 (q, J = 7.4 Hz, 2H), 2.52 (s, 3H), 1.52 (t, J = 7.0 Hz, 3H), 1.441.39 (m, 3H); ESI MS (m / z) 497.20 (MH)+ 237 "Wh ’H-NMR (400 MHz, DMSO-A) 5 9.22 (s, 1H), 8.91 (s, 1H), 8.26 (d, J = 1.0 Hz, 1H), 4.62 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 3.70 (q, J = 7.4 Hz, 2H), 2.45 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 497.15 (MH)+ 238 > Wt ' 0H ’H-NMR (400 MHz, DMSO-A) 5 8.89 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 3.79 (s, 3H), 3.72 (q, J = 7.4 Hz, 2H), 2.44 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.90 (MH)+ 239 w1 O 0 T o / 1 J rcr° Yo o I 'H-NMR (400 MHz, DMSO-A) 5 9.22 (s, 1H), 8.89 (s, 1H), 8.26 (d, J = 0.6 Hz, 1H), 3.89 (s, 3H), 3.71 (q, J = 7.4 Hz, 2H), 2.44 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.85 (MH)+ 240 0 / N. I]' 1 'H-NMR (400 MHz, DMSO-t / 6) 5 9.33 (d, J = 7.1 Hz, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.53 (t, J = 1.0 Hz, 1H), 7.60-7.57 (m, 2H), 3.91 (q, J = 7.4 Hz, 2H), 3.14 (s, 3H), 2.91 (s, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.20 (MH)+ 241 o w w °y O 1 ° 1 o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 8.93 (d, J = 4.2 Hz, 1H), 8.84 (s, 1H), 8.62 (d, J = 1.5 Hz, 1H), 7.70 (d, J = 4.2 Hz, 1H), 3.78 (s, 3H), 3.72 (q, J = 7.4 Hz, 2H), 3.61 (s, 6H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 530.20 (MH)+ 242 > ’H-NMR (400 MHz, DMSO-t / 6) 5 8.95 (d, J = 4.2 Hz, 1H), 8.85 (t, J = 1.0 Hz, 1H), 8.63-8.63 (m, 1H), 7.78 (d, J = 4.4 Hz, 1H), 4.30-4.18 (m, 4H), 3.97 (d, J =12.7 Hz, 2H), 3.86-3.71 (m, 7H), 1.29-1.21 (m, 3H); ESI MS (m / z) 572.20 (MH)+ 243 ( o / IZ \=o f VJ Vo LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 12.08 (s, 1H), 9.76 (d, J = 2.0 Hz, 1H), 9.09 (d, J = 2.0 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 4.00 (q, J = 6.9 Hz, 2H), 3.79-3.74 (m, 5H), 1.25 (t, J = 7.3 Hz, 6H); ESI MS (m / z) 497.95 (MH)+ 244 --\ .o A ’H-NMR (400 MHz, DMSO-t / 6) 5 8.96 (d, J = 4.2 Hz, 1H), 8.87-8.85 (m, 1H), 8.63-8.63 (m, 1H), 8.34-8.32 (m, 2H), 7.87-7.83 (m, 1H), 7.82 (d, J = 4.2 Hz, 1H), 7.79-7.75 (m, 2H), 3.82-3.79 (m, 3H), 3.77 (q, J = 2.4 Hz, 1H), 3.75 (s, 3H), 3.73 (d, J = 2.2 Hz, 1H), 1.26 (td, J = 7.3, 3.4 Hz, 3H); ESI MS (m / z) 592.05 (MH)+ 245 \ <0 A 'H-NMR (400 MHz, DMSO-t / 6) 5 8.93 (d, J = 4.2 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.62-7.58 (m, 3H), 7.49-7.43 (m, 3H), 5.16 (dd, J = 16.8, 13.8 Hz, 2H), 3.78 (s, 3H), 3.72 (q, J = 7.3 Hz, 2H), 3.48 (s, 3H), 1.29-1.25 (m, 3H); ESI MS (m / z) 606.10 (MH)+ 246 w1 O 4 in :z'z o=\ ZI / ’H-NMR (400 MHz, DMSO-t / 6) 5 9.78 (d, J = 2.0 Hz, 1H), 9.17 (d, J = 2.0 Hz, 1H), 8.90 (t, J = 4.5 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.793.74 (m, 5H), 2.87 (d, J = 4.6 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 467.90 (MH)+ 247 --\ zO _S o \=N F3cy^fYJu X        11 V 0 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.79 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 8.89 (d, J = 3.9 Hz, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.793.74 (m, 5H), 2.93-2.88 (m, 1H), 1.25 (t, J = 7.3 Hz, 3H), 0.80-0.75 (m, 2H), 0.64-0.60 (m, 2H); ESI MS (m / z) 494.25 (MH)+ 248 —^O / IZ \=o (i o LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 11.88 (s, 1H), 9.78 (d, J = 2.0 Hz, 1H), 9.09 (d, J = 2.0 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 4.22-4.16 (m, 1H), 3.79-3.74 (m, 5H), 1.27-1.23 (m, 9H); ESI MS (m / z) 512.10 (MH)+ 249 \^o * o LL? ’H-NMR (400 MHz, DMSOZ6) 5 9.81 (d, J = 2.0 Hz, 1H), 9.17 (d, J = 2.0 Hz, 1H), 8.91 (t, J = 5.3 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.793.74 (m, 5H), 3.40-3.33 (m, 2H), 1.27-1.22 (m, 3H), 1.17 (q, J = 7.3 Hz, 3H); ESI MS (m / z) 481.90 (MH)+ 250 z o ) xz o LL? ’H-NMR (400 MHz, DMSOZ6) 5 9.88 (d, J = 2.0 Hz, 1H), 9.69 (t, J = 5.5 Hz, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.7 Hz, 1H), 4.46 (d, J = 5.4 Hz, 2H), 3.81-3.75 (m, 5H), 1.26 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 493.20 (MH)+ 251 co o ) TZ \^O < '% o LL? ’H-NMR (400 MHz, DMSOZ6) 5 9.92 (d, J = 2.2 Hz, 1H), 9.56 (t, J = 6.1 Hz, 1H), 9.21 (d, J = 2.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 4.274.18 (m, 2H), 3.80-3.75 (m, 5H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 536.05 (MH)+ 252 --\ zO xS o V=N ._________A F3C^5_^YJ\ X                II O ’H-NMR (400 MHz, DMSO-X) 5 9.85 (d, J = 2.0 Hz, 1H), 9.19 (d, J = 2.2 Hz, 1H), 9.01 (t, J = 5.5 Hz, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.63 (d, J = 1.7 Hz, 1H), 3.793.74 (m, 5H), 3.23 (t, J = 6.1 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H), 1.10-1.04 (m, 1H), 0.51-0.46 (m, 2H), 0.27 (q, J = 5.0 Hz, 2H); ESI MS (m / z) 508.30 (MH)+ 253 --s zO X 0 \=N F3C—X y- N \=N           0 'H-NMR (400 MHz, DMSO-X) 5 9.91 (d, J = 2.2 Hz, 1H), 9.18 (d, J = 2.2 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.74 (t, J = 6.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.77 (q, J = 7.3 Hz, 5H), 3.18 (d, J = 6.1 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H), 0.94 (s, 9H); ESI MS (m / z) 524.30 (MH)+ 254 —z° zSf °' \=N, __H FsC-Z^-n nJM / 4 O 'H-NMR (400 MHz, DMSO-X) 5 9.78 (d, J = 2.0 Hz, 1H), 9.15 (d, J = 2.2 Hz, 1H), 9.09 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.79-3.74 (m, 5H), 1.41 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H), 0.82-0.79 (m, 2H), 0.68 (dd, J = 6.7, 5.0 Hz, 2H); ESI MS (m / z) 508.25 (MH)+ 255 --\ zO X N yX-N   H CN c r          ' K / N'5L F3C~X       n^ / Y p? \=N X        0 'H-NMR (400 MHz, DMSO-X) 5 9.85 (d, J = 2.0 Hz, 1H), 9.76 (s, 1H), 9.15 (d, J = 2.0 Hz, 1H), 8.86 (s, 1H), 8.63 (d, J = 1.7 Hz, 1H), 3.80-3.75 (m, 5H), 1.65 (dd, J = 8.1, 5.4 Hz, 2H), 1.37-1.32 (m, 2H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 519.05 (MH)+ 256 -—\ zO X °' ^=N, F3C—X    N   N% / \=N X        0 ’H-NMR (400 MHz, DMSO-X) 5 9.77 (d, J = 2.0 Hz, 1H), 9.02 (d, J = 2.0 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.81-3.74 (m, 5H), 3.68 (s, 3H), 3.37 (t, J = 3.4 Hz, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 498.10 (MH)+ 257 xz \=o z \ } k / z 0 LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 12.22 (s, 1H), 9.74 (s, 1H), 9.08 (d, J = 2.2 Hz, 1H), 8.86 (dd, J = 2.1, 0.6 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.79-3.74 (m, 8H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 484.05 (MH)+ 258 / z =.xr o M LL ’H-NMR (400 MHz, DMSO-t / 6) 5 9.72 (d, J = 2.1 Hz, 1H), 8.88 (d, J = 1.8 Hz, 1H), 8.85 (t, J = 1.1 Hz, 1H), 8.62 (d, J = 2.1 Hz, 1H), 3.80-3.73 (m, 5H), 3.08 (d, J = 22.9 Hz, 6H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 482.00 (MH)+ 259 zO zS' °' H ZT^ /    \   \\  zN^-7 N^ / Y V N= / x       o ’H-NMR (400 MHz, DMSO-t / 6) 5 9.79 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.14 (d, J = 2.0 Hz, 1H), 8.88 (d, J = 4.2 Hz, 1H), 8.26 (d, J = 0.7 Hz, 1H), 3.90 (s, 3H), 3.79-3.72 (m, 2H), 2.91 (qd, J = 7.5, 3.7 Hz, 1H), 1.24 (t, J = 7.3 Hz, 3H), 0.80-0.71 (m, 2H), 0.68-0.60 (m, 2H); ESI MS (m / z) 494.05 (MH)+ 260 JI O « 1 O / 1 " J ° ZI G^ 'H-NMR (400 MHz, DMSO-t / 6) 5 11.88 (s, 1H), 9.78 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.09 (d, J = 2.2 Hz, 1H), 8.26 (d, J = 1.0 Hz, 1H), 4.23-4.16 (m, 1H), 3.90 (s, 3H), 3.79-3.72 (m, 2H), 1.26-1.23 (m, 9H); ESI MS (m / z) 512.20 (MH)+ 261 Ji o 4 J Z_ / T'b 0 z-z ___ / 'H-NMR (400 MHz, DMSO-t / 6) 5 9.68 (d, J = 2.2 Hz, 1H), 8.86-8.85 (m, 2H), 8.63 (dd, J = 2.1, 0.6 Hz, 1H), 3.81 (s, 3H), 3.79-3.72 (m, 2H), 3.49-3.36 (m, 4H), 1.28-1.24 (m, 3H), 1.19-1.14 (m, 6H); ESI MS (m / z) 510.35 (MH)+ 262 ) IZ 5=0 z-z. °x r\k< o LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 9.81 (d, J = 2.2 Hz, 1H), 9.23 (s, 1H), 9.17 (d, J = 2.2 Hz, 1H), 8.91 (t, J = 5.4 Hz, 1H), 8.26 (d, J = 1.0 Hz, 1H), 3.90 (s, 3H), 3.76 (q, J = 7.4 Hz, 2H), 3.40-3.33 (m, 2H), 1.25 (t, J = 7.3 Hz, 3H), 1.18 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 482.10 (MH)+ 263 <o / xz ^=° rQ », A? X o LL? 'H-NMR (400 MHz, DMSO-t / 6) 5 12.09 (s, 1H), 9.76 (d, J = 2.0 Hz, 1H), 9.23 (s, 1H), 9.09 (d, J = 2.2 Hz, 1H), 8.26-8.25 (m, 1H), 4.00 (q, J = 7.0 Hz, 2H), 3.90 (s, 3H), 3.77 (q, J = 7.3 Hz, 2H), 1.27-1.23 (m, 6H); ESI MS (m / z) 498.10 (MH)+ 264 Z o ) IZ x° Z Z ) °x xXz f o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.88 (d, J = 2.0 Hz, 1H), 9.69 (t, J = 5.5 Hz, 1H), 9.23 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.26 (d, J = 0.7 Hz, 1H), 4.46 (t, J = 2.7 Hz, 2H), 3.90 (s, 3H), 3.80-3.74 (m, 2H), 1.27-1.23 (m, 3H); ESI MS (m / z) 493.15 (MH)+ 265 zO zs o \=n ^VVS H 0 ’H-NMR (400 MHz, DMSO-t / 6) 5 9.78 (d, J = 2.0 Hz, 1H), 9.22 (s, 1H), 9.15 (d, J = 2.0 Hz, 1H), 9.09 (s, 1H), 8.26 (d, J = 0.7 Hz, 1H), 3.89 (s, 3H), 3.76 (q, J = 7.4 Hz, 2H), 1.42 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H),0.82-0.79 (m, 2H), 0.68 (dd, J = 6.7, 5.0 Hz, 2H); ESI MS (m / z) 508.15 (MH)+ 266 --\ O0 zS °' \=N   9 \ 'H-NMR (400 MHz, DMSO-t / 6) 5 8.96 (d, J = 4.2 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 8.20 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 4.2 Hz, 1H), 7.57 (d, J = 8.1 Hz, 2H), 3.80 (s, 3H), 3.75 (td, J = 7.3, 2.4 Hz, 2H), 3.71 (s, 3H), 2.46 (s, 3H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 606.15 (MH)+ 267 Q^S'0 X               H . , 0 'H-NMR (400 MHz, DMSO-t / 6) 5 9.91 (d, J = 2.2 Hz, 1H), 9.23 (s, 1H), 9.18 (d, J = 2.2 Hz, 1H), 8.74 (t, J = 6.2 Hz, 1H), 8.26 (d, J = 1.0 Hz, 1H), 3.90 (s, 3H), 3.77 (q, J = 7.3 Hz, 2H), 3.18 (d, J = 6.4 Hz, 2H), 1.25 (t, J = 7.3 Hz, 3H), 0.94 (s, 9H); ESI MS (m / z) 524.25 (MH)+ 268 "Wy t ' N^jT N’S 'H-NMR (400 MHz, DMSO-t / 6) 5 8.93 (d, J = 4.2 Hz, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 7.70 (d, J = 4.2 Hz, 1H), 3.78 (s, 3H), 3.76-3.68 (m, 4H), 3.57 (s, 3H), 1.44 (t, J = 7.3 Hz, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 544.10 (MH)+ 269 FX*Ku Co '        N2 ’H-NMR (400 MHz, DMSO-t / 6) 5 8.92 (d, J = 4.2 Hz, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 7.71 (d, J = 4.2 Hz, 1H), 3.81 (d, J = 16.6 Hz, 3H), 3.77-3.68 (m, 6H), 1.43 (t, J = 7.3 Hz, 6H), 1.25 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 558.20 (MH)+ 270 o*s'° " VHU z, ’H-NMR (400 MHz, DMSO-t / 6) 5 9.18 (d, J = 4.2 Hz, 1H), 8.88 (s, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.62 (d, J = 1.7 Hz, 1H), 3.78 (s, 3H), 3.69 (q, J = 7.3 Hz, 2H), 2.37 (s, 3H), 1.74-1.70 (m, 1H), 1.24 (t, J = 7.3 Hz, 3H), 0.83 (td, J = 7.0, 5.1 Hz, 2H), 0.61-0.57 (m, 2H); ESI MS (m / z) 508.20 (MH)+ 271 FWu X-—X  ri 'H-NMR (400 MHz, DMSO-t / 6) 5 12.14 (s, 1H), 8.91 (d, J = 3.2 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.7 Hz, 1H), 4.08 (q, J = 7.0 Hz, 2H), 3.78 (s, 3H), 3.69 (q, J = 7.3 Hz, 2H), 2.42 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 512.20 (MH)+ 272 ZI O^ / r w 1 1 ° JI & o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.11 (t, J = 5.5 Hz, 1H), 8.88 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 3.79 (d, J = 7.8 Hz, 3H), 3.68 (q, J = 7.3 Hz, 2H), 3.46-3.40 (m, 2H), 2.38 (s, 3H), 1.26-1.22 (m, 3H), 1.20 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 496.20 (MH)+ 273 O^° Wu ' N<s J          — °\ / 'H-NMR (400 MHz, DMSO-A) 5 8.95 (s, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 4.03 (s, 3H), 3.91 (s, 2H), 3.79 (s, 3H), 3.72-3.64 (m, 2H), 2.44 (d, J = 5.2 Hz, 3H), 1.66-1.83 (1H), 1.19-1.15 (m, 3H), 0.80 (d, J = 6.7 Hz, 6H); ESI MS (m / z) 598.40 (MH)+ 274 o?s=° XHu , ’H-NMR (400 MHz, DMSO-t / 6) 5 9.02 (t, J = 6.1 Hz, 1H), 8.88 (s, 1H), 8.85 (s, 1H), 8.62 (s, 1H), 3.79 (s, 3H), 3.67 (q, J = 7.3 Hz, 2H), 3.23 (d, J = 6.1 Hz, 2H), 2.40 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H), 0.99 (s, 9H); ESI MS (m / z) 538.30 (MH)+ 275 ’H-NMR (400 MHz, DMSOAs) 5 12.32 (s, 1H), 8.91 (d, J = 3.7 Hz, 1H), 8.85 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.7 Hz, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 3.70 (q, J = 7.3 Hz, 2H), 2.43 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 498.05 (MH)+ 276 z—\ o LL? ’H-NMR (400 MHz, DMSO-t / 6) 5 9.01 (d, J = 4.2 Hz, 1H), 8.86 (t, J = 1.0 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.81 (d, J = 4.4 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.89 (d, J = 6.4 Hz, 2H), 3.79 (s, 3H), 3.69 (q, J = 7.2 Hz, 2H), 1.80-1.70 (m, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.3 Hz, 3H), 0.80 (d, J = 6.8 Hz, 6H); ESI MS (m / z) 599.15 (MH)+ 277 XXHu o x ’H-NMR (400 MHz, DMSO-t / 6) 5 9.01 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.7 Hz, 1H), 7.80 (d, J = 4.4 Hz, 1H), 4.25 (q, J = 7.1 Hz, 2H), 4.12 (q, J = 7.1 Hz, 2H), 3.80 (s, 3H), 3.69 (q, J = 7.3 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H), 1.18 (t, J = 7.3 Hz, 3H), 1.03 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 571.05 (MH)+ 278 Js-° "XX <3 J v nX r a X     Fl / ’H-NMR (400 MHz, DMSO-t / 6) 5 9.56 (t, J = 6.2 Hz, 1H), 8.90 (s, 1H), 8.85 (q, J = 0.9 Hz, 1H), 8.63-8.63 (m, 1H), 3.91 (td, J = 13.8, 6.4 Hz, 2H), 3.78 (s, 3H), 3.68 (q, J = 7.4 Hz, 2H), 2.39 (s, 3H), 1.78 (t, J = 19.1 Hz, 3H), 1.22 (d, J = 7.3 Hz, 3H); ESI MS (m / z) 546.70 (MH)+ 279 ->° 'H-NMR (400 MHz, DMSO-t / 6) 5 8.88 (s, 1H), 8.858.85 (m, 1H), 8.62 (dd, J = 2.1, 0.6 Hz, 1H), 3.82 (s, 3H), 3.79-3.68 (m, 2H), 3.17 (s, 3H), 2.92 (s, 3H), 2.35 (s, 3H), 1.22 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 496.20 (MH)+ 280 8 <0 A ■'XAxA ’H-NMR (400 MHz, DMSO-t / 6) 5 8.87-8.85 (m, 2H), 8.76 (s, 1H), 8.62 (dd, J = 2.1, 0.6 Hz, 1H), 3.78 (s, 3H), 3.66 (q, J = 7.4 Hz, 2H), 2.38 (s, 3H), 1.44 (s, 9H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 524.25 (MH)+ 281 fWj ' NJQpCN 'H-NMR (400 MHz, DMSO-t / 6) 5 9.90 (t, J = 5.6 Hz, 1H), 8.91 (s, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 4.60 (d, J = 5.6 Hz, 2H), 3.78 (s, 3H), 3.69 (q, J = 7.3 Hz, 2H), 2.39 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 507.00 (MH)+ 282 ^S'° F r          0 \ FaC^^^N k. T F x>—X । ° 'H-NMR (400 MHz, DMSO-A) 5 9.29 (s, 1H), 8.87 (s, 1H), 8.85 (dd, J = 2.1, 0.6 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 3.77 (s, 3H), 3.66 (q, J = 7.3 Hz, 2H), 2.36 (s, 3H), 1.49 (s, 3H), 1.26 (t, J = 7.3 Hz, 3H), 0.84-0.71 (m, 4H); ESI MS (m / z) 522.05 (MH)+ 283 ’H-NMR (400 MHz, DMSO-t / 6) 5 8.90 (d, J = 5.6 Hz, 1H), 8.85 (s, 1H), 8.63 (d, J = 1.5 Hz, 1H), 3.81 (s, 3H), 3.78-3.65 (m, 2H), 3.57 (s, 3H), 3.48 (s, 3H), 2.40 (s, 3H), 1.25-1.14 (m, 3H); ESI MS (m / z) 512.25 (MH)+ 284 --\ zO o \=N  0 \ ’H-NMR (400 MHz, DMSO-t / 6) 5 8.85-8.84 (m, 2H), 8.62 (d, J = 1.5 Hz, 1H), 3.79 (s, 3H), 3.71 (q, J = 7.3 Hz, 2H), 3.62 (s, 6H), 2.43 (s, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 544.60 (MH)+ 285 —\ zX FW / “! ’H-NMR (400 MHz, DMSO-A) 5 8.88 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 8.53 (d, J = 5.4 Hz, 2H), 3.78 (s, 3H), 3.70 (q, J = 7.3 Hz, 2H), 2.41 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 468.05 (MH)+ 286 O^S'° ’W,i x 4XV ’H-NMR (400 MHz, DMSO-t / 6) 5 9.06 (q, J = 4.6 Hz, 1H), 8.88 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.62 (d, J = 1.5 Hz, 1H), 3.78 (s, 3H), 3.70 (q, J = 7.3 Hz, 2H), 2.94 (d, J = 4.6 Hz, 3H), 2.38 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 482.40 (MH)+ 287 ’H-NMR (400 MHz, DMSO-A) 5 8.92 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 4.13 (s, 3H), 3.79 (s, 3H), 3.71 (q, J = 7.3 Hz, 2H), 2.45 (s, 3H), 1.23 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 483.65 (MH)+ 288 ^nh X      "A rl ’H-NMR (400 MHz, DMSO-tfc) 5 12.30 (s, 1H), 8.94 (d, J = 4.2 Hz, 1H), 8.84 (d, J = 1.5 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.78 (d, J = 4.2 Hz, 1H), 5.00 (s, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 3.60 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 483.20 (MH)+ 289 Xxftu x° ^-0       r"^ ’H-NMR (400 MHz, DMSO-t / 6) 5 9.02 (d, J = 4.2 Hz, 1H), 8.86 (d, J = 1.5 Hz, 1H), 8.64 (d, J = 1.5 Hz, 1H), 7.83 (d, J = 4.2 Hz, 1H), 4.01 (s, 3H), 3.91 (d, J = 6.4 Hz, 2H), 3.80 (s, 3H), 3.69 (q, J = 7.3 Hz, 2H), 1.75 (t, J = 6.6 Hz, 1H), 1.19 (t, J = 7.3 Hz, 3H), 0.80 (d, J = 6.6 Hz, 6H); ESI MS (m / z) 585.00 (MH)+ 290 ^s-° ° n                     ii ' nx r n-\ x ’H-NMR (400 MHz, DMSO-t / 6) 5 9.02 (d, J = 4.2 Hz, 1H), 8.89-8.84 (m, 1H), 8.64-8.63 (m, 1H), 7.82 (d, J = 4.4 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.99 (s, 3H), 3.80 (s, 3H), 3.74-3.67 (m, 2H), 1.27-1.15 (m, 3H), 1.04 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 556.20 (MH)+ 291 o?s'° '•' vh V / ’H-NMR (400 MHz, DMSO-t / 6) 5 9.02 (d, J = 4.4 Hz, 1H), 8.86 (d, J = 1.2 Hz, 1H), 8.63 (d, J = 1.5 Hz, 1H), 7.82 (d, J = 4.2 Hz, 1H), 3.99 (s, 3H), 3.80 (s, 3H), 3.75 (s, 3H), 3.70 (q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 542.60 (MH)+ 292 o?s5° o. n ’H-NMR (400 MHz, DMSO-t / 6) 5 12.20 (s, 1H), 8.988.96 (m, 1H), 8.86 (s, 1H), 8.64 (s, 1H), 7.76 (d, J = 4.2 Hz, 1H), 3.86 (d, J = 7.3 Hz, 2H), 3.81-3.72 (m, 5H), 1.27-1.19 (m, 4H), 0.61-0.57 (m, 2H), 0.36 (dd, J = 10.5, 4.4 Hz, 2H); ESI MS (m / z) 524.10 (MH)+ 293 \ <nh ’H-NMR (400 MHz, DMSO-t / 6) 5 8.92 (d, J = 4.2 Hz, 1H), 8.84 (s, 1H), 8.61 (s, 1H), 7.70 (d, J = 3.9 Hz, 1H), 4.86 (s, 1H), 3.80 (s, 3H), 3.62 (s, 3H), 3.58-3.49 (m, 2H), 3.44 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 497.05 (MH)+ 294 o 0 1 O 1 1 w J / /      H " fkz ° / ^o ’H-NMR (500 MHz, DMSO-A) 5 9.23 (s, 1H), 8.99 (d, J = 7.8 Hz, 1H), 8.88 (s, 1H), 8.25 (s, 1H), 4.224.17 (m, 1H), 3.89 (s, 3H), 3.66 (q, J = 7.4 Hz, 2H), 2.38 (s, 3H), 1.26-1.22 (m, 9H); ESI MS (m / z) 510.25 (MH)+ 295 ’H-NMR (500 MHz, DMSO-A) 5 9.23 (s, 1H), 9.00 (d, J = 7.6 Hz, 1H), 8.88 (s, 1H), 8.26 (s, 1H), 4.224.17 (m, 1H), 3.89 (s, 3H), 3.69-3.64 (m, 2H), 2.40 (d, J = 15.8 Hz, 3H), 1.26-1.22 (m, 7H); ESI MS (m / z) 507.90 (MH)+ 296 o^ / ° w ^4'      " r w T / o 1 & o LL? ’H-NMR (400 MHz, DMSO-A) 5 9.23 (s, 1H), 9.09 (t, J = 5.5 Hz, 1H), 8.88 (s, 1H), 8.26 (s, 1H), 3.89 (s, 3H), 3.67 (q, J = 7.3 Hz, 2H), 3.37 (q, J = 6.4 Hz, 2H), 2.39 (s, 3H), 1.60 (td, J = 14.1, 7.0 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H), 0.99 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 509.90 (MH)+ 297 \ oO A ■■•A5A 'H-NMR (400 MHz, DMSO-A) 5 9.23 (s, 1H), 9.10 (t, J = 5.4 Hz, 1H), 8.88 (s, 1H), 8.26 (s, 1H), 3.89 (s, 3H), 3.68 (q, J = 7.4 Hz, 2H), 3.46-3.40 (m, 2H), 2.38 (s, 3H), 1.22 (dt, J = 17.0, 7.3 Hz, 6H); ESI MS (m / z) 496.20 (MH)+ 298 8 <0 A *A)0 ’H-NMR (400 MHz, DMSO-A) 5 9.23 (s, 1H), 8.86 (s, 1H), 8.74 (s, 1H), 8.25 (s, 1H), 3.88 (s, 3H), 3.65 (q, J = 7.3 Hz, 2H), 2.38 (s, 3H), 1.44 (s, 9H), 1.27 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 524.45 (MH)+ 299 --\ A AA 'H-NMR (400 MHz, DMSO-t / 6) 5 12.30 (s, 1H), 9.23 (s, 1H), 8.91 (s, 1H), 8.26 (s, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.69 (q, J = 7.3 Hz, 2H), 2.43 (s, 3H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 498.10 (MH)+ 300 F,c w J x 4XVcn 'H-NMR (400 MHz, DMSO-t / 6) 5 10.33 (s, 1H), 9.23 (s, 1H), 8.90 (s, 1H), 8.25 (s, 1H), 3.88 (s, 3H), 3.66 (q, J = 7.3 Hz, 2H), 2.38 (s, 3H), 1.72 (dd, J = 7.9, 5.7 Hz, 2H), 1.37 (dd, J = 7.8, 5.6 Hz, 2H), 1.24 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 533.35 (MH)+ 301 —\ <0 A ’H-NMR (400 MHz, DMSO-A) 5 9.23 (s, 1H), 9.17 (t, J = 5.5 Hz, 1H), 8.89 (s, 1H), 8.26 (s, 1H), 3.89 (s, 3H), 3.68 (q, J = 7.3 Hz, 2H), 3.34 (s, 1H), 3.31 (s, 1H), 2.40 (s, 3H), 1.24 (t, J = 7.5 Hz, 3H), 1.10-1.04 (m, 1H), 0.52-0.48 (m, 2H), 0.34-0.30 (m, 2H); ESI MS (m / z) 522.20 (MH)+...

Claims

1. A compound of formula (I)(I)wherein,R1 is Ci-Ce-alkyl;Y is selected from oxygen (0) or NRY;RYis selected from the group consisting of hydrogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl, C3-Cs-cycloalkyl, C3-Cs-cycloalkyl-Ci-C3-alkyl and -C(O)Rla;Rla is selected from the group consisting of Ci-Ce-alkyl, Ci-Ce-haloalkyl, C3-Cs-cycloalkyl and C3-Cs-cycloalkyl-Ci-C3-alkyl;R2 is C(=W)R7; wherein W is selected from oxygen (0) or sulfur (S);R7 is selected from the group consisting of OR4 and NR5R6;R2a is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C3-C6-cycloalkyl, Ci-Ce-alkoxy, Ci-C6-alkoxy-C3-C6-cycloalkyl, Ci-Ce-haloalkyl and Ci-Ce-haloalkoxy;R4 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and C3-Cs-cycloalkyl;R5 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, OR5a, NR5cR5d, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, C3-Cs-cycloalkyl, C3-Cs-cycloalkyl-Ci-C6-alkyl, -C(O)OR5d, -Ci-C3-alkyl-C(O)OR5d, -Ci-C3-alkyl-C(O)N(R5d)2, 3- to 6- membered non aromatic heterocyclic ring, 3- to 6- membered non aromatic heterocyclic ring-Ci-Ce-alkyl, phenyl and phenyl-Ci-Ce-alkyl; wherein each group may optionally be substituted with one or more groups of R5b;R5a is selected from the group consisting of Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C3-C6-cycloalkyl-Ci-C6-alkyl, phenyl-Ci-Ce-alkyl, and 3- to 6- membered non aromatic heterocyclic ring; wherein said heterocyclic ring and phenyl-Ci-Ce-alkyl groups may optionally be substituted with one or more groups selected from Ci-Ce-alkyl, Ci-Ce-alkoxy or halogen;R5b is selected from the group consisting of halogen, cyano, oxo, hydroxy, Ci-Ce-alkyl, Ci-Ce-alkylthio, Ci-Ce-haloalkyl, Ci-Ce-hydroxyalkyl, -C(O)O-Ci-C6-alkyl and Ci-Ce-alkoxy;R5c is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and CT-CVcycloalkyl;R5dis independently selected from the group consisting of hydrogen and Ci-Ce-alkyl;R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-alkoxy, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and Cs-Ce-cycloalkyl;orR5 and R6 together with the nitrogen atom to which they are attached may form a 3 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-Ce-alkyl, Ci-Ce-alkoxy or Ci-Ce-haloalkyl;orNR5R6 represents -N=S(O)RxRXa, wherein Rx and RXa are independently selected from the group consisting of cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, phenyl, benzyl and 3- to 6- membered non aromatic heterocyclic ring; wherein said phenyl and benzyl rings are may optionally be substituted by one or more groups selected from halogen or Ci-Ce-alkyl;orRx and RXa together with the sulfur atom to which they are attached may form a 3 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-Ce-alkyl, Ci-Ce-alkoxy or Ci-Ce-haloalkyl;Q represents partially saturated or unsaturated 5- to 12-membered heterocyclic ring which is substituted by one or more groups of R3 and optionally substituted by one group of R10;R3 is selected from the group consisting of halogen, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Ci-Ce-haloalkoxy, -S(O)0-2Ci-C3-haloalkyl and -S(0)o iR8=NR9;R8 is selected from the group consisting of Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl and CT-CVcycloalkyl;R9 is selected from the group consisting of hydrogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, C\-Q-cycloalkyl and C(=O)R';R10 is selected from hydrogen or Ci-Ce-alkyl;or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof.

2. The compound of formula (I) according to claim 1, represented by a compound of formula (IA),(IA)wherein, R1, Q, R2, R2a and Y are as defined in claim 1.

3. The compounds of formula (I) according to claim 1 or 2, wherein Q is selected from the groupconsisting of QI a to QIp:Q1k             Q1I             Q1m             Q1n             Q1o             Q1pwherein, # denotes the point of attachment to the pyrazolopyrimidine ring; R10 is selected fromhydrogen or Ci-Ce-alkyl; "n" is an integer ranging from 1 to 2; and R3 is as defined in claim 1.

4. The compound of formula (I) according to claim 1 or 2, wherein R1 is Ci-Cs-alkyl.

5. The compound of formula (I) according to claim 1 or 2, wherein Y is O.

6. The compound of formula (I) according to claim 1 or 2, wherein Y is NRY.

7. The compound of formula (I) according to claim 1 or 2, wherein W is oxygen (0).

8. The compound of formula (I) according to claim 1 or 2, wherein R2 is C(=O)OR4; wherein R4 are as defined in claim 1.

9. The compound of formula (I) according to claim 1 or 2, wherein R2 is C(=O)NR5R6; wherein R5 andR6 are as defined in claim 1.

10. The compound of formula (I) according to claim 1 or 2, whereinR1 is Ci-Cs-alkyl;Y is selected from oxygen (0) or NRY;RYis selected from the group consisting of hydrogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C2-C4-haloalkenyl, Cs-Cs-cycloalkyl, Cs-Cs-cycloalkyl-Ci-Cs-alkyl and -C(0)Rla;Rla is selected from the group consisting of Ci-C4-alkyl, Ci-C4-haloalkyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Cs-alkyl;R2 is C(=W)R7; wherein W is oxygen (O);R7 is selected from the group consisting of OR4 and NR5R6;R2a is selected from the group consisting of halogen, cyano, Ci-C3-alkyl, C3-C6-cycloalkyl;R4 is selected from hydrogen or Ci-C4-alkyl;R5 is selected from the group consisting of hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, OR5a, NR5cR5d, Ci-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-Ci-C4-alkyl, -C(O)OR5d, Ci-C3-alkyl-C(O)OR5d, Ci-C3-alkyl-C(O)N(R5d)2, 4- to 6- membered non aromatic heterocyclic ring, 4- to 6- membered non aromatic heterocyclic ring-Ci-C4-alkyl, phenyl and phenyl-Ci-C4-alkyl; wherein each group may optionally be substituted with one or more groups ofR5b;R5a is selected from the group consisting of Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C1-C4-haloalkyl, C3-C6-cycloalkyl-Ci-C3-alkyl, phenyl-Ci-C3-alkyl, and 5- to 6- membered non aromatic heterocyclic ring; wherein said heterocyclic ring ans phenyl-Ci-C3-alkyl groups may optionally be substituted with one or more groups selected from Ci-C3-alkyl, Ci-C3-alkoxy or halogen;R5b is selected from the group consisting of halogen, cyano, oxo, hydroxy, Ci-C4-alkyl, C1-C4-alkylthio, Ci-C4-haloalkyl, Ci-C4-hydroxyalkyl, -C(O)O-Ci-C4-alkyl and Ci-C4-alkoxy;R5c is selected from hydrogen or Ci-C4-alkyl;R5dis independently selected from hydrogen or Ci-C4-alkyl;R6 is selected from the group consisting of hydrogen, Ci-C3-alkyl and Ci-C3-alkoxy;orR5 and R6 together with the nitrogen atom to which they are attached may form a 3 - to 6membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o 2; said heterocyclic ring is optionally substituted by one or more substituents independently selected from halogen, cyano, oxo, Ci-C3-alkyl, Ci-C3-alkoxy or Ci-C3-haloalkyl;orNR5R6 represents -N=S(O)RxRXa, wherein Rxand RXa are independently selected from cyano, Ci-C3-alkyl, phenyl or benzyl; wherein said phenyl and benzyl rings are may optionally be substituted by one or more groups selected from halogen or Ci-C3-alkyl;orRx andRXa together with the sulfur atom to which they are attached may form a 5-to 6-membered non aromatic heterocyclic ring; wherein said heterocyclic ring optionally contains 1 or 2 heteroatoms independently selected from N, O or S(0)o-2;Q is selected from the group consisting of QI a to Q Ip;wherein, # denotes the point of attachment to the pyrazolopyrimidine ring;R3 is selected from halogen, Ci-Cs-haloalkyl or Ci-Cs-haloalkoxy;R10 is Ci-C3-alkyl;"n" is an integer ranging from 1 to 2;or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof.

11. A composition comprising the compound of formula (I) or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof according to claim 1 and at least one additional component selected from die group consisting of surfactants and auxiliaries.

12. The composition according to claim 11, wherein said composition additionally comprises at least one         biological         active         compatible         compound         selectedfrom fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients.

13. The composition according to claim 11, wherein said compound of formula (I) ranges from 0.1 % to 99 % by weight with respect to the total weight of the composition.

14. A combination comprising a biologically effective amount of the compound of formula (I) according to claim 1 and at least one additional biological active compatible compound selected from fungicides', insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients.

15. A method for protecting crops from attack or infestation by insects and mite pests comprises contacting the crop with the compound of formula (I) or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof according to claim 1, composition thereof according to claim 11, or combination thereof according to claim. 14.

16. The method according to claim 15, wherein said method comprises applying effective dosages of compound of formula (I) in amounts ranging from 1 gai to 5000 gai per hectare in agricul tural or horticultural crops.

17. A method for the protection of seeds, plants and plant parts from soil insects and of the seedlings roots and shoots from soil and foliar insects comprising contacting the seeds before sowing and / orafter pre-germination with the compound of formula (I) or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof according to claim 1, composition thereof according to claim 11, or combination thereof according to claim 14.

18. Use of the compound of formula (I) or salts, stereoisomers, polymorphs, metal complexes or N-oxides thereof according to claim 1, composition thereof according to claim 11, or combination thereof according to claim 14, for combating insects and mite pests in agricultural crops, horticultural crops, household and vector control and parasites on animals.

19. A seed comprising a compound of formula (I) or salts, metal complexes, N-oxides, stereoisomers, polymorphs thereof according to claim. 1, composition thereof according to claim 11 or combination thereof according to claim 14, wherein the amount of compound of formula (I) in said seed ranging from about 0.0001 % to about 1 % by weight.

20. A compound of formula (Z), (A) or (B):(Z)                                (A) nr           (B)wherein, Q is selected from the group consisting of Qla to Qlp:R1, R2, R2a, R3, R10 and n are as defined in claim 1, with the proviso that 2-(ethylthio)-3-(6-(2,2,3,3,3-pentafluoropropoxy)pyridazin-3-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one;2-(ethylthio)-3-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one and 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyrazolo[l,5-a]pyrimidin-7(4H)-one are excluded from the definition of compound of formula (A) and 3-(ethylthio)-4-(5-(2,2,3,3,3-pentafluoropropoxy)pyrazin-2-yl)-lH-pyrazol-5-amine and 3-(ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-2-yl)-lH-pyrazol-5-amine are excluded from the definition of compound of formula (B).